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SUMMARY 
Haematopoiesis is a cell differentiation process, starting from multipotent haematopoietic 
stem cells (HSC) to increasingly more fate-restricted blood cell progenitors. Each step 
during this process is strictly regulated by key transcription factors, activating or repressing 
stemness and lineage-specific genes. Not surprisingly, mutations or translocations 
involving transcription factors are often associated with leukaemia. IKAROS is the 
founding member of a zinc finger transcription factor family primarily involved in 
haematopoietic fate-decision. IKAROS protein is characterized by 2 domains: one at the 
N-terminus, with 4 zinc fingers, necessary for the DNA binding, and one at the C-terminus, 
with 2 zinc fingers, necessary for the homo- hetero-dimerization of the protein and its 
consequent activation. IKAROS is expressed in HSC and during lymphoid commitment 
expression increases, silencing stemness and myelo-erythroid priming genes and enhancing 
lymphoid specific factors. In Ikzf1-knockout mice models, lymphopoiesis is severely 
impaired, with a retardation of T cell development and a block in B, NK and dendritic cell 
differentiation due to a failure of HSC to differentiate into common lymphoid progenitors 
(CLP). Ikzf1 mutant mice developed T-cell leukaemia or lymphoma with a penetrance of 
~95% within 6-8 weeks after birth, and died soon after. In human, IKZF1 alterations are 
rarely associated with T-cell leukaemias, but surprisingly IKZF1 deletions were found to 
occur in 15% of paediatric B cell precursors ALL (BCP-ALL) and in more than 70% of 
paediatric Philadelphia positive BCP-ALL. 
In this thesis, we evaluate the impact of IKAROS in paediatric leukaemia and during the 
B-cell lineage specification. 
 
In Chapter 3, we studied the incidence of IKZF1 point mutations and indels in a European 
cohort of Ph+ BCP-ALL paediatric patients. In particular, we screened, using next 
generation amplicon deep sequencing (NGS), the 7 coding exons of IKZF1 in 98 IKZF1 
non deleted and 61 IKZF1 deleted patients. Seven missense point mutations and 7 
frameshift small indels were identified in IKZF1-non deleted and 3 point mutations were 
detected in IKZF1-deleted patients, all of them with a predicted deleterious effect on 
IKAROS function. Mutations were mainly located in exons 5 and 8, encoding the DNA-
binding and dimerization domains respectively. In IKZF1-non deleted patients, mutations 
seem to indicate the same prognosis as macrodeletions, with a higher incidence of adverse 
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events in patients treated before TKI introduction compared to patients treated with a 
combination therapy including TKIs. 
 
Among the mutated patients identified in our mutation screening, one patient had the same 
single nucleotide deletion both at diagnosis and complete remission, suggesting a 
constitutional status of the mutation. In Chapter 4 we further investigated the constitutional 
status of the IKZF1 mutation in the proband and his family, finding in 3 generations the 
same mutation in the mother and 3 other carriers, as well as a second leukaemia case in the 
family that had occurred more than 45 years ago. The IKZF1 single nucleotide deletion 
gave rise to a truncated protein with loss of the last part of the DNA binding domain and 
the C-terminal dimerization domain, resulting in DNA-binding deficiency and a diffuse 
nuclear localization. The mutant allele was transcribed in proband‟s bone marrow at 
complete remission, as well as in peripheral blood (PB) cells of his sister, an unaffected 
mutation carrier. Finally, the truncated protein was identified in the PB cells of the 
proband‟s sister, in a lower amount compare to the wt-IKAROS isoforms.  
 
In Chapter 5, a model to study Ikaros-mediated gene expression regulation is described and 
characterized. Ikaros expression is enhanced during B-cell development, and pilots B cell-
progenitors out of cell cycle allowing the Ig light chain recombination. To better 
comprehend the kinetics and mechanisms of Ikaros-gene expression regulation, we 
knocked-out endogenous Ikaros from a murine cycling preB cell line, using the CRISPR-
Cas9 technique, and subsequently transduced cells with an inducible Ikaros cassette, that 
allowed to precisely regulating Ikaros translocation in the nuclei. Inducible Ikaros 
efficiently translocated to the nuclei and bound to target gene promoter, but its gene 
expression regulation appeared impaired. Indeed, inducible Ikaros was able to up-regulate 
well known target genes, but failed to down-regulate 3 selected target genes, know to be 
down-regulate after Ikaros induction in an endogenous Ikaros wt model. 
 
In Chapter 6 we took advantage of the Ikaros inducible system to study the metabolic 
changes that occur during B-cell lymphocyte development in a cycling to resting preB cell 
model. Three FRET-sensors specifically designed to evaluate the cellular levels of ATP, 
glucose and AMPK activation status were transduced in our cell model, and preliminary 
measurements were performed using at fluorescent microscopy and FACS after 16 hours 
of Ikaros induction. 
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RIASSUNTO 
L‟ematopoiesi è un processo differenziativo che, a partire da cellule staminali 
ematopoietiche multipotenti, da origine a tutte le cellule del sangue. Ogni step 
differenziativo durante questo processo è finemente regolato da un insieme di fattori di 
trascrizione che agiscono in concerto bloccando la trascrizione di geni legati alla 
staminalità ed attivando geni essenziali per la specificazione ed il differenziamento delle 
diverse linee maturative ematopoetiche: linfoide, mieloide, eritroide e magacariocitoide. 
Non è quindi sorprendente che mutazioni o traslocazioni che interessano questi fattori di 
trascrizione siano spesso associate con l‟insorgenza di leucemie. IKAROS fa parte di una 
famiglia di fattori di trascrizione principalmente coinvolta nella specificazione in senso 
linfoide delle cellule ematopoietiche. IKAROS è caratterizzato da due domini funzionali: 
un dominio N-terminale, composto da 4 zinc-finger, necessario per il legame della proteina 
al DNA, ed un domino C-terminale, formato da 2 zinc-finger, indispensabile per la omo-
etero-dimerizzazione della proteina e la sua conseguente attivazione. IKAROS è espresso a 
livello delle cellule staminali ematopoietiche, e la sua espressione aumenta durante il 
differenziamento linfoide, silenziando geni legati alla staminalità ed allo sviluppo eritro-
mieloide e potenziando l‟espressione di geni legati allo sviluppo linfoide. In topi knockout 
per il gene Ikzf1 la linfopoiesi è gravemente compromessa, con un ritardo nello sviluppo 
delle cellule T ed un completo blocco nel differenziamento dei linfociti B, cellule natural 
killer e delle cellule dendritiche. Questo fenotipo è dovuto all‟incapacità delle cellule 
staminali ematopoietiche di differenziare in cellule progenitrici della linea linfoide in 
assenza di Ikaros. La mancanza di Ikaros in questi topi porta all‟insorgenza di leucemie o 
linfomi a cellule T nel ~95% dei casi entro sei mesi dalla nascita. 
Nell‟uomo, aberrazioni associate ad IKZF1 sono rare nelle leucemie T, ma, al contrario, 
delezioni di parte del gene sono presenti nel 15% delle leucemie pediatriche a fenotipo B 
(BCP-ALL), e la percentuale raggiunge circa il 70% se si considera un particolare 
sottogruppo caratterizzato dalla presenza del cromosoma aberrante Philadelphia. 
In questa tesi abbiamo studiato il ruolo di IKAROS nelle leucemie pediatriche e durante il 
differenziamento dei linfociti B. 
 
Nel terzo capitolo l‟incidenza di mutazioni puntiformi e piccole inserzioni/delezioni (indel) 
del gene IKZF1 viene studiata in una coorte europea di pazienti pediatrici affetti da BCP-
ALL con presenza del cromosoma Philadelphia. Grazie all‟utilizzo del sequenziamento di 
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nuova generazione abbiamo sequenziato i 7 esoni codificanti di IKZF1  in 98 pazienti 
IKZF1-non deleti ed in 61 pazienti IKZF1-deleti. Tra i 98 pazienti non deleti abbiamo 
riscontrato la presenza di 7 mutazioni puntiformi e 7 indel, mentre 3 mutazioni puntiformi 
sono state evidenziate nella coorte di pazienti IKZF1 deleti. Tutte le aberrazioni da noi 
trovate sono predette avere un effetto deleterio sulla funzionalità della proteina. Queste 
aberrazioni genetiche sono principalmente localizzate sul quinto e sull‟ottavo esone, che 
codificano per i domini di legame al DNA e di dimerizzazione, rispettivamente. Nei 
pazienti che non presentavano macrodelezioni di IKZF1, le mutazioni da noi identificate 
sembrano avere lo stesso impatto prognostico delle macro-delezioni, presentando una 
maggior incidenza di eventi avversi nei pazienti trattati prima dell‟introduzione degli 
inibitori di tirosin-chinasi rispetto a quelli a cui sono stati somministrati in sinergia con la 
chemioterapia. 
 
Un paziente mutato identificato durante il nostro screening ha mostrato la presenza della 
stessa delezione di un singolo nucleotide sia nel campione alla diagnosi che in quello in 
remissione, suggerendo una possible origine costituzionale della mutazione. Nel quarto 
capitolo è stata indagata la natura costituzionale della mutazione nel paziente e nella sua 
famiglia. La stessa delezione in eterozigosi è stata identificata nella madre del paziente ed 
in altri 3 portatori in 3 generazioni; abbiamo inoltre scoperto un secondo caso di leucemia 
pediatrica all‟interno della famiglia verificatasi più di 45 anni fa. La delezione riscontrata 
nella famiglia dà origine ad una proteina tronca con la perdita della parte terminale del 
dominio di legame al DNA e la completa perdita del dominio di dimerizzazione al C-
terminale. L‟assenza di questi domini comporta una ridotta affinità di legame al DNA ed 
ad una localizzazione nucleare diffusa. L‟mRNA dell‟allele mutato è stato ritrovato nelle 
cellule del midollo osseo del paziente in remissione completa, così come in cellule 
mononucleate del sangue di una delle sorelle, anch‟essa portatrice della delezione. Nelle 
medesime cellule è stata riscontrata anche la presenza della proteina tronca, seppur in 
minor quantità rispetto alle isoforme wt. 
  
Nel quinto capitolo viene descritto e caratterizzato un nuovo modello cellulare murino per 
lo studio della regolazione dell‟espressione genica mediata da Ikaros. L‟espressione di 
Ikaros aumenta durante il differenziamento dei linfociti B, ad è necessario per arrestare il 
ciclo cellulare di cellule B progenitrici permettendo il riarrangiamento della catena leggera 
delle immunoglobuline. Per meglio comprendere la cinetica ed il meccanismo con cui 
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Ikaros media l‟espressione genica, abbiamo creato una linea murina di cellule preB 
knockout per il gene Ikzf1 grazie alla tecnica di “gene editing” della CRISPR-Cas9, ed 
abbiamo quindi trasdotto queste cellule con una cassetta contenente un sistema inducibile 
di Ikaros, che ci permette di controllare la traslocazione di Ikaros dal citoplasma al nucleo. 
Ikaros-inducibile è in grado di traslocare efficacemente nel nucleo e di legarsi al promotore 
di un suo gene target molto noto, ma la sua abilità di regolare l‟espressione genica appare 
parzialmente compromessa. Infatti, Ikaros-inducibile promuove l‟aumento di espressione 
di alcuni suoi geni target, ma non è in grado di silenziare 3 geni da noi selezionati e noti 
per essere silenziati da Ikaros. 
 
 Nel sesto capitolo abbiamo utilizzato il sistema di Ikaros-inducibile per studiare i 
cambiamenti metabolici che avvengono durante lo sviluppo dei linfociti B, utilizzando un 
modello cellulare murino di cellule preB. Tre sensori basati sulla tecnica FRET, per 
quantificare i livelli cellulari di ATP, glucosio e di attivazione della proteina AMPK, sono 
stati trasdotti nel nostro modello cellulare, e sono quindi state eseguiti esperimenti 
preliminari utilizzando tecniche di microscopia a fluorescenza e FACS dopo 16 ore di 
induzione.
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GLOSSARY 
 
4OHT - 4-hydroxytamoxifen 
ALL - Acute lymphoblastic leukaemia 
AML - Acute myeloid leukaemia 
APS - Ammonium persulphate 
BCP-ALL - B cell precursor acute lymphoblastic leukaemia 
BCR - B cell receptor 
bp - Base pair 
BTK - Bruton‟s tyrosine kinase 
C-/- - Ikzf1 homozygous null deletion 
CCR - Clinical complete remission 
cDNA - Complementary DNA 
CFP - Cyan fluorescent protein 
ChIP - Chromatin immune-precipitation 
CIR - Cumulative incidence of relapse 
CK2 - Casein kinase 2 
CLP - Common lymphoid progenitor 
CML - Chronic myeloid leukaemia 
CMP - Common myeloid progenitor 
COG - Children oncology group 
DAPI - 4‟,6-diamino-2-phenylindole 
DFS - Disease free survival 
DMSO - Dimethyl sulfoxide 
DN - Dominant negative 
DN-/- - Ikzf1 homozygous dominant negative mutation 
DN+/- - Ikzf1 heterozygous dominant negative mutation 
DP - Double positive thymocytes 
EFS - Event free survival 
ERt2 - Ligand-binding domain of the oestrogen receptor 
EtOH - Ethanol 
FACS - Fluorescence-activating cell sorting 
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FRET - Förster resonance energy transfer 
GFP - Green fluorescent protein 
GMP - Granulocyte-monocyte progenitor 
GWAS - Genome-wide association study 
HA - hemagglutinin 
HDAC - Histone deacetylase complex 
HR - High risk 
HSC - Haematopoietic stem cell 
HSCT - Haematopoietic stem cell transplantation 
IF - Immune-fluorescence 
IgH/L - Immunoglobulin heavy/light chain 
IKAROS/Ikaros - Human/murine ikaros protein 
IKZF1/Ikzf1 - Human/murine ikaros gene 
ΔIKZF1 - IKZF1 macro-deletions 
Kb - Kilo-base 
LMPP - Lymphoid-primed multipotent progenitor 
LOH - Loss of heterozygosity 
MAF - Mutant allele frequency 
MDa - Mega-Dalton 
MEP - Megakaryocyte-erythrocyte progenitor 
MLPA - Multiplex ligation-dependent probe amplification 
MPP - Multipotent progenitor 
MRD - Minimal residual disease 
MSCV - Murine stem cell virus 
NGS - Next generation sequencing 
NK - Natural killer 
NHEJ - Non-homologous end joining 
NuRD - Nucleosome remodeler deacetylase 
ON - Overnight 
OS - Overall survival 
PBMC - Peripheral blood mononuclear cells 
PBS - Phosphate-buffer saline 
PC-HC - Pericentromeric heterochromatic region 
PEST - Proline, glutamic acid, serine and threonine sequence 
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PFA - Paraformaldehyde 
PI - Propidium iodide 
Ph - Philadelphia chromosome 
PP1 - Protein phosphatase 1 
RFLP - Restriction fragment length polymorphism 
RQ-PCR - Real time quantitative polymerase chain reaction 
RT-PCR - Retro-transcription polymerase chain reaction 
SDS - Sodium dodecyl sulphate 
siRNA - Small interfering 
SLC - Surrogate light chain 
SLE - Systemic lupus erythematosus 
SNP - Single nucleotide polymorphism 
SYK - Spleen tyrosine kinase 
TCR - T cell receptor 
TEMED - N,N,N‟tetramethylethylenediamine 
TKI - Tyrosine kinase inhibitor 
Treg - Regulatory T cell 
TSS - Transcription start site 
WBC - White blood cell count 
WGS - Whole genome sequencing 
wt - Wild type 
YFP - Yellow fluorescent protein 
ZF - Zinc finger 
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CHAPTER 1 
INTRODUCTION 
1.1 TRANSCRIPTION FACTOR IKAROS 
1.1.1 IKAROS TRANSCRIPTION FACTOR FAMILY 
The IKZF1 gene is composed of 8 exons spread over 6.2 Kb, located at sub-band p12.2 of 
chromosome 7 (Figure 1.1 A). Exon1 and the 5‟ half of exon2 are not translated into 
protein, but contribute to the regulation of the gene. The other 7 exons encode a 519 amino 
acid protein
1
. IKAROS belongs to the zinc finger protein superfamily, which totals 5% of 
protein coding sequences of the eukaryotic genome. Generally speaking the classical zinc 
finger domain, the Cys2-His2, comprises two antiparallel β-sheets folded on an α-helix. In 
the core of the domain, 2 cysteines in the β-sheets and 2 histidines in the α-helix coordinate 
a zinc atom, which confers rigidity to the entire structure. From these four coordination 
residues there are 3 other hydrophobic residues in the core of the domain important for 
structural maintenance. Residues in position -1, 3 and 6 contact a triplet of nucleotides on 
one strand of DNA, and a residue in position 2 interacts with a base next to the triplet on 
the other strand of DNA. Altogether, these four residues are responsible for the sequence-
specific DNA recognition of zinc finger proteins
2–4
. 
IKAROS structure 
IKAROS contains 6 Cys2-His2 zinc finger motifs (ZF) in 2 clusters. The N-terminal 
domain, encoded by exons 3 to 5, is formed by 4 zinc fingers responsible for the DNA-
protein interaction, as demonstrated by gel shift and DNA foot-printing assays
5
. Zinc 
fingers 2 and 3 are essential for the DNA-protein interaction, since their depletion leads to 
the complete loss of DNA binding activity
6
, while zinc fingers 1 and 4 regulate the 
interactions to specific genomic sites
7
. Zinc fingers 5 and 6, located at the C-terminal 
domain, are responsible for IKAROS dimerization, which greatly enhances the binding 
affinity to DNA. Both zinc fingers are required to gain a stable dimerization
8
. 
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IKAROS isoforms 
Alternative splicing of the IKZF1 gene generates at least 10 different isoforms. These 
isoforms retain the last exon, encoding the C-terminal dimerization domain, and differ 
from each other regarding the inclusion of other exons
6,8
. Besides the full-length IK1 
isoform, there are at least 9 different isoforms: IK2, IK3, IK4, IK5, IK6, IK7, IK8, IK9 and 
IKX. IK1 to IK4 are able to interact with DNA, while IK5 to IK9 completely or partially 
lack the N-terminal domain but retain the dimerization domain (Figure 1.1 B). They are 
referred to as dominant negative (DN) isoforms, as they are able to interact with longer 
Ikaros isoforms impairing their DNA-binding (Figure 1B). In haematopoietic cells IK1 and 
IK2, the longest isoforms, are most abundantly detected. Many of the other isoforms were 
detected at different stages of haematopoietic development in myeloid (IKX)
9
, lymphoid 
(IK1, IK2 and IK4)
6
, and erythropoietic (IK3)
1
 cells. Fluorescent microscopy performed on 
IKAROS transfected-fibroblasts and thymocytes revealed that only DNA-binding isoforms 
can actively translocate into the nucleus, while DN isoforms remain in the cytoplasm. DN 
isoforms only display nuclear localisation when co-transfected with DNA binding 
isoforms, demonstrating that short isoforms can only pass through the nuclear membrane 
when in complexes with longer isoforms. Remarkably, IK1 loses its ability to activate the 
transcription of a reporter gene under the control of four copies of IKAROS recognition 
sites when it is co-expressed with DN isoforms like IK6 and IK7, while when coupled with 
longer isoforms, such as IK2 or IK3, IK1 can activate transcription
8
. 
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Figure 1.1: Schematic representation of IKZF1 gene. A) Schematic representation of the IKZF1 locus and 
chromosome position. Coding exons are depicted in blue, non-coding exons in light blue. B) The main 
IKAROS isoforms + indication of ZFs 1-4 DNA binding and 5-6 dimerization. Modified from Olsson et al., 
2015 
 
Post-translational modifications of IKAROS 
IKAROS function is post-translationally regulated by phosphorylation. Indeed Casein 
Kinase 2 (CK2) is responsible for IKAROS phosphorylation at multiple sites between 
amino acids 389 and 398, and in positions 13, 23, 63, 101 and 294
10
. Phosphorylation at 
these sites affects IKAROS activity, as phospho-mimetic mutants (mutants where 
phospho-sites are mutated into aspartate to mimic the negative charge of a phosphate 
residue) at position 13 and 294 show a complete abolishment of IKAROS binding to  DNA 
resulting in a diffuse nuclear localization of the protein and a block of  the cell  cycle in G1 
phase
11,12
. Protein phosphatase 1 (PP1) is responsible for the dephosphorylation of residues 
at phosphosites. IKAROS interacts with PP1 through a conserved PP1-binding motif 
located at its C-terminus. Deletions of the PP1-binding motif result in poor DNA affinity, 
nuclear mislocalization, and a faster rate of IKAROS degradation
13
. 
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Recently, Spleen Tyrosine Kinase (SYK) and Bruton‟s Tyrosine Kinase (BTK) have been 
shown to phosphorylate IKAROS. Highresolution confocal microscopy showed that 
IKAROS partially co-localizes with SYK and BTK, and that these kinases are able to 
phosphorylate IKAROS at specific, unique sites. DT40 chicken lymphoma cells deficient 
for SYK or BTK, as well as experiments on single phospho-resistant mutants (mutants 
where phospho-sites where substituted by alanines, that mimic a non-phosphorylated 
amino acid) showed an aberrant cytoplasmic localization of IKAROS, indicating a pivotal 
role of phosphorylation in IKAROS activation and localization. Both SYK and BTK are 
essential for IKAROS nuclear translocation, as mutations in SYK or BTK target residues 
impaired IKAROS localization. Finally, SYK and BTK phosphorylation can overrule the 
inhibitory effects of CK2-phosphorylated residues as phospho-mimetic mutated CK2 sites 
on the Ikaros protein fail to translocate to the nucleus when either SYK or BTK are 
depleted by siRNA
14,15
 (Figure 1.2). 
 
Figure 1.2: Schematic presentation of post-translational modifications that regulate IKAROS activity. 
Phosphorylation by BTK and SYK kinases promote nuclear translocation of IKAROS, where it binds DNA. 
CK2 phosphorylation of IKAROS in the nucleus impairs DNA binding, pericentromeric localization and 
increased its degradation rate, which were restored via de-phosphorylation by PP1. 
 
IKAROS zinc finger family members 
Ikaros is the founding member of a family of 5 transcription factor proteins including 
Helios, Aiolos, Eos and Pegasus
16
. The first 4 components of the family, found by using 
degenerated primers on the conserved N-terminal and C-terminal regions, display 4 zinc 
fingers at the DNA-interaction N-terminal domain that recognize the canonical GGAAA 
sequence, whereas Pegasus, the most divergent of the family members, contains only 3 
zinc fingers at the N-terminus and recognizes the atypical GNNNGNNG consensus 
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sequence
17
. Next to Ikaros itself, Helios and Aiolos are the most studied proteins of the 
Ikaros family, since they display the highest similarity with Ikaros and are implicated in 
haematopoiesis. 
 
Aiolos: Aiolos, encoded by IKZF3, shows the highest similarity with Ikaros, and can 
heterodimerize with Ikaros and Helios. Despite high sequence homology, Aiolos is not 
present in haematopoietic stem cells with Ikaros, but is expressed from the Pro-B cell stage 
onwards and is upregulated in all later and mature stages of B lymphocyte development
18
. 
In T cells Aiolos is expressed at the CD4
-
CD8
-
 and the more mature CD4
+
CD8
+
 stage, and  
has been shown to be required for NK cell maturation
19
. Besides its role in haematopoiesis, 
Aiolos acts as an anti-apoptotic factor by regulating Bcl-2 expression and by directly 
binding Bcl-XL proteins
20
. Aiolos is transcribed in multiple isoforms, differing between 
each other in the number of N-terminal zinc fingers. Aiolos isoforms have different cellular 
localization, and are able to change the cellular localization of other Ikaros family 
members
21
. 
 
Helios: The expression of Helios, encoded by IKZF2, is restricted to haematopoietic stem 
cells (HTCs) and a subset of lymphoid cells, in particular early T cells
22
. As a member of  
the Ikaros protein family, Helios dimerizes with Ikaros and Aiolos and can  co-localize in 
vivo with Ikaros long or DN isoforms
22
. Helios was most studied as an important factor in 
Treg development and function. Helios+ peripheral Treg cells display a higher ability to 
suppress antigen-specific and TCR specific T cells responses, and are able to down-
regulate cytokine expression by T cells in Helios-reporter mice
23
. 
1.1.2 THE ROLE OF IKAROS AS REGULATOR OF GENE 
EXPRESSION 
Ikaros was initially identified in 1992 by Georgopoulos and colleagues, in their effort to 
find new transcription factors involved in early T cell commitment. In their first paper, 
Ikaros was shown to bind one of the enhancer elements of the CD3δ gene, promoting its 
expression. In vitro analysis of other B- and T-specific promoter regions and DNase 
footprinting experiments revealed binding sites at the promoters of TdT, λ5, and other 
lymphoid-restricted genes
24,25
; moreover, Ikaros and Aiolos can activate the transcription 
of reporter genes under control of the Ikaros consensus binding site
6,8
. Further reports from 
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other groups emphasize a major role of Ikaros as a repressor of gene expression
26
, 
elucidating the dual function of Ikaros as an activator and repressor of gene expression. 
The sub-cellular localization of IKAROS  
To exert its function, IKAROS needs to localize in apposition to pericentromeric regions in 
the nucleus. In mature B cells, confocal microscopy experiments highlighted a spotted, 
toroidal localization in the nucleus, which disappeared during S phase of the cell cycle. 
Immunofluorescence combined with fluorescent in situ hybridization showed the 
localization of IKAROS at heterochromatic regions (marked by γ satellite probes). Of note, 
genes down-regulated by Ikaros were positioned at pericentromeric-heterochromatic (PC-
HC) regions and co-localized with Ikaros. Positioning at PC-HC regions is specific for 
down-regulated genes and is related to developmental stages. For example, Igll1 (a 
component of the surrogate light chain) locus was found juxtaposed to Ikaros  at the PC-
HC region in mature B cells, but not in preB cells
26
. These data were confirmed by a 
second paper of the same group, showing that Ikaros-regulated genes were dynamically 
repositioned during the cell cycle. In mature resting B cells, Ikaros is barely detected in the 
nuclei, but following B cells stimulations Ikaros nuclear signals increased and after 3 days 
the typical Ikaros-PC-HC foci were observed. In concomitance, Igll1, CD8α and Rag genes 
(all direct targets of Ikaros) were repositioned at the PC-HC regions. This spatial 
redistribution clearly parallels Ikaros repositioning
27
. Rag and TdT were also dynamically 
repositioned in the transition from resting to cycling immature T cells, and invariably, this 
re-localization led to the significant down-regulation of gene expression. Quite 
surprisingly, Koipally and colleagues demonstrated that  also the activation of Ikaros target 
gene expression required PC-HC localization, as reporter vectors containing Ikaros binding 
sites were shown to be activated only by Ikaros isoforms that are able to localize at PC-HC 
in NIH-3T3 transfected cells
28
. Two interpretations of this phenomenon are proposed: 
Ikaros localization at PC-HC regions repositioned NuRD complexes at these regions, 
decreasing their concentration as well as their inhibitory effects in other portions of the 
genome; or Ikaros target genes present at PC-HC regions are bound by Ikaros and the 
NuRD component Mi-2β, that remodelled chromatin in the proximity of its binding sites, 
enhancing the promoter accessibility to activators. 
Ikaros localizes to PC-HC regions by direct binding to γ satellite sequences present at these 
sites
2
, and this binding is preserved during cell cycle progression, when Ikaros DNA 
binding affinity to its target genes is decreased
29
. A model of Ikaros function was 
proposed, to link its ability to independently bind promoters and pericentromeric 
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heterochromatin with the Ikaros-mediated repositioning of its target genes to PC-HC: 
according to this model, Ikaros dimers contact the promoters of target genes, and 
subsequently interact with other multimeric Ikaros complexes located at the PC-HC region, 
thereby recruiting these genes to PC-HC sites
2,30
. 
IKAROS in the regulation of gene expression and chromatin remodelling  
The regulation of gene expression by Ikaros may either be direct or mediated through 
chromatin modifier complexes. The putative bipartite activation domain of Ikaros, 
originally identified in a double-hybrid assay
8
, was shown to be not essential for the 
regulation of gene expression, as its mutation does not impair the transcriptional activation 
of reporter genes
28
. 
Evidence for a direct regulation of gene expression came initially from the analysis of the 
TdT promoter in CD4
+
 CD8
+
 double positive thymocytes. An Ikaros binding site was 
identified within the core Ets recognition sequence. Gel-shift assays displayed competition 
between Ikaros and Ets binding at this locus, as increasing the concentration of one led to a 
progressive decrease in the binding of the other
30
. Down-regulation of TdT coincided with 
the appearance of inhibitory chromatin marks that preceded pericentromeric re-
localization, suggesting different temporal mechanisms of gene expression control by 
Ikaros. 
Similar competitive binding inhibition was observed by the analysis of Igll1 and VpreB 
promoters in mature and immature B cells. In these cells Ikaros competes with the 
transcription factor EBF to bind at these loci (Figure 1.3 A) and down-regulate these genes 
during B lymphoid development
31,32
. 
The most studied mechanism of transcription regulation by Ikaros is through the 
recruitment of chromatin modifier complexes. Ikaros and Aiolos localize with a 2 MDa 
complex containing the ATPase Mi-2 nucleosome remodeler of the NuRD (nucleosome 
remodeler deacetylase) complex, histone deacetylase complexes (HDACs) and Sin3A and 
Sin3B proteins
33,34
. 
The NuRD complex co-localized with the typical toroidal structures formed by Ikaros and 
Aiolos at PC-HC regions and their pointed localization disappear in Ikaros-deficient cells, 
indicating a primary role of Ikaros in the localization of the complex to heterochromatin
33
 
(Figure 1.3B). 
Ikaros-mediated transcriptional repression is mainly exploited through deacetylation of 
target gene promoters by HDACs
34,35
. However HDAC-independent transcriptional 
repression by Ikaros has been reported. Ikaros has been shown to interact with the co-
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repressor ctBP and ct-interacting protein (ctIP), and the Ikaros-ctBP/ctIP complexes can 
repress transcription of reporter genes without HDAC recruitment
36,37
. In vitro experiments 
show how Ikaros-ctBP and Ikaros-ctIP can interact with basic components of the 
transcriptional machine like TFIIB and TBP, implicating the transcription pre-initiation 
complex as an interesting target for Ikaros‟ HDAC-independent transcriptional 
repression
37
. 
Ikaros has been suggested to act as an activator of transcription by recruiting Brg1-
SWI/SNF to upstream regions of its target genes resulting in nucleosome remodelling and 
activation of transcription
38
. Ikaros-Brg-1 complexes display a diffuse distribution in active 
T cells, potentially overlapping with euchromatin regions, and never co-localize with the 
NuRD complex, as revealed by immune-precipitation assays
33
 (Figure 1.3 C). Even the 
Ikaros-NuRD interaction, typically considered as transcriptionally repressive, could lead to 
different regulatory outcomes. Indeed a recent genome-wide study of Ikaros and Mi-2β 
binding in double positive (DP) thymocytes revealed that Ikaros can localize the NuRD 
complex to active chromatin sites involved in T-cell development
39
. Furthermore, an 
antagonistic interplay between Ikaros and Mi-2β at the CD4 locus was highlighted in DP 
thymocytes: Mi-2β helps to recruit acetyl transferases at the silencer region of the CD4 
locus, possibly antagonizing Ikaros and its associated repressive activity
35
. 
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Figure 1.3: Examples of IKAROS function as transcription factor. A) Concentration-dependent 
competitive binding of IKAROS and EBF transcription factors at the promoter region of Igll1. B) 
Recruitment of the de-acetylase NuRD-Mi-2β complex by IKAROS to promoters leads to down-regulation 
of transcription. C) Nucleosome-remodeler SWI/SNF is recruited by IKAROS up-stream of target genes and 
result in target gene activation. 
Associations between Ikaros and the transcription elongation process were recently 
determined. Ikaros associates with NuRD and the positive transcription elongation factor b 
(P-TEFb) in haematopoietic cells, as revealed by tandem immune-affinity mass 
spectrometry. The building of this complex depends on Ikaros expression, as low levels of 
Ikaros lead to an association with the NuRD complex only, inhibiting the recruitment of P-
TEFb and Ikaros-NuRD at promoter regions of well-established Ikaros target genes
40
. 
The experiments discussed above describe the dual function of Ikaros as both an activator 
and repressor of gene expression. Ikaros-mediated regulation of gene expression is 
dependent on cell type, developmental and cell cycle stage. 
1.1.3 IKAROS AND HAEMATOPOIESIS 
Haematopoiesis is a hierarchical process in which multipotent progenitors undergo a 
restriction in developmental potential culminating in the production of the lineage-
committed blood cells. Haematopoiesis occurs in the foetal liver during embryonic 
development, and in the bone marrow and the thymus of the adult
41,42
. All blood cells 
derive from multipotent haematopoietic stem cells (HSC), the only haematopoietic cell 
type that preserves self-renewal potential and multipotency, which reflects the ability to 
differentiate into lineage-specific cells
42,43
. Characterization of differentially expressed cell 
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surface markers or surrogate markers activated by lineage-specific cassettes have helped to 
isolate and characterize haematopoietic stem cells as well as lineage restricted progenitors. 
HSC initially give rise to multipotent progenitors (MPP), that maintain the lineage-
differentiation potential of HSCs but lack self-renewal properties. MPPs can then give rise 
to 3 lineage specific progenitors: lymphoid-primed multipotent progenitor cells (LMPP) 
that preserve the lymphoid and myeloid potential but are no longer committed to the 
erythro-megakaryocyte lineage; megakaryocyte-erythrocyte progenitors (MEPs) that 
exclusively preserve the potential to differentiate into erythro-megakaryocytes; and 
common myeloid progenitors (CMPs) that possess erythro-megakaryocyte as well as 
myeloid differentiation potential
44
. LMPPs can subsequently differentiate into granulocyte-
monocyte progenitors (GMPs) and the common lymphoid progenitors (CLPs), which give 
rise to B and T lymphocytes and natural killer (NK) cells
45
 (Figure 1.4). 
 
Figure 1.4: Hierarchical model of haematopoiesis differentiation. HSC, haematopoietic stem cell; MPP, 
multipotent progenitor; LMPP, lymphoid-primed multipotent progenitor; CLP, common lymphoid 
progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte-erythrocyte progenitor; EP, 
erythrocyte progenitor; MkP, megakaryocyte progenitor; GP, granulocyte progenitor, MacP, macrophage 
progenitor; NK, natural killer. Modified from Cedar & Bergman 2011 
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Focusing on the B lymphoid restricted lineage, B cell development progresses through a 
series of developmental stages characterized by the expression of different molecular 
markers, and show oscillation between cell cycle progression and cell cycle arrest. This 
alternation between proliferation and quiescence is necessary for the somatic 
rearrangement of the heavy and light immunoglobulin chains, as Rag 1 and 2 activity is 
restricted to G1 phase to avoid genomic instability
46,47
. CLPs give rise to the first 
committed B cell progenitor, pre-pro-B cells, which transit through other lineage-
commitment stages termed pro-B, cycling pre-B, resting pre-B, and immature B cell. 
RAG-mediated immunoglobulin rearrangement at the Ig heavy chain (IgH) locus begins at 
the early pre-pro-B stages. The rearranged IgH locus encodes the Igµ chain, which is 
expressed at the pre-B stage together with the surrogate light chain (SLC).  The SLC is 
composed of the 2 invariant proteins λ5 and VpreB (encoded by Igll1 and VpreB1 genes). 
Together, Igµ and SLC form the pre-BCR complex. Pre-BCR signalling is an important 
feedback signal in B cell development, as only cells with productive Igµ rearrangements 
can proceed to the next maturation steps. Pre-BCR signalling induces a burst of 
proliferation and a simultaneous down-regulation of λ5, inhibiting SLC expression. SLC 
inhibition and the subsequent termination of pre-BCR signalling pilots cycling pre-B cells 
out of the cell cycle towards commencing IgL chain rearrangements. This is a critical step 
in the B-lymphocyte development, as cycling pre-B cells have virtually unlimited 
proliferative potential. Successful IgL recombination gives rise to an immature B cell 
expressing the BCR complex on its surface. Immature B cells are then selected for their 
ability to crosslink with self-antigens, and only non-autoreactive cells are selected to 
become mature B cells and migrate outside the bone marrow
31,47
. 
The role of IKAROS in haematopoiesis 
Each haematological cell type is specified by a series of signalling networks headed by 
different transcription factors in a hierarchical as well as combinatorial manner
45
. 
Multipotent HSCs and MPPs show low levels of lineage-specific gene expression patterns, 
while during cell specification distinct lineage determinants enhance their expression 
and/or activity, antagonizing other lineage-specific factor and thereby establishing cell fate. 
In the last decades, knockout animal models have depicted the network of interactions 
needed for B-cell specification. The most relevant transcription factors that orchestrate the 
B-cell development include PU.1 (for HSC to LMPP specification), E2A and EBF (for the 
control of gene expression in pro-B cells during Ig chain rearrangement), PAX5 (that 
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restricts the developmental options to the B cell lineage repressing other gene specification 
cassettes), and Ikaros
41
. 
During embryogenesis, Ikaros mRNA was detected at primitive and definitive sites of 
haematopoiesis. The longest IK1 and IK2 isoforms are expressed in the yolk sack, as well 
as in foetal liver, early thymus and post-natal spleen. The shorter IK4 isoform is detected 
in the maturing thymus, but its expression declines during mid gestation, while the longest 
isoforms remain detectable after birth. Ikaros isoforms IK1, IK2 IK3 IK4 and IK5 were 
detected in the early stages of brain development, but the expression dropped during late 
development and at day 1 after birth, suggesting a restriction in Ikaros expression to a 
specific brain cell population
48. Ikaros‟ role and importance in haematopoiesis is well 
depicted by genetic ablation studies in mice. Homozygous deletion of the C-terminal 
dimerization domain resulted in the generation of Ikaros
 
null mice (C-/-)
49
. C-/- mice 
present a complete absence of B cells and their precursors, dendritic APC and NK cells, 
both in foetal and post-natal stages. T cell precursors were not detectable in the thymus 
during foetal life, but appeared 3–6 days after birth at a hundredfold lower abundance 
compared to WT mice. Furthermore, these lymphocytes showed an impaired development 
skewed to the CD4
+ 
lineage, and hyper-proliferated when stimulated through their TCR. 
The erythro-myeloid lineage seems not to be affected by the Ikaros null mutation, as both 
erythro- and myeloid precursors and mature cells were found in bone marrow and spleen 
(Figure 1.5 A). A more severe phenotype was displayed by homozygous Ikaros dominant 
negative (DN-/-) mice, where the N-terminal zinc fingers 1, 2 and 3 were deleted, leading 
to the production of a protein that no longer binds to DNA but is still capable of 
dimerization with other Ikaros family members. Phenotypically, post-natal DN-/- mice 
displayed a rudimentary, nearly invisible embryonic thymus, and a complete absence of 
peripheral lymph nodes. Cytometric analysis of the bone marrow and rudimentary thymus 
revealed complete ablation of B, NK, dendritic and T cell precursors as well as mature 
cells. Only a small population of Thy-1
lo
 cells were detected in the bone marrow, probably 
representing early arrested B and T lymphoid progenitors. Like in the C-/- mice, the 
erythro-myeloid compartment did not show developmental impairment in DN
-/-
 mice, as 
erythrocytes and granulocytes were detected in both bone marrow and spleen
50
. However, 
extending the analysis up to 6 weeks, the DN-/- mice‟ haematocrit dropped to <50% 
compared to WT mice
51
 (Figure 1.5 B). 
Analysis of the bone marrow of heterozygous DN+/- mice displayed a normal phenotype, 
with T and B cell precursor abundance comparable to WT controls, until 2-3 months after 
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birth. At that point intermediate precursors of T cells started to accumulate in the thymus 
and spleen, and soon after mice developed T cell leukaemia or lymphomas with a very 
high degree of penetrance (95-100%)
52
 (Figure 1.5 C). 
 
Figure 1.5: Schematic representation of haematological deficiencies in Ikaros mutated mice. IKZF1 
null C-/- mice (A), homozygous Ikaros dominant negative DN-/- mice (B) and heterozygous Ikaros 
dominant negative DN+/- mice (C). Haematological deficiencies are highlighted in red. Impaired production 
of a certain progenitor is reported as a smaller picture compare to the other lineages. Leukemic cells are 
drawn with red edges. 
 
Taken together, these data depict a pivotal role for Ikaros in lymphopoiesis. The more 
severe phenotype shown by DN-/-
 
mice compared to the null-mutated C-/-
 
mice suggests 
aninterplay between Ikaros and other Ikaros family members during lymphoid 
commitment. Indeed, Aiolos and Helios are shown to heterodimerise with Ikaros and to 
have a role in T and B cell development
19,53
, supporting this hypothesis. 
The homozygous DN-/-
 
mouse model, with the complete depletion of all lymphoid-related 
lineages, tells us that Ikaros plays an important role at the very beginning of the lymphoid 
commitment, at the level of HSC or LMPP progenitors. To elucidate this point, further 
analysis on DN-/-
 
and C-/- mice were conducted, that revealed a 30-40% HSC long term 
repopulation rate reduction, indicating a role of Ikaros in self-renewal
51
. In the same study, 
molecular analysis of mRNA in HSC cells established a lack of expression of Flt3 and c-
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Kit tyrosine kinase receptors, implicated in B cell specification and HSC viability, 
respectively. 
 
The contribution of Ikaros to haematopoietic ontogeny was recently elucidated in a very 
elegant way by using a GFP reporter cassette under the control of the Ikzf1 promoter 
enhancer. By the analysis of bone marrow cells from transgenic mice, a GFP signal was 
detected in HSC progenitors and in the LMPP fraction, which maintain lymphoid and 
myeloid potential albeit with limited erythro-megakaryocyte potential. The same 
experiment repeated in Ikaros null cells showed the presence of LMPP progenitor cells that 
didn‟t express the Flt3 marker. These progenitors were unable to differentiate into the B 
cell lineage even in the presence of B cell specification factors in culture media, but 
preserved their ability to generate T lymphocytes (this observation could explain the origin 
of postnatal T lymphocytes in C-/- mice). However, these cells showed a skewed 
differentiation potential towards the myeloid lineage. Dissection of the role of Ikaros in 
erythro-myeloid development showed that during myeloid development Ikaros expression 
is restricted to the granulocyte-macrophage progenitors (GMP) branch, and is poorly 
expressed in megakaryocyte-erythrocyte progenitor cells (MEP). In Ikaros null cells, MEP 
cells numbers increased, whereas the GMP cell population decreased. Moreover, MEP 
cells displayed a skewed differentiation towards the megakaryocyte lineage, indicating that 
Ikaros is required for cell-fate decision during myelopoiesis, promoting GMP progenitors 
and erythroid differentiation
54
. 
 
The same authors conducted a microarray study on the same cell populations to clarify the 
mechanisms underlying Ikaros control on haematopoietic differentiation. In Ikaros
+/+
 GFP 
reporter mice, HSCs show expression of all haematopoietic lineages: erythroid, myeloid 
and lymphoid, in addition to self-renewal and stem cell related genes. Lineage-restricted 
progenitors were then analysed. MEP cells expressed only erythroid transcripts while 
LMPPs displayed a strong lymphoid and myeloid signature with a down-regulation of HSC 
and erythroid related genes. In GMP cells genes related to myeloid commitment were up-
regulated, but surprisingly retain a low level of expression of lymphoid specific genes 
(Figure 1.6). The same analyses were then performed on Ikaros-null C-/- HSC, LMPP and 
GMP cells. In the absence of Ikaros, lymphoid-related genes were strongly down-regulated 
in HSCs and all the other haematopoietic precursors. On the contrary, stemness-related 
genes were up-regulated in all progenitors‟ compartment, as well as myeloid priming genes 
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(Figure 1.6). Taken together, these data confirm the pivotal role of Ikaros in lymphoid 
commitment from the very first stages of haematopoiesis. They also indicate the 
importance of Ikaros in extinguishing the expression of stem cell and erythroid genes and 
in preventing the premature induction of myeloid genes
55
. 
 
Figure 1.6: A model of multilineage transcriptional priming and IKAROS contribution. Lineage-
specific transcriptional programs are all activated in HSC. Subsequent lineage restrictions are marked by 
changes in lineage-specific transcripts. A) The multilineage restriction process in Ikaros WT cells and B) in 
Ikaros null mice. Modified from Ng et al. 2009. 
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1.2 IKAROS AND LEUKAEMIA  
1.2.1 ACUTE LYMPHOBLASTIC LEUKAEMIA  
Acute lymphoblastic leukaemia (ALL) is a malignant clonal disease of the bone marrow in 
which lymphoblastic progenitors blocked at an early developmental stage (blasts) 
abnormally proliferate replacing the normal haematopoietic cells in the marrow. ALL is 
the most common childhood cancer, representing 80% of all leukaemias and 25% of all 
cancers that occur in children and adolescents, and can originate both from B cell (85%) 
and T cell (15%) lineages
56
. Leukemic cells arise from pre-leukemic clones as a result of 
accumulation of somatic genetic aberrations during life, often already starting in utero
57,58
. 
Nowadays leukaemia is considered a heterogeneous disease, characterized by different 
genetic alterations such as chromosomal translocations, aneuploidy, mutations in proto-
oncogenes or tumour suppressors, and focal deletions (Figure 1.7)
59,60
. Diagnosis of ALL 
is carried out by light microscopy inspection of bone marrow aspirate and 
immunophenotypic profiling using flow cytometry. Clinical studies during the past 70 
years identified a set of clinical and laboratory parameters that correlate with the patients‟ 
response to therapy
60–62
. Adverse prognostic markers include high leukocyte counts at 
diagnosis (WBC), age <1 year or >9 years, and adverse cytogenetic aberrations like the 
t(9;22) or MLL rearranged translocations, or acquired hypodiploid status. A combination 
of these markers is used in treatment protocols to stratify patients in groups based on risk 
of treatment failure. Patients with favourable markers are treated with less toxic regiments, 
while those showing high-risk factors attend more aggressive regiments. The patients‟ 
response to treatment is evaluated by detecting residual leukemic cells commonly indicated 
as minimal residual disease (MRD). MRD is typically detected by PCR amplification of 
the recombined immunoglobulin or T cell receptor gene rearrangement, and it has been 
shown to be a powerful independent prognostic marker in both paediatric and adult 
patients
63
. The introduction of risk-stratified treatment and multi-drug combination 
therapies result in a cure rate of more than 85% (or event free survival EFS) for ALL 
paediatric patients
64
. Nevertheless, in spite of great improvements in ALL treatment, 15% 
of patients still experience relapses or die and these patients now represent the new frontier 
of clinical and biomedical research in ALL. 
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Figure 1.7: Frequency of genetic subtypes in paediatric ALL. From Mullighan 2012. 
 
1.2.2 PHILADELPHIA POSITIVE B CELL ACUTE 
LYMPHOBLASTIC LEUKAEMIA 
The Philadelphia chromosome (Ph) was the first chromosomal aberration discovered in 
association with a human disease. In 1960 Nowell and Hungerford observed in adults with 
chronic myeloid leukaemia (CML) a chromosomal translocation, t(9;22) resulting in a 
reduced size of chromosome 22
65
. Later on, the translocation has been more precisely 
described as a reciprocal balanced translocation between chromosomes 9 and 22 
t(9;22)(q34;q11)
66
. The direct consequence of this translocation is the juxtaposition of the 
ABL1 gene on chromosome 9 and the BCR gene on chromosome 22, forming the chimeric 
gene BCR-ABL1. Wild-type ABL1 is a non-receptor tyrosine kinase expressed during 
haematopoiesis that shuttles between the cytoplasm and the nucleus. The N-terminus of 
ABL1 negatively regulates its kinase activity, and its loss as a consequence of the 
translocation results in a constitutive activation of the kinase activity
67
. The physiological 
function of the BCR protein is still unclear, but its major contribution in the chimeric 
protein seems to be related to its coiled-coil domain that facilitates dimerization and 
autophosphorylation, increasing the kinase activity of the fusion protein
68
. The 
autoactivation and autophosphorylation of BCR-ABL1 leads to a direct and indirect 
activation of multiple pathways including AMP, MTOR, PI3K, MAPK and a common 
downstream target of most of them, STAT5. The aforementioned pathways all converge 
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ultimately into a unique point: loss of control of proliferation and protection from 
apoptosis
69
. 
In addition to being the major cytogenetic aberration in CML BCR-ABL1 translocations are 
also detected in 2 to 3% of paediatric B cell precursor (BCP) ALL and in 20% of adult 
patients with ALL
60
. Despite its low incidence in children, Ph+ BCP ALL is still a major 
concern for clinicians as the presence of the Ph chromosome correlates with a very adverse 
prognosis. International efforts to help improve outcome of rare subgroups of ALL patients 
(Ponte di Legno childhood ALL consortium) reported a 7-years event free survival (EFS) 
and overall survival (OS) rates of 25 and 36% for 326 Ph+ ALL patients diagnosed 
between 1985 and 1996, and 32 and 45% for 610 Ph+ patients between 1995 and 2005. 
Relapse was the main cause of treatment failure, and haematopoietic stem cell 
transplantation (HSCT) in first remission was considered the best treatment option, 
although EFS and OS remained below 50% even with HSCT from a matched donor
70,71
. 
The development of tyrosine kinase inhibitor (TKI) based drugs initiated a new era in the 
treatment of Ph+ malignancies. Imatinib was the first small molecule developed to 
selectively target the BCR-ABL1 tyrosine kinase activity, by blocking the binding site for 
ATP
72
. The introduction of imatinib in the clinical protocols revolutionised the therapy for 
patients affected by CML, increasing the EFS at 5 years from 35% to over 80%
73
. In 2009, 
the Children Oncology Group (COG) published the results of the first paediatric clinical 
trial to evaluate the efficacy of imatinib in the treatment of Ph+ ALL. The 3-years EFS rate 
from the initial study was 80% compared to 35% in the pre TKI era, and the data was 
confirmed stable over time by new analysis showing a 7-years EFS rate of 71% compare to 
the 21.4% of the historical pre TKI group. The same study showed no additional benefit of 
HSCT on the outcome of patients, reassessing its importance for patients that respond 
poorly to the chemotherapy plus TKI
74,75
. A parallel study was conducted mainly in Europe 
to evaluate the efficacy of imatinib, the EsPhALL phase 3. In this study patients were 
classified as good or poor responders on the basis of the initial response to induction 
therapy, and then the study randomized the good-risk patients‟ chemotherapy with or 
without imatinib, while all poor-risk patients were ascribed to chemotherapy plus imatinib. 
The 4-years disease free survival (DFS) for good risk patients treated with imatinib was 
75.2% and 55.9% for those who received chemotherapy only. The EFS of the poor-risk 
population was 53.5%, still much higher than the classical EFS of patients in the pre-TKI 
era
76
. 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
31 
 
Although the encouraging results obtained by the introduction of imatinib in treatment of 
pediatric Ph+ ALL, 20-25% of patients still experience treatment failure or resistance to 
chemotherapy. Mechanisms of resistance of Ph+ ALL cells include duplications and 
increased BCR-ABL protein signalling, up-regulation of parallel pathways such as the Src-
family kinase pathway, and mutations occurring at the kinase domain that impair the 
efficient binding of imatinib
69,77
. To overcome these issues, second generation TKIs like 
nilotinib and dasatinib were developed
78,79
. These second generation drugs are more potent 
inhibitors of BCR-ABL1 in vitro, are generally active on the imatinib-resistant TKI 
mutations with the relevant exception of T315I mutation, and can trigger other kinase 
signal pathways, such as the Src-family pathway
80,81
. 
1.2.3 THE ROLE OF IKAROS IN ACUTE LYMPHOBLASTIC 
LEUKAEMIA 
The first link between IKAROS and leukaemia was established with the help of mice 
models. 
Mice heterozygous for a dominant negative mutation on Ikaros (DN+/-) developed 
aggressive forms of lymphoma or leukaemia with a high degree of penetrance. The blasts 
clonally developed in the thymus from T cell precursors, and showed a loss of the WT 
Ikzf1 allele in most of the cases
52
. A second breed of transgenic mice carrying a point 
mutation in the DNA-binding domain displayed an even more severe phenotype. T-cell 
leukaemia/lymphoma evolved in >65% of Ikaros
plstc/+ 
mice, while in homozygosity the 
mutation caused foetal mortality with severe anaemia, block of granulocyte differentiation, 
excessive macrophage formation and impaired lymphopoiesis
82
. A third mutated mouse 
was developed by Kirstetter et al. inserting, in frame, the LacZ gene in the second exon of 
Ikzf1. This hypomorphic allele produced a very low amount of truncated Ikaros protein 
(lacking the protein part encoded by exon2). All these mice developed T cell 
leukaemia/lymphoma in the thymus in an average of 20 weeks
83
. 
Several teams, driven by these results, investigated the putative role of IKZF1 in human T 
malignancies. Surprisingly, IKZF1 aberrations are rare in human T-ALL. A multi-
parameter study of 25 T-ALL investigating the IKAROS status at DNA (by array CGH), 
RNA (by RQ-PCR) and protein level (by western blot and immunofluorescence) reported 
only one case with defective IKAROS
84
. Whole genome sequencing (WGS) and 
transcriptome sequencing identified IKZF1 deletions/mutations in 9 out of 106 (8%) cases 
of paediatric early T-cell precursors (ETP) ALL
85
. 
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IKAROS aberrations in leukaemias: from IK6 to the deletions’ era 
Most of the initial studies that addressed the impact of IKAROS in human leukaemia 
focused on the expression pattern of IKZF1 isoforms. An analysis by RT-Q-PCR on 17 
bone marrow samples of CML in blast crisis revealed the presence of the dominant 
negative isoform IK6 in 5 out of 15 samples
86
. The absence of IK6 in chronic phase CML, 
as well as in normal granulocyte/macrophage and erythrocyte colonies, led to  the 
suggestion of  a pathogenic role of IK6 in human haematological malignancies, and in 
particular, on the progression to a blast crisis in CML
86,87
. By using the same approach, 
IK6 was detected in 14 out of 41 patients with B-cell ALL
88
. In the following years, studies 
demonstrated the presence of IK6 in paediatric and adult B-ALL, paediatric AML and 
more rarely, in T-ALL
87,89–91
. Interestingly, IK6 was more frequently detected in Ph+ 
paediatric ALL
88,92,93
. Inducing BCR-ABL1 expression in human or murine preB cells 
caused the appearance of IK6, and treatment with imatinib partially restored the aberrant 
expression of IK6
94
. In 2008, Iacobucci and colleagues showed the presence of IK6 in 91% 
of adult Ph+ ALL patients, and in 49% of the entire patient cohort IK6 was the 
predominant isoform. IK6 correlated with a higher percentage of blast cells at diagnosis 
(suggesting that expression of IK6 is associated only with blasts), and its percentage was 
higher in relapsed samples compared to diagnosis, indicating a role of IK6 in resistance to 
multidrug and TKI chemotherapy
89
. At that time, the production of the IK6 variant was 
thought to be caused by aberrant splicing, but analysis of the exon splice junction regions 
failed to reveal recurrent aberrations related to anomalous splicing
89,93,95
. 
The advent of the comparative genomic hybridization (CGH) technology shed new light on 
the IKZF1 status in BCP-ALL. In 2008, Mullighan and colleagues reported various IKZF1 
deletions (ΔIKZF1) in 76.2% of paediatric Ph+ BCP-ALL. The deletions were 
predominantly monoallelic and confined to a subset of IKZF1 exons, most frequently Δ4-7 
exons. The Δ4-7 deletion was reported to be the main cause of IK6 generation, as all 
patients with IK6 expression carried the Δ4-7 deletion. Moreover, other intragenic 
deletions, such as Δ3-7 and Δ2-7, were presented when dominant negative isoforms IK9 
and IK10 were observed, corroborating the observation that ΔIKZF1s are at the basis of 
dominant negative isoforms in human leukaemias
96
. ΔIKZF1 can be subdivided in 3 
different categories:dominant negative, haploinsufficient, and null deletions. Deletions 
spanning exons 4 to 7 (Δ4-7) and exons 3 to 7 (Δ3-7) are the most common in paediatric 
Ph+ ALL, occurring in 30% and 3.5% of patients respectively
97
. The RAG protein very 
likely causes these deletions, as the breakpoints in introns juxtaposed exons 3, 4 and 8 are 
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highly conserved and are flanked by recombination signal sequences. Other monosomic 
intragenic deletions occur in 22% of cases
96
. These deletions, depleting the DNA binding 
domain, give rise to dominant negative proteins. Monoallelic null deletions gathered focal 
deletions of exon 2 (containing the ATG start codon) or exon 8, which encode for the 
dimerization domain, and invariantly result in a reduced level of IKAROS, i.e. 
haploinsufficiency. Moreover, Chromosome 7 monosomy or large deletions of its short 
arm were classified as haploinsufficient deletions as well. Finally, biallelic deletions occur 
in about 13% of BCP ALL. These deletions are frequently null deletions, leading to a 
complete loss of IKAROS protein in the cell; these are named as null deletions
98
. Of note, 
some recent studies have revealed the presence of IK6 in the absence of the Δ4-7 deletion 
in a few cases of BCP ALL, suggesting that aberrant splicing can generate IKAROS 
dominant negative isoforms in leukaemia, but deletions remain the main cause of IK6 
production
99,100
. 
After 2008, subsequent studies have depicted the occurrence of ΔIKZF1 in paediatric and 
adult ALL: IKZF1 deletions are now known to occur in 70% of Ph+ BCP ALL
96,101
, 30% 
of high-risk paediatric BCP ALL
102
, 15% of general B cell ALL
96,103
, and in more than 
60% of adult CML in blast crisis
86,96
. These high incidences in leukaemias of distinct 
lineage origin provides strong evidence of a principal role for IKAROS in leukemogenesis. 
The leukemogenic role of IKAROS 
Despite the link between IKAROS and leukaemia being well established, the mechanisms 
underlying its leukemogenic effect are still elusive. Studies on transgenic murine models 
depicted Ikaros as a master regulator of early B lymphocyte development. Ikaros has been 
shown to negatively regulate pre-BCR signalling
31
 and positively regulate the recombinase 
activating genes Rag1 and Rag2
104
; thus promoting maturation of preB lymphocytes. 
Furthermore, in preB cells Ikaros binds and suppresses c-Myc expression, guiding cells 
from a potentially indefinite proliferation state to the resting and maturation stage
105
. 
Down-regulation of Ikaros, or expression of dominant negative variants, results in a block 
of differentiation at the early preB stage and a predisposition to leukaemia/lymphoma. 
From a clinical point of view, IKZF1 deletions seem to be associated with treatment 
resistance to glucocorticoids, leading to a decrease in apoptosis and increased proliferation 
compared to WT IKZF1 BPC ALL cells
106
. 
In order to elucidate the impact of ΔIKZF1 in ALL, a gene expression study on adult BCP-
ALL was set up. From the analysis of 31 ΔIKZF1 versus 20 IKZF1 WT patients, several 
pathways were down-regulated, such as B-cell differentiation, apoptosis and DNA repair, 
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while JAK-STAT signalling and haematopoietic stem cell affiliated genes were found to be 
up-regulated
101
. The up-regulation of HSC genes in Ikaros deficient mice was already 
known, and very recently this observation was corroborated by data from Churchman and 
colleagues demonstrating the efficacy of retinoic acid compounds in reversing the HSC-
like phenotype and increasing the response of murine Ph+ ΔIKZF1 BCP-ALL cells to 
TKIs
97
. 
Clinical impact of ΔIKZF1 
Clinical studies in the last decade linked IKAROS aberrations with prognosis in BCP-
ALL. The presence of ΔIKZF1s in paediatric patients is associated with a higher WBC, 
older age, and high MRD at day 29, all general markers of poor prognosis. Moreover, 
ΔIKZF1s are significantly more frequent in high risk patients, both stratified by MRD or by 
other clinical data according to national protocols. In separate cohorts with different 
treatment strategies IKAROS deletions, both focal and non-focal, confer poor prognosis in 
terms of overall survival (OS) and EFS, particularly due to an increased cumulative 
incidence of relapse (CIR) in ΔIKZF1 patients (Table 1.1)107–112. Indeed, IKZF1 deletions 
were the only sub microscopic genetic aberration that is detected at diagnosis and 
preserved at relapses in BPC-ALL, and can predict relapses
112
. Multivariate analysis 
identified ΔIKZF1s as an independent prognostic factor, in respect to gender, age, WBC, 
MRD and presence of cytogenetic abnormalities
102,113,114
. Of note, all these studies were 
conducted before the introduction of TKIs in the clinical practice; it would be interesting to 
investigate if these observations are still valid in the TKI era. 
Considering the high percentage of IKZF1 deletions in paediatric Ph+ BCP-ALL patients, 
a recent study estimated their impact before and after the TKI introduction in the clinical 
practice. In the pre TKI era, ΔIKZF1s conferred a worse disease free survival (DFS) rate 
compare to IKZF1 WT patients, mainly because of a higher incidence of relapse. In the 
imatinib era, IKZF1 deleted patients showed a trend of inferior DFS rate, without reaching 
significance. Interestingly, when the post-TKI group was subdivided in accordance with 
the early clinical response, IKZF1 deletions were predicative of a worse DFS rate in good-
risk stratified patients
103
. 
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Table 1.1: Clinical features of different cohorts of paediatric patients in relation to IKZF1 status. 
Adapted from Olsson & Johansson 2015. EFS, event free survival; CIR, cumulative incidence of relapse; 
MRD, minimal residual disease; HR, high risk; NR, not reported; del, deleted; WT, wild type; WBC, white 
blood cell count. * 5 years probability; † 4 years probability; ‡ 10 years probability; § 8 years probability 
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ΔIKZF1s are repeatedly reported to identify patients with a higher incidence of relapse and, 
overall, a lower incidence of EFS in different BCP-ALL sub-categories, including Ph+ 
ALL and the so called “B-other” patients that do not show any cytogenetic aberration at 
diagnosis
102,113
. For those reasons, some groups proposed to include IKZF1 status 
screening in clinical routine as a predictor of treatment failure in paediatric ALL. In this 
regard, some groups published results on the integration of IKZF1 status and MRD in 
paediatric patients classified as B-others and normally stratified as intermediate risk in 
clinical protocols
115,116
. In all these studies, IKZF1 was shown as an independent predictor 
of relapse, and its integration with MRD allows the prediction of 79% of relapses, more 
than based on MRD data alone
117
. 
IKZF1 SNPs and predisposition to leukaemia 
A first genome-wide association study (GWAS) on 907 British paediatric ALL cases 
compared to 2398 controls identified 10 SNPs mapping at IKZF1, ARID5B and CEBPE 
loci that were significantly enriched in the ALL population
118
. In particular, IKZF1 
rs4132601 SNP (that maps to the 3‟ region) showed the strongest correlation with ALL and 
its presence correlated with a significant reduction of IKZF1 mRNA. The same SNP was 
subsequently identified in another GWA study on a French cohort(441 ALL samples 
compared to 570 controls)
119
, and was confirmed as a risk variant in a German-British 
validation study
120
. Interestingly, a validation study of the impact of rs4132601 in a 
Chinese paediatric ALL cohort (570 ALL cases compared to 673 controls) did not find any 
significant correlation. The authors underlined that, in the European and in the Chinese 
populations, the SNP is present in different linkage-disequilibrium blocks, suggesting that 
this could be the cause of the different results obtained. Rs4132601 positively correlates 
with the age at diagnosis in a Polish study on 508 paediatric ALL patients, as homozygous 
carriers of the variant are significantly younger at the time of diagnosis than heterozygous 
and non-carriers
121
. The same SNP was shown to inversely correlate with AML diagnosis 
in a French cohort
122
. 
Another SNP, the rs11978267, was originally described to distinguish T-ALL from B-
other and B-hyperdiploid ALL in an European cohort of paediatric ALL, but the result was 
not confirmed in the validation cohort
123
. Interestingly, rs11978267 was then identified in 
the children oncology group‟s (COG) paediatric ALL cohort GWA study124 as positively 
correlated with B-ALL and infant ALL
125
. 
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De novo IKZF1-germline mutation: a case report 
An IKZF1 germline mutation was described in a newborn child affected by severe 
haematological condition soon after birth, with a severe anaemia and a general 
pancytopenia. The bone marrow aspiration at five days of age revealed a marked 
hypoplasia, with few erythroid precursors, absence of myeloid precursors, and abundance 
of lymphocytes. Immunophenotyping highlighted the absence of B- and NK cells, and an 
abundance of T cells with a normal CD4:CD8 ratio, skewed to the TCR-αβ expression. 
Because of the severe pancytopenia, the newborn underwent an allogeneic bone marrow 
transplant following a reduced intensity myeloablative treatment and followed by a 
cyclosporine plus methotrexate treatment to prevent graft versus host disease. Even if the 
neutrophil count increased after the bone marrow transplant, 40 days after the clinical 
condition of the patient kept deteriorating and died of multiorgan failure. As the bone 
marrow analysis revealed a phenotype similar to Ikzf1 knock-out mice models, the IKZF1 
status was evaluated by Sanger sequencing, identifying a heterozygous missense point 
mutation (p.Tyr210Cys) within the zinc finger 4 coding sequence. Immunofluorescence 
analysis performed on the newborn‟s peripheral blood mononuclear cells (PBMC) using an 
α-IKAROS antibody revealed a diffuse nuclear staining of the protein, indicating that the 
harboured-mutation caused a DNA-binding affinity impairment. Both child‟s parents were 
negative for the mutation, pointing out a de novo germline origin of the mutation that arose 
in the parent‟s gametes. 
Post-translational modifications of IKAROS and leukaemia 
IKAROS activity is controlled by several mechanisms, and could be impaired in leukemic 
cells even in the absence of genetic aberrations. The role of post translational modifications 
on IKAROS tumour suppressor activity has emerged in the last few years. Gene expression 
analysis of paediatric B-ALL cases expressing low levels of SKY or BTK kinases 
displayed deregulation of well-known IKAROS target genes, such as MEF2C, RAG1 and 
FLT3
14,15
. The inhibition of these two kinases in B-ALL results in down-regulation of 
IKAROS activity and its sequestration in the cytoplasm. CK2 kinase, another regulator of 
IKAROS, has been shown to be up-regulated in high-risk paediatric B-ALL. The up-
regulation of CK2 activity leads to inactivation of IKAROS and activation of cell-cycle 
related genes and the PI3K pathway. CK2 inhibition restored IKAROS activity in high-risk 
B-ALL cells heterozygous for ΔIKZF1, promoting cell-cycle arrest. The efficacy of 
pharmacological inhibition of CK2 was demonstrated in human leukemic xenograft mice, 
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where the subsequent restoration of IKAROS activity led to a reduction of blast cell 
proliferation and a prolonged survival of mice
126
. 
1.2.4 IKAROS IN OTHER MALIGNANCES 
Genome-wide association studies have linked IKZF1 to systemic lupus erythematosus 
(SLE), a complex autoimmune disease characterized by auto-antibody production and a 
complex phenotype. IKAROS SNPs rs10911362 and rs2362293, and the upstream SNP 
rs4917014 have been shown to confer susceptibility to SLE, with a higher risk of nephritis 
and decreased risk of facial rash
127–129
. IKAROS mRNA is significantly lower in SLE 
peripheral blood mononuclear cells (PBMC) compared to healthy controls, potentially due 
to the SNPs, even if a clear correlation is lacking
130
. The lower amount of IKAROS leads 
to an impairment of interferon signalling and the STAT4 pathway, well known pathways 
linked to SLE
127,128
. 
 
The rs10272724 (T>C) polymorphism correlates with a decreased risk of type I diabetes, 
another auto-immune disease where auto-antibodies trigger the pancreatic β-cells 
responsible for insulin production. The T>C allele was also protected in familiar cases of 
type I diabetes, even if the mechanism is unclear, as the protective allele does not result in 
expression differences of IKZF1 alleles
131
. 
 
The dominant negative isoform IK6 was detected in 36% of pituitary adenomas
132
. The 
same group previously demonstrated the importance of IKAROS in the regulation of the 
growth hormone (GH) and prostaglandin production as demonstrated by Ikaros null mice 
studies, and IKAROS is necessary for the correct development of the pituitary gland
133
. 
The presence of IK6 mediated cell growth and protection from apoptosis, mediated by up-
regulation of the anti-apoptotic protein Bcl-XL
134
, and by promoting the expression of the 
tumorigenic isoform FGFR4, that is transforming both in vitro and in vivo and causes 
pituitary tumours in mice
135–137
. 
 
IKAROS is down-regulated in over 60% of colorectal cancers by epigenetic promoter 
hypermethylation
138
. Deregulation of IKAROS target genes connected with tumour 
progression were demonstrated in colorectal primary tumours by its reintroduction in 
colorectal cells followed by ChIP-ChIP and RQ-PCR analysis. 
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
39 
 
REFERENCES 
 
1.  Olsson L, Johansson B. Ikaros and leukaemia. Br J Haematol. 2015 
May;169(4):479–91.  
 
2.  Cobb BS, Morales-Alcelay S, Kleiger G, Brown KE, Fisher AG, Smale ST. 
Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. 
Genes Dev. 2000 Sep 1;14(17):2146–60.  
 
3.  Laity JH, Lee BM, Wright PE. Zinc finger proteins: new insights into structural and 
functional diversity. Curr Opin Struct Biol. 2001 Feb;11(1):39–46.  
 
4.  Payne MA. Zinc finger structure-function in Ikaros Marvin A Payne. World J Biol 
Chem. 2011 Jun 26;2(6):161–6.  
 
5.  Ernst P, Hahm K, Smale ST. Both LyF-1 and an Ets protein interact with a critical 
promoter element in the murine terminal transferase gene. Mol Cell Biol. 1993 
May;13(5):2982–92.  
 
6.  Molnár A, Georgopoulos K. The Ikaros gene encodes a family of functionally 
diverse zinc finger DNA-binding proteins. Mol Cell Biol. 1994 Dec;14(12):8292–
303.  
 
7.  Schjerven H, McLaughlin J, Arenzana TL, Frietze S, Cheng D, Wadsworth SE, et 
al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc 
fingers of Ikaros. Nat Immunol. 2013 Oct;14(10):1073–83.  
 
8.  Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate 
Ikaros activity, a molecular control of lymphocyte development. EMBO J. 1996 Oct 
1;15(19):5358–69.  
 
9.  Payne KJ, Huang G, Sahakian E, Zhu JY, Barteneva NS, Barsky LW, et al. Ikaros 
isoform x is selectively expressed in myeloid differentiation. J Immunol. 2003 Mar 
15;170(6):3091–8.  
 
10.  Song C, Li Z, Erbe AK, Savic A, Dovat S. Regulation of Ikaros function by casein 
kinase 2 and protein phosphatase 1. World J Biol Chem. 2011 Jun 26;2(6):126–31.  
 
11.  Gurel Z, Ronni T, Ho S, Kuchar J, Payne KJ, Turk CW, et al. Recruitment of ikaros 
to pericentromeric heterochromatin is regulated by phosphorylation. J Biol Chem. 
2008 Mar 28;283(13):8291–300.  
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
40 
 
12.  Gómez-del Arco P, Maki K, Georgopoulos K. Phosphorylation controls Ikaros‟s 
ability to negatively regulate the G(1)-S transition. Mol Cell Biol. 2004 
Apr;24(7):2797–807.  
 
13.  Popescu M, Gurel Z, Ronni T, Song C, Hung KY, Payne KJ, et al. Ikaros stability 
and pericentromeric localization are regulated by protein phosphatase 1. J Biol 
Chem. 2009 May 15;284(20):13869–80.  
 
14.  Ma H, Qazi S, Ozer Z, Zhang J, Ishkhanian R, Uckun FM. Regulatory 
phosphorylation of Ikaros by Bruton‟s tyrosine kinase. PLoS One. 2013 
Jan;8(8):e71302.  
 
15.  Uckun FM, Ma H, Zhang J, Ozer Z, Dovat S, Mao C, et al. Serine phosphorylation 
by SYK is critical for nuclear localization and transcription factor function of 
Ikaros. Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18072–7.  
 
16.  John LB, Ward AC. The Ikaros gene family: transcriptional regulators of 
hematopoiesis and immunity. Mol Immunol. 2011 May;48(9-10):1272–8.  
 
17.  Perdomo J, Holmes M, Chong B, Crossley M. Eos and pegasus, two members of the 
Ikaros family of proteins with distinct DNA binding activities. J Biol Chem. 2000 
Dec 8;275(49):38347–54.  
 
18.  Morgan B, Sun L, Avitahl N, Andrikopoulos K, Ikeda T, Gonzales E, et al. Aiolos, a 
lymphoid restricted transcription factor that interacts with Ikaros to regulate 
lymphocyte differentiation. EMBO J. 1997 Apr 15;16(8):2004–13.  
 
19.  Wang JH, Avitahl N, Cariappa A, Friedrich C, Ikeda T, Renold A, et al. Aiolos 
regulates B cell activation and maturation to effector state. Immunity. 1998 
Oct;9(4):543–53.  
 
20.  Rebollo A, Ayllón V, Fleischer A, Martínez CA, Zaballos A. The association of 
Aiolos transcription factor and Bcl-xL is involved in the control of apoptosis. J 
Immunol. 2001 Dec 1;167(11):6366–73.  
 
21.  Caballero R, Setien F, Lopez-Serra L, Boix-Chornet M, Fraga MF, Ropero S, et al. 
Combinatorial effects of splice variants modulate function of Aiolos. J Cell Sci. 
2007 Aug 1;120(Pt 15):2619–30.  
 
22.  Hahm K, Cobb BS, McCarty AS, Brown KE, Klug CA, Lee R, et al. Helios, a T 
cell-restricted Ikaros family member that quantitatively associates with Ikaros at 
centromeric heterochromatin. Genes Dev. 1998 Mar 15;12(6):782–96.  
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
41 
 
23.  Sugita K, Hanakawa S, Honda T, Kondoh G, Miyachi Y, Kabashima K, et al. 
Generation of Helios reporter mice and an evaluation of the suppressive capacity of 
Helios(+) regulatory T cells in vitro. Exp Dermatol. 2015 Jul;24(7):554–6.  
 
24.  Lo K, Landau NR, Smale ST. LyF-1, a transcriptional regulator that interacts with a 
novel class of promoters for lymphocyte-specific genes. Mol Cell Biol. 1991 
Oct;11(10):5229–43.  
 
25.  Hahm K, Ernst P, Lo K, Kim GS, Turck C, Smale ST. The lymphoid transcription 
factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the 
Ikaros gene. Mol Cell Biol. 1994 Nov;14(11):7111–23.  
 
26.  Brown KE, Guest SS, Smale ST, Hahm K, Merkenschlager M, Fisher AG. 
Association of transcriptionally silent genes with Ikaros complexes at centromeric 
heterochromatin. Cell. 1997 Dec 12;91(6):845–54.  
 
27.  Brown KE, Baxter J, Graf D, Merkenschlager M, Fisher AG. Dynamic repositioning 
of genes in the nucleus of lymphocytes preparing for cell division. Mol Cell. 1999 
Feb;3(2):207–17.  
 
28.  Koipally J, Heller EJ, Seavitt JR, Georgopoulos K. Unconventional potentiation of 
gene expression by Ikaros. J Biol Chem. 2002 Apr 12;277(15):13007–15.  
 
29.  Li Z, Song C, Ouyang H, Lai L, Payne KJ, Dovat S. Cell cycle-specific function of 
Ikaros in human leukemia. Pediatr Blood Cancer. 2012 Jul 15;59(1):69–76.  
 
30.  Trinh LA, Ferrini R, Cobb BS, Weinmann AS, Hahm K, Ernst P, et al. Down-
regulation of TDT transcription in CD4(+)CD8(+) thymocytes by Ikaros proteins in 
direct competition with an Ets activator. Genes Dev. 2001 Jul 15;15(14):1817–32.  
 
31.  Thompson EC, Cobb BS, Sabbattini P, Meixlsperger S, Parelho V, Liberg D, et al. 
Ikaros DNA-binding proteins as integral components of B cell developmental-stage-
specific regulatory circuits. Immunity. 2007 Mar;26(3):335–44.  
 
32.  Sabbattini P, Lundgren M, Georgiou A, Chow C, Warnes G, Dillon N. Binding of 
Ikaros to the lambda5 promoter silences transcription through a mechanism that 
does not require heterochromatin formation. EMBO J. 2001 Jun 1;20(11):2812–22.  
 
33.  Kim J, Sif S, Jones B, Jackson A, Koipally J, Heller E, et al. Ikaros DNA-binding 
proteins direct formation of chromatin remodeling complexes in lymphocytes. 
Immunity. 1999 Mar;10(3):345–55.  
 
34.  Koipally J, Renold A, Kim J, Georgopoulos K. Repression by Ikaros and Aiolos is 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
42 
 
mediated through histone deacetylase complexes. EMBO J. 1999 Jun 
1;18(11):3090–100.  
 
35.  Naito T, Gómez-Del Arco P, Williams CJ, Georgopoulos K. Antagonistic 
interactions between Ikaros and the chromatin remodeler Mi-2beta determine 
silencer activity and Cd4 gene expression. Immunity. 2007 Nov;27(5):723–34.  
 
36.  Koipally J, Georgopoulos K. Ikaros interactions with CtBP reveal a repression 
mechanism that is independent of histone deacetylase activity. J Biol Chem. 2000 
Jun 30;275(26):19594–602.  
 
37.  Koipally J, Georgopoulos K. A molecular dissection of the repression circuitry of 
Ikaros. J Biol Chem. 2002 Aug 2;277(31):27697–705.  
 
38.  Payne KJ, Dovat S. Ikaros and tumor suppression in acute lymphoblastic leukemia. 
Crit Rev Oncog. 2011 Jan;16(1-2):3–12.  
 
39.  Zhang J, Jackson AF, Naito T, Dose M, Seavitt J, Liu F, et al. Harnessing of the 
nucleosome-remodeling-deacetylase complex controls lymphocyte development and 
prevents leukemogenesis. Nat Immunol. 2012 Jan;13(1):86–94.  
 
40.  Bottardi S, Mavoungou L, Milot E. IKAROS: a multifunctional regulator of the 
polymerase II transcription cycle. Trends Genet. 2015 Jul 3;  
 
41.  Busslinger M. Transcriptional control of early B cell development. Annu Rev 
Immunol. 2004 Jan;22:55–79.  
 
42.  Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev 
Immunol. 2011 Jul;11(7):478–88.  
 
43.  Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic 
stem cells is deterministic and isolatable by phenotype. Immunity. 1994 
Nov;1(8):661–73.  
 
44.  Adolfsson J, Månsson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, et al. 
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic 
potential a revised road map for adult blood lineage commitment. Cell. 2005 Apr 
22;121(2):295–306.  
 
45.  Singh H, Medina KL, Pongubala JMR. Contingent gene regulatory networks and B 
cell fate specification. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):4949–53.  
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
43 
 
46.  Zhang L, Reynolds TL, Shan X, Desiderio S. Coupling of V(D)J recombination to 
the cell cycle suppresses genomic instability and lymphoid tumorigenesis. 
Immunity. 2011 Feb 25;34(2):163–74.  
 
47.  Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation 
by pre-B-cell receptor signalling. Nat Rev Immunol. 2009 Mar;9(3):195–205.  
 
48.  Molnár A, Wu P, Largespada DA, Vortkamp A, Scherer S, Copeland NG, et al. The 
Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding 
proteins, highly conserved in human and mouse. J Immunol. 1996 Jan 
15;156(2):585–92.  
 
49.  Wang JH, Nichogiannopoulou A, Wu L, Sun L, Sharpe AH, Bigby M, et al. 
Selective defects in the development of the fetal and adult lymphoid system in mice 
with an Ikaros null mutation. Immunity. 1996 Dec;5(6):537–49.  
 
50.  Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, et al. The 
Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994 Oct 
7;79(1):143–56.  
 
51.  Nichogiannopoulou A, Trevisan M, Neben S, Friedrich C, Georgopoulos K. Defects 
in hemopoietic stem cell activity in Ikaros mutant mice. J Exp Med. 1999 Nov 
1;190(9):1201–14.  
 
52.  Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads 
to rapid development of leukemia and lymphoma. Cell. 1995 Oct 20;83(2):289–99.  
 
53.  Kelley CM, Ikeda T, Koipally J, Avitahl N, Wu L, Georgopoulos K, et al. Helios, a 
novel dimerization partner of Ikaros expressed in the earliest hematopoietic 
progenitors. Curr Biol. 1998 Apr 23;8(9):508–15.  
 
54.  Yoshida T, Ng SY-M, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic 
lineage restrictions directed by Ikaros. Nat Immunol. 2006 Apr;7(4):382–91.  
 
55.  Ng SY-M, Yoshida T, Zhang J, Georgopoulos K. Genome-wide lineage-specific 
transcriptional networks underscore Ikaros-dependent lymphoid priming in 
hematopoietic stem cells. Immunity. 2009 Apr 17;30(4):493–507.  
 
56.  Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a 
genetic update. Exp Hematol Oncol. 2014 Jan;3:16.  
 
57.  Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. 
Prenatal origin of acute lymphoblastic leukaemia in children. Lancet (London, 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
44 
 
England). 1999 Oct 30;354(9189):1499–503.  
 
58.  Cazzaniga G, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I, et al. 
Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in 
monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood. 2011 Nov 
17;118(20):5559–64.  
 
59.  Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008 Mar 
22;371(9617):1030–43.  
 
60.  Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013 
Jun 1;381(9881):1943–55.  
 
61.  Ghazavi F, Lammens T, Van Roy N, Poppe B, Speleman F, Benoit Y, et al. 
Molecular basis and clinical significance of genetic aberrations in B-cell precursor 
acute lymphoblastic leukemia. Exp Hematol. 2015 Aug;43(8):640–53.  
 
62.  Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights 
and treatment implications. Nat Rev Clin Oncol. 2015 Mar 17;12(6):344–57.  
 
63.  Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. 
Clinical significance of minimal residual disease in childhood acute lymphoblastic 
leukemia and its relationship to other prognostic factors: a Children‟s Oncology 
Group study. Blood. 2008 Jun 15;111(12):5477–85.  
 
64.  Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. 
Pediatr Clin North Am. 2015 Feb;62(1):61–73.  
 
65.  NOWELL PC, HUNGERFORD DA. Chromosome studies on normal and leukemic 
human leukocytes. J Natl Cancer Inst. 1960 Jul;25:85–109.  
 
66.  Rowley JD. Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. 
Nature. 1973 Jun 1;243(5405):290–3.  
 
67.  Franz WM, Berger P, Wang JY. Deletion of an N-terminal regulatory domain of the 
c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 1989 Jan;8(1):137–
47.  
 
68.  Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences 
essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 
regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991 Jul 
12;66(1):161–71.  
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
45 
 
 
69.  Cilloni D, Saglio G. Molecular Pathways: BCR-ABL. Clin Cancer Res. 2011 Dec 
8;18(4):930–7.  
 
70.  Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. 
Outcome of treatment in children with Philadelphia chromosome-positive acute 
lymphoblastic leukemia. N Engl J Med. 2000 Apr 6;342(14):998–1006.  
 
71.  Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. 
Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome-
Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. J Clin 
Oncol. 2010 Sep 27;28(31):4755–61.  
 
72.  Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects 
of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive 
cells. Nat Med. 1996 May;2(5):561–6.  
 
73.  Druker BJ, Guilhot F, O‟Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. 
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N 
Engl J Med. 2006 Dec 7;355(23):2408–17.  
 
74.  Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. 
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-
Positive Acute Lymphoblastic Leukemia: A Children‟s Oncology Group Study. J 
Clin Oncol. 2009 Oct 5;27(31):5175–81.  
 
75.  Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. 
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive 
acute lymphoblastic leukemia: Children‟s Oncology Group study AALL0031. 
Leukemia. 2014 Jul;28(7):1467–71.  
 
76.  Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. 
Imatinib after induction for treatment of children and adolescents with Philadelphia-
chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, 
open-label, intergroup study. Lancet Oncol. 2012 Sep;13(9):936–45.  
 
77.  Bernt KM, Hunger SP. Current concepts in pediatric Philadelphia chromosome-
positive acute lymphoblastic leukemia. Front Oncol. 2014 Jan;4:54.  
 
78.  Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et 
al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid 
leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 
2012 Feb 2;119(5):1123–9.  
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
46 
 
79.  Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib 
versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 
Jun 17;362(24):2251–9.  
 
80.  Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, et al. Imatinib 
resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children‟s 
Oncology Group (COG) study. Br J Haematol. 2012 May;157(4):507–10.  
 
81.  O‟Hare T. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 
against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer 
Res. 2005 Jun 1;65(11):4500–5.  
 
82.  Papathanasiou P, Perkins AC, Cobb BS, Ferrini R, Sridharan R, Hoyne GF, et al. 
Widespread Failure of Hematolymphoid Differentiation Caused by a Recessive 
Niche-Filling Allele of the Ikaros Transcription Factor. Immunity. Elsevier; 2003 
Jul 7;19(1):131–44.  
 
83.  Kirstetter P, Thomas M, Dierich A, Kastner P, Chan S. Ikaros is critical for B cell 
differentiation and function. Eur J Immunol. 2002 Mar;32(3):720–30.  
 
84.  Marçais A, Jeannet R, Hernandez L, Soulier J, Sigaux F, Chan S, et al. Genetic 
inactivation of Ikaros is a rare event in human T-ALL. Leuk Res. 2010 
Apr;34(4):426–9.  
 
85.  Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The 
genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 
Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights 
Reserved.; 2012 Jan 12;481(7380):157–63.  
 
86.  Nakayama H, Ishimaru F, Avitahl N, Sezaki N, Fujii N, Nakase K, et al. Decreases 
in Ikaros activity correlate with blast crisis in patients with chronic myelogenous 
leukemia. Cancer Res. 1999 Aug 15;59(16):3931–4.  
 
87.  Nakayama H, Ishimaru F, Katayama Y, Nakase K, Sezaki N, Takenaka K, et al. 
Ikaros expression in human hematopoietic lineages. Exp Hematol. 2000 
Nov;28(11):1232–8.  
 
88.  Nakase K, Ishimaru F, Avitahl N, Dansako H, Matsuo K, Fujii K, et al. Dominant 
negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic 
leukemia. Cancer Res. 2000 Aug 1;60(15):4062–5.  
 
89.  Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, et al. Expression 
of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic 
leukemia patients treated with tyrosine kinase inhibitors: implications for a new 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
47 
 
mechanism of resistance. Blood. 2008 Nov 1;112(9):3847–55.  
 
90.  Nishii K, Katayama N, Miwa H, Shikami M, Usui E, Masuya M, et al. Non-DNA-
binding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic 
leukemia. Leukemia. 2002 Jul 1;16(7):1285–92.  
 
91.  Meleshko AN, Movchan L V., Belevtsev M V., Savitskaja T V. Relative expression 
of different Ikaros isoforms in childhood acute leukemia. Blood Cells, Mol Dis. 
2008 Nov;41(3):278–83.  
 
92.  Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann W-K, et al. The 
BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in 
pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004 Mar 1;199(5):673–85.  
 
93.  Olivero S, Maroc C, Beillard E, Gabert J, Nietfeld W, Chabannon C, et al. Detection 
of different Ikaros isoforms in human leukaemias using real-time quantitative 
polymerase chain reaction. Br J Haematol. 2000 Sep;110(4):826–30.  
 
94.  Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, et al. BCR-
ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B 
lymphoblastic leukemia cells. Oncogene. 2006 Feb 16;25(7):1118–24.  
 
95.  Tonnelle C, Imbert M-C, Sainty D, Granjeaud S, N‟Guyen C, Chabannon C. 
Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B 
common adult acute lymphoblastic leukemias that express high levels of the CD34 
antigen. Hematol J. 2003 Jan;4(2):104–9.  
 
96.  Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 
lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008 
May 1;453(7191):110–4.  
 
97.  Churchman ML, Low J, Qu C, Paietta EM, Kasper LH, Chang Y, et al. Efficacy of 
Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer 
Cell. 2015 Aug 26;28(3):343–56.  
 
98.  Dupuis A, Gaub MP, Legrain M, Drenou B, Mauvieux L, Lutz P, et al. Biclonal and 
biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia. 
2013 Feb;27(2):503–7.  
 
99.  Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, et al. 
High frequency of IKZF1 genetic alterations in adult patients with B-cell acute 
lymphoblastic leukemia. Eur J Haematol. 2013 Sep 7;91(3):201–8.  
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
48 
 
100.  Volejnikova J, Mejstrikova E, Dörge P, Meissner B, Zimmermannova O, Svojgr K, 
et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by 
flow cytometry predict prognosis of childhood BCR/ABL-negative acute 
lymphoblastic leukemia. Pediatr Blood Cancer. 2013 Mar;60(3):420–7.  
 
101.  Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, et al. IKAROS 
deletions dictate a unique gene expression signature in patients with adult B-cell 
acute lymphoblastic leukemia. PLoS One. 2012 Jan;7(7):e40934.  
 
102.  Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of 
IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009 Jan 
29;360(5):470–80.  
 
103.  van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal S V, 
Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and 
IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor 
ALL. Blood. American Society of Hematology; 2013 Oct 10;122(15):2622–9.  
 
104.  Reynaud D, A Demarco I, L Reddy K, Schjerven H, Bertolino E, Chen Z, et al. 
Regulation of B cell fate commitment and immunoglobulin heavy-chain gene 
rearrangements by Ikaros. Nat Immunol. 2008 Jun 22;9(8):927–36.  
 
105.  Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and Aiolos inhibit pre-
B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010 
Sep;30(17):4149–58.  
 
106.  Ruiz A, Jiang J, Kempski H, Brady HJM. Overexpression of the Ikaros 6 isoform is 
restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a 
role in B-cell survival. Br J Haematol. 2004 Apr;125(1):31–7.  
 
107.  Ofverholm I, Tran AN, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A, et 
al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor 
ALL treated according to NOPHO protocols. Leukemia. 2013 Sep;27(9):1936–9.  
 
108.  Olsson L, Castor A, Behrendtz M, Biloglav A, Forestier E, Paulsson K, et al. 
Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a 
population-based series of pediatric B-cell precursor acute lymphoblastic leukemia 
diagnosed between 1992 and 2011. Leukemia. 2013 Jul 4;28(2):302–10.  
 
109.  Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, et al. IKZF 
1 and CRLF 2 gene alterations correlate with poor prognosis in Japanese BCR - 
ABL 1 -negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr 
Blood Cancer. 2013 Oct 27;60(10):1587–92.  
 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
49 
 
110.  Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, et al. IKZF1 
deletion is associated with a poor outcome in pediatric B-cell precursor acute 
lymphoblastic leukemia in Japan. Cancer Med. 2013 Jun;2(3):412–9.  
 
111.  Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, et al. What 
is the relevance of Ikaros gene deletions as a prognostic marker in pediatric 
Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? 
Haematologica. 2013 Aug;98(8):1226–31.  
 
112.  Kuiper RP, Waanders E, van der Velden VHJ, van Reijmersdal S V, Venkatachalam 
R, Scheijen B, et al. IKZF1 deletions predict relapse in uniformly treated pediatric 
precursor B-ALL. Leukemia. 2010 Jul;24(7):1258–64.  
 
113.  Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines 
JGCAM, Peters STCJM, et al. A subtype of childhood acute lymphoblastic 
leukaemia with poor treatment outcome: a genome-wide classification study. Lancet 
Oncol. 2009 Feb;10(2):125–34.  
 
114.  Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin J-P, et al. 
IKZF1 deletion is an independent predictor of outcome in pediatric acute 
lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. 
Haematologica. 2013 Mar;98(3):428–32.  
 
115.  Venn NC, van der Velden VHJ, de Bie M, Waanders E, Giles JE, Law T, et al. 
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion. 
Leukemia. 2011 Dec 9;26(6):1414–6.  
 
116.  Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V, et al. 
Breakpoint-specific multiplex polymerase chain reaction allows the detection of 
IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell 
precursor acute lymphoblastic leukemia. Haematologica. 2012 Oct 12;98(4):597–
601.  
 
117.  Waanders E, van der Velden VHJ, van der Schoot CE, van Leeuwen FN, van 
Reijmersdal S V, de Haas V, et al. Integrated use of minimal residual disease 
classification and IKZF1 alteration status accurately predicts 79% of relapses in 
pediatric acute lymphoblastic leukemia. Leukemia. 2011 Feb;25(2):254–8.  
 
118.  Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. 
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute 
lymphoblastic leukemia. Nat Genet. 2009 Sep;41(9):1006–10.  
 
119.  Orsi L, Rudant J, Bonaventure A, Goujon-Bellec S, Corda E, Evans T-J, et al. 
Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the 
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
50 
 
ESCALE study (SFCE). Leukemia. 2012 Dec;26(12):2561–4.  
 
120.  Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M, 
et al. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in 
precursor B-cell acute lymphoblastic leukemia of childhood. Blood. 2010 Mar 
4;115(9):1765–7.  
 
121.  Górniak P, Pastorczak A, Zalewska-Szewczyk B, Lejman M, Trelińska J, 
Chmielewska M, et al. Polymorphism in IKZF1 gene affects age at onset of 
childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2014 Sep;55(9):2174–8.  
 
122.  Rudant J, Orsi L, Bonaventure A, Goujon-Bellec S, Corda E, Baruchel A, et al. Are 
ARID5B and IKZF1 polymorphisms also associated with childhood acute 
myeloblastic leukemia: the ESCALE study (SFCE)? Leukemia. 2012 Aug 
27;27(3):746–8.  
 
123.  Treviño LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. 
Germline genomic variants associated with childhood acute lymphoblastic 
leukemia. Nat Genet. 2009 Sep;41(9):1001–5.  
 
124.  Linabery AM, Blommer CN, Spector LG, Davies SM, Robison LL, Ross JA. 
ARID5B and IKZF1 variants, selected demographic factors, and childhood acute 
lymphoblastic leukemia: a report from the Children‟s Oncology Group. Leuk Res. 
2013 Aug;37(8):936–42.  
 
125.  Ross JA, Linabery AM, Blommer CN, Langer EK, Spector LG, Hilden JM, et al. 
Genetic variants modify susceptibility to leukemia in infants: a Children‟s Oncology 
Group report. Pediatr Blood Cancer. 2013 Jan;60(1):31–4.  
 
126.  Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, et al. Epigenetic regulation of gene 
expression by Ikaros, HDAC1 and Casein Kinase II (CK2) in leukemia. Leukemia. 
Macmillan Publishers Limited; 2015 Dec 7;  
 
127.  Cunninghame Graham DS, Morris DL, Bhangale TR, Criswell LA, Syvänen A-C, 
Rönnblom L, et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with 
systemic lupus erythematosus. PLoS Genet. 2011 Oct;7(10):e1002341.  
 
128.  Hu S, Wen L, Hu X, Yin X, Cui Y, Yang S, et al. IKZF1: a critical role in the 
pathogenesis of systemic lupus erythematosus? Mod Rheumatol. 2013 
Mar;23(2):205–9.  
 
129.  Leng R-X, Wang W, Cen H, Zhou M, Feng C-C, Zhu Y, et al. Gene-gene and gene-
sex epistatic interactions of MiR146a, IRF5, IKZF1, ETS1 and IL21 in systemic 
lupus erythematosus. PLoS One. 2012 Jan;7(12):e51090.  
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
51 
 
 
130.  Hu W, Sun L, Gao J, Li Y, Wang P, Cheng Y, et al. Down-regulated expression of 
IKZF1 mRNA in peripheral blood mononuclear cells from patients with systemic 
lupus erythematosus. Rheumatol Int. 2011 Jun;31(6):819–22.  
 
131.  Swafford AD-E, Howson JMM, Davison LJ, Wallace C, Smyth DJ, Schuilenburg H, 
et al. An Allele of IKZF1 (Ikaros) Conferring Susceptibility to Childhood Acute 
Lymphoblastic Leukemia Protects Against Type 1 Diabetes. Diabetes. 2011 Jan 
26;60(3):1041–4.  
 
132.  Ezzat S, Yu S, Asa SL. Ikaros isoforms in human pituitary tumors: distinct 
localization, histone acetylation, and activation of the 5‟ fibroblast growth factor 
receptor-4 promoter. Am J Pathol. 2003 Sep;163(3):1177–84.  
 
133.  Ezzat S, Mader R, Fischer S, Yu S, Ackerley C, Asa SL. An essential role for the 
hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated 
somatic growth. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2214–9.  
 
134.  Ezzat S, Zhu X, Loeper S, Fischer S, Asa SL. Tumor-derived Ikaros 6 acetylates the 
Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol Endocrinol. 
2006 Nov;20(11):2976–86.  
 
135.  Abbass SA, Asa SL, Ezzat S. Altered expression of fibroblast growth factor 
receptors in human pituitary adenomas. J Clin Endocrinol Metab. 1997 
Apr;82(4):1160–6.  
 
136.  Ezzat S, Smyth HS, Ramyar L, Asa SL. Heterogenous in vivo and in vitro 
expression of basic fibroblast growth factor by human pituitary adenomas. J Clin 
Endocrinol Metab. 1995 Mar;80(3):878–84.  
 
137.  Yu S, Asa SL, Ezzat S. Fibroblast growth factor receptor 4 is a target for the zinc-
finger transcription factor Ikaros in the pituitary. Mol Endocrinol. 2002 
May;16(5):1069–78.  
 
138.  Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F, Corominas M, Grana O, Ciudad 
L, et al. Long-Range Epigenetic Silencing Associates with Deregulation of Ikaros 
Targets in Colorectal Cancer Cells. Mol Cancer Res. 2011 Jul 7;9(8):1139–51.  
 
  
CHAPTER 1.2: IKAROS AND LEUKAEMIA 
52 
 
 
CHAPTER 2: AIM OF THE THESIS 
53 
 
CHAPTER 2 
AIM OF THE THESIS 
The aim of the PhD project was to elucidate the role of the transcription factor IKAROS in 
leukemogenesis and in normal B-lymphocyte development. In the first part of the thesis we 
applied next generation amplicon deep sequencing to evaluate the presence and the role of 
IKZF1 aberrations in paediatric Ph+ ALL, uncovering a new class of IKZF1-aberrant 
patients, and we discovered the first case of a familial IKZF1 germline mutation that 
predisposes to leukaemia. In the second part of this thesis, we characterized 2 inducible 
Ikaros systems to study Ikaros-mediated gene expression and metabolic changes during 
cycling- to resting- preB cell stages. 
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ABSTRACT 
IKZF1 deletions are the second most frequent genetic alterations in pediatric Philadelphia-
positive B-cell precursor acute lymphoblastic leukaemia (Ph+ BCP-ALL), and are 
associated with poor outcome. We applied next-generation amplicon deep sequencing 
technology to investigate single nucleotide variants along the entire coding sequence of 
IKZF1 in 98 Ph+ IKZF1 non-deleted pediatric patients. We identified deleterious mutations 
in 12 out of 98 patients (12.2%): 5 missense point mutations and 7 frameshift mutations. 
Eight of 12 patients had aberrations in IKZF1 Exon4, of which, 6 were within the Zinc 
Finger 2 (ZF2) domain and 1 within ZF3. 
Compared to IKZF1 wild-type, IKZF1 status comprising mutations as well as deletions 
conferred a reduced disease-free survival (DFS) in Ph+ patients not treated with tyrosine 
kinase inhibitors (TKIs). Prognostic impact of IKZF1 mutations and deletions was less 
pronounced in patients treated with imatinib. 
 
                                                 
1
 This chapter is an extended version of the Letter to the Editor we published on LEUKEMIA, 2015 
Oct;29(10):2107-10. The original article is inserted in the Appendix of this thesis. 
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3.1 INTRODUCTION 
Philadelphia-positive B-cell precursor acute lymphoblastic leukaemia (Ph+ BCP-ALL) 
identifies an unfavourable subgroup of pediatric ALL characterized by the presence of the 
BCR-ABL1 chimeric protein
1
. However, Ph+ BCP-ALL is a clinically heterogeneous 
disease and although tyrosine kinase inhibitor (TKI) had improved outcome in pediatric 
patients, 30% still relapse or die
2
. 
Recurrent genomic deletions within the IKAROS (IKZF1) gene locus have been identified 
in Ph+ BCP-ALL
3
, and since their discovery, the biology and the clinical impact of the 
IKZF1 status has been intensively studied
4–6
. 
IKAROS is a transcription factor composed of two regions: the C terminal, including two 
zinc finger (ZF) domains, responsible for the homo-hetero dimerization of the protein
7
, and 
a N-terminal domain with four ZFs, responsible for the DNA binding activity: ZF2 and 
ZF3 ensure a stable DNA binding, while ZF1 and ZF4 regulate the interaction to specific 
genomic sites
8–10
. Deletions of IKZF1 can be subdivided into 3 categories: dominant-
negative deletions, characterized by loss of the DNA binding domain, deletions causing 
haploinsufficiency that lack the C-terminal dimerization domain, and null-deletions, that 
correspond to biallelic C-terminus deletions or loss of the ATG codon
11
. 
Even though the role of IKZF1 deletions as a prognostic factor has been extensively 
investigated, little is known about other genetic alterations
4,12,13
. The aim of this study was 
to assess the incidence of single-nucleotide mutations and in/del in the coding sequence of 
IKZF1 in patients described as IKZF1 WT with no evidence of deletions. 
3.2 MATERIAL AND METHODS 
Patients 
Leukemic bone marrow samples of 98 Ph+ BCP-ALL pediatric patients at diagnosis were 
analyzed in this study. The cases were collected from six European centres that 
participated in the “Ponte di legno” (pre-TKI) cohort and the European study for Ph+ ALL 
(EsPhALL) cohort, based on a combination of high-risk chemotherapy and imatinib 
treatment
2
. Sample preparation and IKZF1 deletion status (checked by MLPA) analysis 
were performed as described previously
14
. In addition, 61 paediatric Ph+ Ikaros deleted 
BCP-ALL patients derived from the “Ponte di Legno” and “EsPhALL” cohorts and 
included in van der Veer et al., 2014 were screened for IKAROS mutations. Written 
informed consent according to the Declaration of Helsinki was obtained from patients 
and/or parents/guardians. 
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454 next generation sequencing 
Sequence analysis of IKZF1 transcribed sequences, from Exon2 to Exon8, was performed 
using amplicon next generation sequencer GS Junior 454 (Roche Applied Science, 
Penzberg, Germany), using two-step universal-tailed amplicon sequencing. Briefly, during 
the first PCR the seven IKZF1 coding exons are amplified using specific primers (Table 
3.1) fused with “universal tail” sequences. The PCR products were then purified with 
agercount AMPure beads (Beckman Coulter Inc) following manufacturer‟s instructions. 
Then a second round PCR was carried out using universal primers and adding multiplex 
identifiers (MID)-labeled primers to barcode the samples. The amplicons were purified 
again with AMPure beads and quantified using PicoGreen (Invitrogen) following 
manufacturer‟s instructions. Amplicons were then diluted to the appropriate concentration 
and the obtained library was amplified by emulsion PCR and then sequenced by GS Junior 
454. The predicted coverage was 250 reads per amplicon (range 102-853 reads), with a 
minimum coverage of 50 reads in both strands. Sequences obtained were analyzed using 
Amplicon Variant Analyzed (AVA) Software (Roche Applied Science, Penzberg, 
Germany) (NCBI RefSeq NM_006060). All variants were compared with published SNPs 
databases (http://www.ncbi.nlm.nih.gov/projects/SNP/; http://cancer.sanger.ac.uk/ 
cancergenome/projects/cosmic/). To predict the functional impact of identified mutations, 
SIFT
15
 and PolyPhen2
16
 bioinformatic tools are applied. 
 
3.1: Primers used to amplify coding exons2-8 of IKAROS. 
 
Statistical Analysis 
DFS was calculated from date of ﬁrst remission to the date of event, which included 
relapse, death in complete remission, or second malignancy, whichever occurred ﬁrst. 
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Outcome was censored at the date of last patient contact when no events had been 
observed. Follow-up was carried out on December 31, 2008, for the pre-TKI cohort, and 
on December 31, 2010, for the EsPhALL cohort, with a median (interquartile range) 
follow-up of 5.0 years (2.8-6.0) and 2.8 years (1.5-3.7), respectively. The Kaplan-Meier 
method was used to estimate the probabilities of DFS with standard errors (SE) calculated 
according to Greenwood‟s method. Curves were compared using the log-rank test. All tests 
were two-sided. Analyses were performed using SAS 9.2 (SAS Institute, Cary, NC) at the 
EsPhALL Trial Center. 
Sanger Sequencing 
PCR reactions were performed using FastStart High Fidelity Taq Polymerase (Roche 
Diagnostic, D), using 10ng of patients genomic DNA. Primers used are described in Table 
3.1. PCR products were purified using Agercount Ampure XP beads (Beckman coulter, 
Inc. CA USA). Sequences were carried out using BigDye Terminator Kit (version 3.1, Life 
technologies) and run on the ABI 310 Analyzer (Life technologies). 
3.3 RESULTS 
98 samples at diagnosis of patients affected by Ph+ BCP-ALL with no IKZF1 
macrodeletions were collected for this study. The bone marrow samples were collected 
from 6 European centres: Associazione Italiana di Ematologia Pediatrica (Italy), the 
German Berlin-Frankfurt-Munster study group (Germany), the Childhood Leukemia 
Investigation Prague (Czech Republic), the Dutch Childhood Oncology Group (The 
Netherlands), the European Organization for Research and Treatment of Cancer Children‟s 
Leukemia Group, the French Acute Lymphoblastic Leukemia Study Group (France), and 
the Children‟s Cancer and Leukemia Group (United Kingdom). 
Sequencing analysis of IKZF1 coding exons, from exon2 to exon8, were performed using 
an amplicon sequencing strategy on the next generation sequencer GS Junior 454 platform. 
Today next generation sequencing (NGS)-based sequencing strategies are a well accepted 
robust substitute for Sanger sequencing
17
 that can be applied in a clinical setting. Moreover 
NGS reliably detects mutations well below the detection rate of Sanger sequencing, 
provides a precise mutant allele frequency rate (MAF), and allows a robust and sensitive 
detection of insertions or deletions. Sequences of 882 amplicons were collected with 
predicted average coverage per amplicon of 250 reads (range 102-853) and a minimum 
coverage of 50 reads in forward and reverse strands. In total, 313 variants were obtained. 
To identify predicted deleterious mutations a pipeline (Figure 3.1) was applied that 
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excluded intronic variants, homopolymeric stretches, known SNPs and silent mutations. In 
addition, a threshold of 10% of variants detection in both strands was set. Finally, 14 
variants were obtained  with predicted deleterious effects in the IKZF1 coding sequence 
corresponding to 12 distinct mutations in 12 out of 98 patients (12.2%) including three 
patients from three different centres that were carrying the same mutation (Figure 3.2A and 
Table 3.2). 
 
Figure 3.1: Sequence analysis pipeline to retrieve potential deleterious variants. A total of 313 variants 
were obtained from NGS. From them, we excluded variants presented in intronic regions as well as variants 
called in homopolymeric sequencing or in overlapping regions between 2 different amplicons but present in 
one of them only. Finally we excluded variants present in less than 10% of the reads for a quality parameter, 
and variants already known as SNPs or new silent mutations. 
 
The 12 mutations can be subdivided into 2 categories: mutations localized in the DNA 
binding domain with a predictive dominant-negative effect (5 missense mutations), and 
haploinsufficiency aberrations, predicted to affect dimerization of IKAROS indirectly 
impairing DNA binding (7 frameshift mutations). 
The 5 missense mutations were located in exon5, of which 4 were localized within the ZF2 
coding sequence, essential for DNA-protein interaction. All missense mutations were 
predicted to be “probably deleterious” by PolyPhen216 (score 0.999) and “damaging” by 
SIFT
18
 (score 0.001) bioinformatic tools. 
Regarding the mutated amino acids in the ZF2 domain, Asn159 and Arg162 (Figure 2A) 
are known to be crucial for the maintenance of the α-helix domain structure, and their 
substitutions are described to impaired the DNA binding activity of the protein
9
. The 
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Cys150 (mutated into Arg) is one of the 4 Cys/His residues that coordinate the zinc atom 
of the domain, and the mutation is predicted to severely impair the function of the domain 
as well. Of note, the p.Asn159Ser (c.A476>G) substitution is carried by 3 patients (3% in 
our study cohort). Altogether 6 patients carried point mutations in the ZF2 coding sequence 
with a predicted deleterious impact. 
The 7 frameshift mutations (2 deletions, 4 insertions and 1 Indel) were identified at 
different positions within the IKZF1 locus, 2 in exon5, 1 in exon7 and 4 in exon8. These 
mutations cause shifts in the reading frame that predict formation of premature stop codons 
and consequent depletion the C-terminal dimerization domain of the protein. 
 
 
 
 
Figure 3.2: Ikaros aberrations in pediatric Ph+ BCP-ALL. A) Location and type of IKZF1 mutations: 
grey squares define the coding exons of IKZF1; red squares represent the zinc-finger domains. Each circle 
represents a detected mutation. B) Overview of IKZF1 in Ph+ BCP-ALL pediatric patients. Distributions 
were calculated for each group on the basis of the number of IKZF1-mutated patients detected by amplicon 
NGS in 98 patients. NGS, next-generation sequencing. 
 
The Mutant Allele Frequency (MAF) of IKZF1 mutations compared to the blast cells count 
was in most cases consistent with heterozygous mutation in the entire blast population; 
only in three cases (MRC-UK-12, BFM-G-1 and AIEOP-24) MAF suggested a IKZF1 
mutated subpopulation. Two patients carried double mutations: in one case, the 2 
mutations in exon5 were reciprocally exclusive (p.Glu142Profs*49 and p.Arg143Gln), 
whereas in the second case mutations were located in different exons (p.Leu160Val in 
Exon5 and p.Arg274* in Exon7). In both cases one of the two mutations was present at a 
A 
B 
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higher MAF (63% for p.Glu142Profs* vs. 22% for p.Arg143Gln, and 58% for 
p.Leu160Val vs. 36% for p.Arg274*), indicating the presence of leukemic sub-populations 
characterized by different IKZF1 mutations. For six of 12 mutated patients the remission 
samples were available, and Sanger sequencing was applied to screen for possible germline 
origin of the mutations. Among these, one patient displayed the same mutation in his 
leukaemia-free bone marrow sample. The mutated exon of the remission sample was then 
sequenced using GS Junior 454 to obtain the MAF at remission. The mutation, a single-
nucleotide deletion within the zinc finger 3 coding sequence was present in 52- and 50% of 
the reads at diagnosis and at remission respectively, indicating a potential germline nature 
of the mutation. This case will be further discussed in the forth chapter of this thesis. 
The clinical characteristics of the 12 mutated patients are described in Table 3.2. Among 
the 6 mutated patients that had been treated before the introduction of TKI (pre-TKI 
cohort) 4 relapsed and 1 died in continuous complete remission (CCR). The latter is in line 
with the previously reported impact of IKZF1 deletions in pre-TKI patients and suggests 
that IKZF1 mutations behave in the same manner as deletions in terms of their associations 
with poor outcome in Ph+ patients. Of the 6 mutated patients that were treated with 
imatinib (EsPhALL cohort) one failed (died in CCR), which is in line with the behaviour 
of IKZF1 deleted patients in the imatinib era. 
 
Table 3.2: clinical characteristics of mutated patients. The characteristics of mutated patients do not 
differ significantly from patients enrolled in the Van der Veer study
 
in terms of sex (p=1), age (p=0,37) and 
early response (p=0,06).  *Early clinical Response was defined as <1000 cells/μL in peripheral blood after 7 
days of treatment with prednisone and a single intrathecal dose of methotrexate, or ≤5% leukemic blast cells 
in the bone marrow at day 21 (depending on national induction protocols). WBC, White Blood Cell Count; 
AlCCR, alive continuous complete remission; CCR, Clinical Complete Remission; MAF, mutant allele 
frequency calculated as number of mutated reads/number of total reads. 
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Recently, we reported the impact of IKZF1 deletions on outcome of Ph+ BCP-ALL
14
. This 
study included 191 patients; 84 recruited in the pre-TKI cohort and 107 in the EsPhALL, 
post TKI cohort. Overall, 65 patients  (40%) were defined as „wild-type‟ on the basis of the 
absence of IKZF1 deletions, and among them, 64 where included in our screening (one was 
excluded due to lack of material) (Figure 3.2A). Six of these carried IKZF1 deleterious 
mutations, 3 from the pre-TKI cohort and 3 from the EsPhALL cohort. 
IKZF1-mutated and -deleted patients were grouped together (N=132, „IKZF1-aberrant‟ 
patients) and their outcome compared to that of „true‟ WT IKZF1 (without deletion or 
mutations) Ph+ BCP-ALL patients (N=59). The new DFS curves of pre-TKI and EsPhALL 
cohorts confirmed the poor prognosis of patients with IKZF1 aberrations (deletions plus 
mutations) (4-year DFS 28.1% [SE 6.4] vs. 64.3% [SE 9.7], P=0.0036 in pre-TKI; 4-year 
DFS 55.7% [SE 6.8] vs. 59.8% [SE 11.6] (P= 0.348) in EsPhALL) (Figure 3.2C). 
 
 
Figure 3.2: Description and outcome of IKZF1- aberrant and -WT cohorts. A) Scheme of the Ph 
positive BCP ALL patient cohort analyzed by MLPA and patients subsequently analyzed by amplicon NGS 
for IKZF1 aberrations at the single nucleotide level. B) Percentages of different IKZF1 deletions in IKZF1-
deletet cohort. C) Outcome by IKZF1 status in pre- and post-TKI cohorts. DFS was analyzed in patients with 
and without IKZF1 aberrations (deletions and missense/frameshift mutations) in pre TKI cohort (IKZF1-
aberrant n = 58; IKZF1-wild-type n = 26) (Top), in EsPhALL cohort (IKZF1-aberrant n = 74; IKZF1-wild-
type n = 33) (Bottom) 
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As IKZF1 mutations could also occur in conjunction with IKZF1 deletions
19
, we screened 
by GS Junior 454 61 pediatric Ph+ BCP-ALL samples at diagnosis previously identified as 
IKZF1 deleted
14
. We sequenced Exons 4 and 8 as they are the exons most frequently 
mutated in the previous IKZF1 wild type cohort. 39% of deleted patients carried the most 
common Δ4-7 deletion, 17% carried the Δ2-7 and 22% of them carried monosomy of 
chromosome 7 or large deletions that comprehend the entire IKZF1 locus (Figure 3.2B). 
We identified point mutations in 3 patients: p.R143>W (probably deleterious” for 
PolyPhen2 and “damaging” for SIFT), p.L411>F (probably deleterious for PolyPhen2 and 
neutral for SIFT) and p.I509>T (possibly damaging for PolyPhen2 and damaging for 
SIFT). The MAF of the variants (28% for p.R143>W, 11.5% for p.L411>F and 12.8% for 
p.I509>T) suggest the presence of an IKZF1-mutated blasts subpopulation.  p.I509>T and 
p.R143>W are carried by 2 patients presenting a Δ4-7 deletion, while p.L411>F is present 
in conjunction with the Δ2-7 deletion. The p.R143>W is necessary located in the non-
deleted allele, as located in the exon4, whereas the other 2 single-nucleotide mutations, 
located in exon8, it is not possible to know whether they occurred in the deleted or the non-
deleted allele. 
3.4 DISCUSSION 
In conclusion, this work has demonstrated the presence of IKZF1 mutations in >10% of 
pediatric Ph+ BCP-ALLs previously classified as IKZF1 WT on the basis of deletion 
analysis alone. The higher incidence of IKZF1 mutations identified in our study compare to 
previous papers
19,20
 can be attributed to the difference in  sensitivity of technologies (NGS 
in our study and Sanger sequencing in the others
19,20
). NGS is more sensitive and permits 
to identify mutations present in percentages lower than the detection limit of Sanger 
sequencing. This data strengthened our decision to take advantage of NGS for our 
screening to depict a more comprehensive landscape of IKZF1 alternations in Ph+ pediatric 
ALL patients. 
Exon5, which encodes for ZF2 and ZF3 domains, carried 9 out of 14 aberrations: 7 point 
mutations and 2 deletions. The presence of the high number of mutations in these domains 
and the recurrence of one of the mutations in 3% of patients prompted us to consider this 
region as a hotspot locus for mutation acquisition. All missense mutations are predicted to 
be deleterious by two bioinformatic tools and by in vitro mutagenesis studies
9
, and all  
small in-del aberrations lead to the formation of premature stop codons. Overall, our 
observations have contributed to the refinement of DFS analysis of Ph+ BCP-ALL patients 
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with IKZF1 aberrations. Separate Kaplan Meyer curves for IKZF1 deleted, mutated, and 
WT patients are not feasible, due to the small number of mutated patients for which 
complete clinical data were available. Nevertheless, considering the pre- and post- TKI 
cohorts, some observations can be made. In the pre-TKI cohort, IKZF1-mutated patients 
showed a similar outcome as compared to IKZF1 deleted patients (four out of six patients 
experienced an adverse event, such as relapse or death). The prognostic impact of the 
IKZF1 mutations in imatinib-treated patients is more attenuated and may indicate the 
presence of other pathogenic mechanisms
21
, as well as a possible effect of  TKI therapy on 
the activation status of IKZF1. Recently, another group published an IKZF1 mutational 
screening in pediatric ALL patients with different cytogenetic characteristics using 
Illumina MultiSeq sequencing
13
. They Identified IKZF1 mutations in 5.7% of patients (9 
out of 140 patients), none of them in BCR-ABL1 subgroup, probably due to the very low 
number of Ph+ patients included in their screening (6 out of 140 patients). Of note, 5 out of 
9 IKZF1-aberrations (3 point mutations and 2 indels) occurred in the exon 5, corroborating 
our observation of an increased mutational rate in this locus. IKZF1 mutated and WT 
patients do not significantly differ in terms of EFS and CIR, but when IKZF1 deletions and 
mutations are combined, aberrant IKZF1 patients presented a lower EFS compare to IKZF1 
WT patients. Considering the high incidence of nucleotide aberrations observed in our 
study (and in the Olsson L. et al., study, in a more heterogeneous cohort of pediatric 
leukemic patients), in both IKZF1 deleted or non-deleted patients, we would like to stress 
the importance of including these mutations in the overview of IKZF1 aberrations (Figure 
3.3). This new category of IKZF1 mutated patients, previously masked in the IKZF1 WT 
group, behaves in a way similar to IKZF1 deleted patients in both the pre and post TKI era, 
and needs to be considered for a precise estimation of the impact of aberrant IKZF1 in 
leukemogenesis and disease progression. 
Figure 3.3: Overview of IKZF1 status in Ph positive BCP-ALL pediatric patients. Percentages were 
calculated for each group based on the number of IKZF1 mutated patients detected by NGS Amplicon 
sequencing in 98 non deleted and 61 deleted IKZF1 patients. The IKZF1 mutations detected in IKZF1 
deleted patients were: p.R143>W, p.L411>F and p.I509>T. 
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ABSTRACT 
Although leukaemia is a somato-genetically well characterized disease, the bases of 
familial predisposition are poorly understood. Among leukemic hallmark aberrations, 
deletions of the lymphocyte transcription factor IKZF1 are described to occur in 15% of 
BCP-ALL paediatric patients. Here we report the first case of a family showing 
transmission of a heterozygous single nucleotide deletion of the IKZF1 coding sequence. 
The deletion causes a reading frame shift resulting in a depletion of the dimerization-
activation domain, leading to haploinsufficiency in cells where IKAROS is expressed. The 
mutation is found in three generations of the family of which 5 cases were positive and 6 
cases were negative for the mutation. Two members of the family in subsequent 
generations presented with pediatric leukaemia. The aberrant transcript was identified in 
bone marrow of the proband at diagnosis and remission and in peripheral-blood cells of an 
unaffected relative, and the truncated protein presented a diffuse nuclear localization in a 
cellular model, indicating impaired DNA binding. This is the first family with recurrent 
pediatric leukaemia in two generation associated with transmission of a deleterious 
heterozygous mutation in IKZF1, even if penetration of leukaemia is low. 
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4.1 INTRODUCTION 
Acute Lymphoblastic Leukaemia, a malignant disorder of the hematopoietic lymphoid 
progenitors in the bone marrow, is the most common pediatric leukaemia, as well as the 
leading cause of childhood cancer-related mortality
1
. The disease is characterized by 
distinct somato-genomic alterations, including aneuploidy and chromosomal re-
arrangements, and is further known to carry other submicroscopic DNA aberrations, such 
as small deletions/insertions or point mutations affecting genes involved in cell cycle 
regulation, apoptosis or lymphoid differentiation
2
 
A particular unfavourable subgroup of acute leukaemia carries a somatic t(9;22) 
translocation encoding the BCR-ABL1 tyrosine kinase chimeric protein
3
. Despite the 
advent of tyrosine kinase inhibitors (TKI) that improved outcome of patients up to 70%, 
one third of pediatric patients with a t(9;22) translocation still suffer of relapse or decease 
during treatment
4
. 
IKZF1 is a Zinc Finger transcription factor primary involved in the specification and 
differentiation of the lymphoid lineage by activating the lymphoid transcription program 
and repressing the stem cell and myeloid/erythroid differentiation program in 
hematopoietic stem cells
5,6
. 
The most common IKZF1 alterations are intragenic deletions of exons Δ3-6 (30% IKZF1 
aberrations) or exons Δ1-6 (15%), followed by other deletions of other combined-exons or 
large chromosome 7 deletions
7
. Despite pediatric ALL is a well characterized disease, little 
is known about genetic predisposition to leukaemia development
8
. Familial studies on 
Swedish offspring databases revealed a higher probability to develop leukaemia in 
individuals with affected siblings. These data are significant for individuals affected by 
AML
9
, while the correlations between an ALL-affected sibling and probability to develop 
ALL is significant only in twins cases
10
. The latter could be attributed to the prenatal origin 
of leukemic cells in one twin that in utero passed to the co-twin. Only recently, a recurrent 
mutation of PAX5 has been found in three unrelated families
11,12
 with familial 
predisposition to B-ALL, linking the familial predisposition  to leukaemia to a well-known 
somatically mutated gene in B-ALL. 
In 2013, a case of a newborn child carrying an IKZF1 de novo germline mutation was 
described
13
. The newborn presented pancytopenia, selective B and NK lymphopenia and a 
T cell differentiation skewed for the TCR-αβ positive cells. Sanger sequencing analysis 
revealed a p.Tyr210Cys missense point mutation in the zinc finger 4 domain. The mutation 
resulted in DNA-binding affinity impairment and a consequent diffuse nuclear localization 
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of IKAROS. The newborn died of multi-organ failure within 40 days. Both parents 
displayed 2 copies of wt-IKZF1. 
In the previous chapter of this thesis, we reported a screening of aberrations at the IKZF1 
locus, such as point mutations or very small insertions/deletions of pediatric Philadelphia 
positive B cell precursor Acute Lymphoblastic Leukaemia (Ph+ BCP-ALL). Analysis 
performed on remission samples of IKZF1 mutated patients revealed that one patient 
carried a mutation at a high mutation frequency in the leukemic-free bone marrow, 
suggesting a potential germline origin of the mutation. Here we investigated the 
segregation of this mutation in the family of the proband and report preliminary molecular 
characterization of IKZF1 c.556_delG. 
4.2 MATERIAL AND METHODS 
Sleeping beauty system 
IKZF1 wt or c.556_delG coding sequences, fused with FLAG, were cut using the SfiI 
restriction enzyme and subsequently cloned into the p.UC19 vector between 2 tandem 
inverted repeats sequences, under the control of the EF1a promoter. A PGK promoter 
controls the translation of a polycistronic mRNA cassette encoding for GFP and a 
puromycin resistant protein. 
In order to establish a stable cell line, HeLa cells were co-transfected with IKZF1-sleeping 
beauty vectors and SB-transposase vectors BS100X
14
. Transfection was carried out using 
FuGENE®-transfections following manufacturer‟s instructions. Twenty-four hours after 
transfection, positive transfected cells were selected by 1μg/ml of puromycin for 3 days. 
HEK-293T transfection 
For transient transfection, p.RRL vectors containing IKZF1 wt or c.556_delG coding 
sequences fused with FLAG and a GFP reporter gene were used. 4µg of p.RRL vector 
were added to 500 µl of 0.4M CaCl2 solution. 500µl of 2x HEBS (12mM dextrose, 50mM 
HEPES, 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4 + 2H2O in sterile water) were then 
added to the plasmid mix drop by drop. The transfecting solution was then added to cells 
drop by drop. The cell medium was changed 12h after transfection. 
Immunofluorescence 
Cells were incubated for 24h in multi well chamber slides. Cells were washed with PBS
-/-
 
and fixed with 4% paraformaldehyde (PFA) in PBS-/- for 10‟ at room temperature. Fixed 
samples were washed twice in PBS
-/- 
and then permeabilized with 0.5% of TritonX-100 for 
5‟. Cells were incubated for 30‟ at room temperature with blocking solution (3% normal 
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goat serum, 0.1% TritonX-100 in PBS-/-). Primary antibodies were diluted 1:1000 in 
blocking solution and added to the samples overnight at 4 °C in a humidity chamber. 
Coverslips were washed 3x with PBS-/-
 
and incubated with secondary antibodies 
conjugated with appropriate fluorophores diluted 1:10000 in blocking solution for 1h at 
room temperature in a humidity chamber in the dark. Coverslips were washed 3x PBS-/- 
and mounted in Vecatsheald (Vector laboratories) with DAPI 0.1µg/ml. samples were 
visualised using a Leica DMBL microscope. Images were analysed using Leica IM1000 
software. 
Reverse transcription 
Reverse transcription was performed using Superscript First-Strand Synthesis system 
(Invitrogen). 1µg of RNA was mixed with 1µl of 10mM dNTPs mix and 1µl of 0.25mM 
random primers, topped up to 13µl with RNase-free H2O. The RNA mix is incubated at 65 
°C for 5‟ and then 1‟ at 4 °C. A mix composed by 1µl of 0.1M of DTT, 1µl RNasi-OUT, 
5µl of 4x first strand buffer and 1µl of 200U/µl Superscript III reverse transcriptase was 
added to the RNA mix. The final mix was incubated at 25 °C for 5‟, at 50 °C for 1h and at 
75°C for 15‟. The obtained cDNAs were diluted 10x. 
Sanger Sequencing 
PCR reactions were performed using FastStart High Fidelity Taq Polymerase (Roche 
Diagnostic, D), using 10ng of patient‟s genomic DNA or 10ng of cDNA. Primers used are 
reported here below. PCR products were purified using Agercount Ampure XP beads 
(Beckman coulter, Inc. CA USA). Sequencing was carried out using the BigDye 
Terminator Kit (version 3.1, Life technologies) and run on the ABI 310 Analyzer (Life 
technologies). 
DNA_IKZF1_Exon5_fw AAGGAGCTGGCAGGTTTAGTC 
DNA_IKZF1_Exon5_rv GGTTAGCCAGCAAGGACACA 
c.DNA_IKZF1_Exon5_fw CCCTTCAAATGCCACCTCT 
c.DNA_IKZF1_Exon5_rv AGGTCTTCTGCCATTTCACTG 
rs4132601_fw TCTGCTCACAGAAGGGTGTG 
rs4132601_rv AGGAAAGGGCAAAGCAGTTT 
Protein extraction and quantification 
One to 3 x106 cells are washed once in cold PBS-/- supplemented with protein inhibitor 
cocktail (Roche) and then resuspended in 1 volume of cold PBS-/- supplemented with 
protein inhibitor cocktail. One volume of 2x sample buffer (100mM Tris pH 6.8, 20% 
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glycerol and 2% of sodium dodecyl sulphate (SDS)) is added to cells, and the cell mix is 
subsequently boiled at 95 °C for 10‟. Protein concentration is measured using the 
PierceTM BCA protein assay kit (Thermo scientific) according to manufacturer‟s 
instruction. After quantification, 10% v/v of β-mercaptoethanol and 0.002% of 
bromophenol blue are added to the protein assay. Proteins are stored at -20 °C. 
Western blot 
Proteins and Benchmark pre-stained protein ladder (Beckman) are loaded on a SDS-
polyacrylamide gel. The gel is formed by an upper staking gel (4% w/v acrylamide, 
125mM Tris-HCl pH 6.8, 0.1% SDS, 0.067% ammonium persulphate (APS) and 0.12% 
N,N,N‟tetramethylethylenediamine (TEMED)) and a running gel (10% acrylamide, 
390mM Tris-HCl pH 8.8, 0.1% SDS, 0.05% APS and 0.1% TEMED). Bio-Rad minigel 
system is used for the electrophoretic run together with running buffer (25mM Tris base, 
192mM glycin and 0.1% SDS). The electrophoretic run is performed at 30mA per gel for 
90‟. Proteins are transferred to polyvinylidene fluoride (PVDF) using the trans-blot® SD 
semi-dry transfer cell (Bio-Rad) in transfer buffer (48mM Trizma base, 39mM glycin, 
0.037% w/v SDS and 20% v/v ethanol) for 1h at 140mA/25mV per gel. The membrane is 
incubated 1h in blocking solution (5% w/v fat free milk powder (Marvel), 1.2g/l Tris pH 
7.4 and 8.75g/l NaCl) and subsequently incubated ON at 4 °C with diluted primary 
antibody IKAROS H-100 (Santa Cruz biotech) in blocking solution with agitation. 
Membrane is then washed 3x10‟ in T-TBS (1.2g/l Tris pH 7.4, 8.75g/l NaCl and 0.1% 
tween20 20%) and subsequently incubated with horseradish peroxidase-coupled secondary 
antibodies (αRabbit and αMouse secondary antibodies are provided by Amersham) diluted 
1:5000 in blocking solution for 1h at room temperature. The membrane is washed 3x10‟ 
with T-TBS and the detection is done using Luminata Crescendo Western HRP substrate 
(Millipore) following manufacturer‟s instruction with Kodak X-Omat photographic films. 
4.3 RESULTS 
Identification of an IKZF1 germline mutation 
Recently, we applied amplicon next generation sequencing (NGS) to determine the status 
of IKZF1 regarding nucleotide mutations and small indels at single nucleotide level
15
. 
NGS (next generation sequencing) allows to determine the presence of mutations and in 
addition provides quantitative information on the mutant allele frequency (MAF), 
calculated as a percentage of mutated reads upon the total number of reads obtained for a 
specific amplicon. Generally speaking, mutations with a MAF well below 50% point to a 
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somatogenetic mutation in the leukemic blast population, whereas mutations with MAFs of 
50% and above maybe attributed to a germline mutation (with our without LOH). 
As reported in Chapter 3, we identified 14 new deleterious mutations at the IKZF1 locus. 
One of these mutations with MAF of 50% indicating a potential germline origin was 
further explore here. 
The mutation consisted of a single nucleotide deletion c.556_delG located in the fifth exon 
of IKZF1, within the zinc finger 3 coding sequence. At the mRNA level the deletion would 
lead to a change in the reading frame and the formation of a premature stop codon 
(p.Asp186Thrfs*7) depleting ZF4 and the C-terminal dimerization domain resulting in a 
truncated protein. The mutation originally detected by NGS was confirmed by Sanger 
sequencing and was detected with the same MAF (50%) in a remission, blast-free, bone 
marrow sample both by NGS and Sanger sequencing (Figure 4.1 A&B), corroborating a 
potential germline origin of the mutation or, at least, a mutation in very early 
hematopoietic progenitors. The second allele carried neither mutations nor deletions, as 
confirmed by NGS and MLPA analysis respectively. 
As IKZF1 could be transcribed in at least 10 different isoforms, some of which do not 
incorporate exon5, we performed Sanger sequencing on cDNA derived from proband‟s 
remission specimen, with specific primers that mapped within exon5. The IKZF1-mutated 
allele was transcribed in leukemic-free bone marrow of the proband (Figure 4.1 B). 
The patient was diagnosed at the age of 5 years with acute lymphoblastic leukaemia 
carrying the BCR-ABL1 translocation. At diagnosis, the WBC was 12.5x10
9
 cells/l, with a 
50% of blasts in the bone marrow identified by cytomorphological analysis. The patient 
was classified as good early responder on the basis of a blood-cell count <1000 blast/μl 
after 7 days of glucocorticoid therapy, and achieved cytomorphological complete 
remission after induction therapy. Despite of this, the patient died in clinical complete 
remission. To further explore the germline origin of the proband‟s mutation, efforts were 
put to re-contact his family. Following consultation and informed consent the family 
agreed to collaborate in order to establish the nature of the IKZF1 mutation. At first 
consent was obtained to screen DNA of the parents, and the mother was identified with 
IKZF1 c.556_delG establishing the inherited nature of the IKZF1 mutation (Figure 4.1 C). 
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Figure 4.1: Sequencing of IKZF1 exon5 of the proband. Sanger sequence at diagnosis (A) and at 
complete remission (B), and sequencing of proband‟s father and mother (C). The mutation is indicated by a 
red star. CR, complete remission. 
 
Thanks to further cooperation of the family, we were able to track the transmission of the 
mutated allele through three generations (Figure 4.2). DNA from oral-swabs of 8 relatives 
were analyzed. The 2 sisters of the proband (IIIb and IIIc) both carry the mutation, as well 
as the daughter (IVa) of (IIIb). In the second generation, the maternal uncle of the proband 
(IId) does not carry the mutation. The second leukaemia case in this family was a second 
brother (IIc) of proband‟s mother who was reported to have died of leukaemia during 
childhood. The latter event dated back to more than 40 years and no material is available to 
screen for the mutation status of IKZF1. Four healthy mutation carriers do not present a 
clinical history of haematological disturbances, but further follow-up is ongoing to verify 
uncommon characteristics not subjected to routine clinical tests. 
CHAPTER 4: IKZF1 FAMILIAL GERMLINE MUTATION AND LEUKAEMIA 
77 
 
 
Figure 4.2: pedigree of the family. The proband is indicated by an arrow. Small black squares indicated B-
ALL affected children. (+) marks carriers of the c.G556_del1 mutated allele. 
 
Recent Genome Wide Association studies identified particular SNPs as risk variants for 
ALL
16,17
. Among these the IKZF1 risk allele rs4132601 showed the strongest association 
with leukemic risk
16
. Testing of the proband for the presence of the IKZF1 risk allele 
rs4132601 resulted negative. 
Functional evaluation of the c.556_delG deletion 
To test the impact of the frameshift mutation on IKAROS protein, HeLa cells were 
permanently transfected with wt- or c.556_delG- IKZF1 coding sequence using the 
sleeping beauty transposase technique. IKZF1 sequence was fused with a FLAG-sequence 
to ease identification of the ectopic protein. Sleeping beauty is a transposable element 
(DNA elements that have the unique ability to move around in the genome) derived from 
fish genome that has the feature to permanently integrate in vertebrate genomes. The 
translation of the mutated IKZF1 transcript was verified by western blotting, using an α-
FLAG (F7425, Sigma Aldrich) for IKAROS protein detection. As reported in Figure 4.3 
A, the aberrant allele was translated in a truncated protein at the predicted molecular 
weight of ~28 KDa. The presence of different bands in the wt-IKAROS samples may be 
due to different post-translational modifications. 
We next examined the sub-cellular localization of truncated protein by Leica DMBL 
fluorescent microscopy in HEK-293T cells transiently transfected with wt- or c.556_delG- 
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IKZF1 coding sequence (Figure 4.3 B). IKAROS protein was detected by an α-IKAROS 
antibody (red) designed to recognize the N-terminus, that is maintained in the truncated 
form (IKAROS H100, Santa Cruz biotechnology), while nuclei were stained with DAPI 
(blue). 293T cells do not expressed endogenous IKAROS and were already used in 
previous studies for IKAROS sub-cellular localization
13,18
. Wt-IKAROS was localized in 
the nuclei and showed the typical dotted staining, indicating its binding to heterochromatic 
pericentromeric regions (HC-PC) as described in the literature
19–22
. On the contrary, 
c.556_delG-IKAROS aberrant protein displayed a diffused pattern in the nuclear region. 
As we applied fluorescent microscopy we were not able to precisely determine if truncated 
IKAROS localized in the nuclei or at perinuclear regions. Nevertheless, these data 
demonstrate that the c.556_delG deletion compromised IKAROS DNA binding. 
 
Figure 4.3: Functional analysis on c.556_delG-IKAROS. A) HeLa transfected cells were lysed and 10μg 
of proteins were loaded in a gel. Wt-HeLa cells were loaded as negative control. Ectopic IKAROS was 
detected using an α-FLAG antibody. B) Pictures show IKAROS localization in HEK-293T cells transiently 
transfected with wt- and c.556_delG IKAROS sequences. IKAROS protein was stained using an α-IKAROS 
antibody against the N-terminus. 
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One of the proband‟s sisters, IIIb, decided to cooperate in order to deepen the effect of the 
mutation in blood cells. 
Peripheral-blood mononuclear cells (PBMC) were isolated by ficoll-hypac technique. RNA 
and proteins were extracted from 10M cells for further experiments. The expression of the 
mutated allele was evaluated by mRNA retro-transcription and Sanger sequencing of the 
fifth exon. As reported in Figure 4.4, the mutated allele was expressed in PBMC cells of 
the proband‟s sister. We then assessed if the mutated transcript is translated into a 
truncated protein by western blotting. Anti-IKAROS antibody against the N-terminus part 
of the protein was used. 
 
Figure 4.4: Sanger sequencing of proband’s sister IIIb: Sanger sequencing of the fifth exon of IKZF1 
performed on the DNA (A) and mRNA (B) samples of IIIb. The mutation is indicated with a red star. 
 
Proteins were extracted from whole PBMC of IIIb; as a positive control, we loaded 
proteins derived from the c.556_delG-HeLa cell line. PBMC-proteins from a normal donor 
were included in the analysis as negative control. The truncated protein was detected in 
IIIb PBMC (Figure 4.5). Of note, the abundance of truncated protein was much lower 
compare to the normal, longer isoforms, suggesting a high degradation rate of the aberrant 
protein
23
 or the presence of post-transcriptional/translational mechanisms that modify its 
expression. Taking together, these data indicated that the mutant allele is expressed in 
normal peripheral blood cells. 
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Figure 4.5: Western blot analysis of truncated-IKAROS in blood cells of IIIb. 30μg of proteins were 
extracted from PBMCs of IIIb(second lane) and loaded in a 12% acrylamide/bis-acrylamide gel. Control 
PBMC extracted proteins from a healthy donor was loaded as a negative control. 10μg of proteins extracted 
from a HeLa cell line transfected with c.556_delG-IKZF1 sequence were loaded as positive control. 
IKAROS was detected using an α-IKAROS N-terminal antibody. 
 
4.4 DISCUSSION 
In conclusion, we identified a reading frame-shift mutation affecting IKZF1, one of the 
most studied genes in relation to pediatric and adult B-ALL, in a family with recurrent 
ALL in two generations. The mutation was identified during a screening of IKZF1 
mutations in a cohort of Ph+ B-ALL pediatric patients, and the familial recurrence of the 
mutation was confirmed starting from detection of the mutation in the mother of the 
proband. The mutation shows reduced penetrance with one known carrier (proband) that 
developed Ph+ BCP-ALL and IIc who succumbed from leukaemia during childhood 
(material to establish the IKZF1 mutation status was not available in this case), while the 
other four mutation carriers do not display manifested haematological disorders. 
Aberrant IKZF1 is known to be involved in ALL but considered a secondary mutation that 
occurs after the appearance of strong pathogenic first hit aberrations such as the 
BCR/ABL1 fusion  (Philadelphia chromosome)
24
. Interestingly, in the case of the proband 
of this study the IKZF1 alteration being of germline nature acts as a primary leukemic 
event, whereas the BCR-ABL1 translocation appeared later. Considering the low 
penetrance of leukaemia in the family, it is reasonable that second-hits acting in synergy 
with the c.556_delG need to occur in haematopoietic cells in order to establish a leukemic 
clone. 
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The difference between the mild phenotype observed in our cases and the severe condition 
described in the de novo IKZF1 germline case
13
 may  be attributed  to  the  precise nature 
of the respective mutation. In the case of the newborn patient, the mutation was a missense 
point mutation that compromised the DNA-binding affinity but not the dimerization 
domain, leading to a dominant negative phenotype, in which case wt-IKAROS would be 
sequestered by the mutated protein. In our case, the mutation leads to a shift in the reading 
frame, erasing the forth zing finger and the C-terminal dimerization domain, generating a 
truncated protein. This aberrant protein lost DNA binding and dimerization capacity in 
which case the wt-IKAROS protein retains physiological functions. 
An Epstein-Barr virus-immortalized cell line
25
 was established from the mature B 
lymphocytes isolated from IIIb. Further analysis on this cell line in addition to a deeper 
clinical investigation on the healthy mutation carriers will help to understand the impact of 
an IKZF1-haploinsufficient mutation on the human haematopoietic system. 
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ABSTRACT 
Ikaros is a zinc finger transcription factor protein that pays a pivotal role in 
haematopoiesis. It is expressed from haematopoietic stem cell progenitors, and its level 
increases dramatically during lymphoid commitment. In lymphoid progenitors, Ikaros 
switches off myeloid, erythroid and stem-cell primed-genes and activates lymphoid-
specific genes, piloting B and T cells progenitors towards differentiation. Despite the 
importance of Ikaros in haematopoiesis, till recently a clear genome-wide map of Ikaros-
target genes was not available, and still now the underlying mechanisms of Ikaros-
mediated gene expression regulation are not fully understood. In this study, we combine an 
inducible Ikaros system with Ikaros-ko cell model, to discern the real effects of inducible 
Ikaros activation from pre-existing modifications caused by active endogenous Ikaros. 
Firstly, we confirmed the absence of endogenous Ikaros protein, and then we verified the 
ability of exogenous inducible Ikaros to translocate in the nucleus in response to 4-
hydroxytamoxyfen treatment and to bind the promoter of a previously described Ikaros 
target gene. Inducible Ikaros is able to up-regulate the Lig4 and Zfp36 genes, but failed to 
repress the expression of Myc, Ccnd2 and Igll1 genes. In Ikaros-ko cells, inducible Ikaros 
did not significantly arrest the cell cycle, as demonstrated by cell cycling profiling 
experiments. 
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5.1 INTRODUCTION 
B cell development progress through a series of developmental stages aimed at maturation 
of a functional, not self-responsive, B cell receptor. At the pre-proB stage starts the 
immunoglobulin heavy chain (IgH) recombination process. The rearranged IgH is 
assembled with the surrogate light chains (SLC) λ5 and VpreB proteins to form the preB 
cell receptor (preBCR). PreBCR expression induces a proliferative expansion in cycling-
preB cells, and simultaneously induces a negative feedback signal that down-regulates 
SLC proteins expression and the cell cycle regulator c-Myc. PreBCR signal termination 
pilots cells out of the cell cycle and starts the rearrangement of the immunoglobulin light 
chain (IgL) locus. This stage is defined as resting-preB. The assembling of mature IgL with 
the IgH give rise to a mature BCR that identifies immature B cells
1,2
. A network of 
transcription factors that in a combinatorial manner specify cell fate orchestrates each step 
of the differentiation process. Ikaros is a transcription factor expressed from the HSC stage 
that plays a pivotal role in the commitment and specification of the lymphoid lineage
3
. 
Studies on transgenic mice highlighted a severe phenotype connected to Ikzf1 depletion, 
with a complete ablation of B and NK progenitors, and an impaired development of T-cell 
progenitors
4,5
. These mice invariantly developed a aggressive form of T- 
leukaemia/lymphoma within 6 weeks after birth
4
. In human, IKZF1 is rarely 
mutated/deleted in T-cell acute lymphoblastic leukaemia (T-ALL), but was found 
frequently deleted in paediatric and adult B-cell acute lymphoblastic leukaemia (B-ALL), 
in particular in cases harbouring the BCR-ABL chromosomal translocation
6
. 
During Haematopoiesis, Ikaros is essential for priming the lymphoid-specific genes in 
HSC and multipotent progenitor (MPP) cells. In Ikzf1 null mice, MPP failed to give rise to 
common lymphoid progenitor (CLP) cells, explaining the severe phenotype observed in 
mice. Moreover, MPP cells displayed an abnormal up-regulation of stemness- and 
myeloid-related genes. Therefore, Ikaros is involved in both lymphoid commitment and in 
extinguishing stem-cells and other lineage-specific genes signatures
7
. Ikaros deficiency in 
proB cells arrested them at this stage, due to defects in preBCR signalling
8
. At the cycling-
preB stage, Ikaros acts in synergy with Aiolos to silence the SLC encoding-genes Igll1 and 
VpreB and to activate Rag1/2 to promote the IgL rearrangement 
9,10
. In parallel, Ikaros and 
Aiolos downregulate c-Myc 
11
 and other cell-cycle promoters such as cyclines Ccnd2, 
Ccnd3 and the cyclin-dependent kinase 6 (Cdk6), leading to arrest in cell cycle and 
accumulation of cells in G1 phase
10
. Although Ikaros targets were intensively investigated 
in the last years, the mechanisms by which Ikaros exploits its function are still poorly 
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understood. As a transcription-repressor, Ikaros is frequently associated with the NuRD 
complex, composed by the Mi-2β nucleosome remodeler sub-unit and by the HDAC 
deacetylase proteins
12
. Ikaros-NuRD complex was shown to localize at pericentromeric-
heterochromatic regions of the genome together with their repressed-genes
13 
5.2 MATERAL AND METHODS 
Cell Culture 
The murine preB cell line B3 was isolated and cloned in Professor Fisher‟s lab from a 
lymphoma in an IL-7 transgenic mouse (Fisher et al 1995). This cell line was maintained in 
culture in Iscove‟s modified Dulbecco medium (IMDM) containing 10% (v/v) foetal calf 
serum (FCS) (Biosera) and antibiotics (100U/ml Penicillin and 100µg/ml Streptomycin, 
GIBCO, Invitrogen). Cells were kept in culture at a density between 0.1 and 1 x 10
6
 
cells/ml. The human embryonic kidney 293T cell line cells were cultured in Dulbecco 
modified Eagle medium (DMEM) supplemented with 10% (v/v) FCS, 2mM L-glutamine 
and antibiotics. 
Virus production 
293T cells were cultured in 10cm petri dishes at approximately 40% of confluence in 9 ml 
of DMEM medium. MSCV vector (4µg) and 4µg of pECO or 10A1 envelop helper 
plasmid DNA were added to 500 µl of 0.4M CaCl2 solution.  500µl of 2x HEBS (12mM 
dextrose, 50mM HEPES, 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4 + 2H2O in sterile 
water) and were then added to the plasmid mix drop by drop. The transfecting solution was 
then added to cells drop by drop. The cell medium was changed 12h after transfection. 
After 24h, 3.5ml of fresh media was added to cells, and virus-containing media were 
collected at 36, 48 and 60 hours from transfection, and pooled together. 
Infection 
The retroviral media was filtered with a 0.22µm filter, and is supplemented with 10mM pH 
7.6 HEPES and 4µg/ml polybrene (Sigma-Aldrich). 1.3 millions B3 cells were suspended 
in 3ml of retroviral media and plated in a 6-well plate. Cells were then centrifuged for 90‟ 
at 37 °C at 2500rpm to increase the infection rate. Retroviral media was then changed with 
fresh one and cells were put at 37 °C. 48h later, infected cells were sorted by FACS for 
positivity of specific fluorophores. 
Cell sorting 
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Cells were sorted using a FACSAria IIu, based on positivity to mCherry. For sorting, cells 
were resuspended in basic sorting buffer (1x phosphate buffered saline (PBS) Ca/Mg
++
 
free, 1mM EDTA, 25mM HEPES pH 7.0, 1% FCS) and collected in PBS Ca/Mg
++
 free 
supplemented with 20% of FCS. Sorted cells were then cultured for at least 24h in 
complete media supplemented with 5µg/ml of gentamycin. 
Cell cycle analysis 
0.5x10
6 
cells were washed once in PBS-/-, and then resuspended in 300µl of propidium 
iodide buffer (PBS-/- supplemented with 10µg/ml RNAsi A (life technologies, NY, USA), 
50µg/ml propidium iodide (Sigma-Aldrich) and 0.05% v/v NP40 (Calbiochem, Merck 
Millipore)). Cells were incubated 10‟ at room temperature and 20‟ on ice and subsequently 
analysed using a DB LSRII flow cytometer. 
Immunofluorescence 
B3 cells were plated for 1h in 12-well plates with poly-L-lysine coated coverslips 
(BioCoat). Coverslips were washed with PBS
-/-
 and fixed with 4% paraformaldehyde 
(PFA) in PBS
-/-
 for 10‟ at room temperature. Fixed samples were washed twice in PBS-/- 
and then permeabilized with 0.5% TritonX-100 for 5‟. Cells were incubated for 30‟ at 
room temperature with blocking solution (3% normal goat serum, 0.1% TritonX-100 in 
PBS
-/-
). Primary antibodies were diluted 1:1000 in blocking solution and added to the 
samples overnight at 4 °C in a humid chamber. Coverslips were washed 3x with PBS
-/- 
and 
incubated with secondary antibodies conjugated with appropriate fluorophores diluted 
1:10000 in blocking solution for 1h at room temperature in a humid chamber in the dark. 
Coverslips were washed 3x PBS
-/-
 and mounted in Vecatshield (Vector laboratories) with 
DAPI 0.1µg/ml. samples were viewed using a TCS SP5 Leica laser scanning confocal 
microscope. Images were analysed using Leica confocal software. 
Protein extraction and quantification 
1 to 3 x10
6 
cells were washed once in cold PBS-/-
 
supplemented with protein inhibitor 
cocktail (Roche) and then re-suspended in 1 volume of cold PBS
-/- 
supplemented with 
protease inhibitor cocktail. One volume of 2x sample buffer (100mM Tris pH 6.8, 20% 
glycerol and 2% of sodium dodecyl sulphate (SDS)) was added to cells, and the cell mix 
was subsequently boiled at 95 °C for 10‟. Protein concentration was measured using the 
Pierce
TM
 BCA protein assay kit (Thermo scientific) according to manufacturer‟s 
instruction. After quantification, 10% v/v of β-mercaptoethanol and 0.002% of 
bromophenol blue were added to the protein assay. Protein were stored at -20 °C. 
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Western blot 
Proteins and Benchmark pre-stained protein ladder (Beckman) were loaded on a SDS-
polyacrylamide gel. The gel is formed by an upper staking gel (4% w/v acrylamide, 
125mM Tris-HCl pH 6.8, 0.1% SDS, 0.067% ammonium persulphate (APS) and 0.12% 
N,N,N‟tetramethylethylenediamine (TEMED)) and a running gel (10% acrylamide, 
390mM Tris-HCl pH 8.8, 0.1% SDS, 0.05% APS and 0.1% TEMED). Bio-Rad minigel 
system is used for the electrophoretic run together with running buffer (25mM Tris base, 
192mM glycin and 0.1% SDS). The electrophoretic run was performed at 30mA per gel for 
90‟. Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane using the 
trans-blot® SD semi-dry transfer cell (Bio-Rad) with transfer buffer (48mM Trizma base, 
39mM glycin, 0.037% w/v SDS and 20% v/v ethanol) for 1h at 140mA/25mV per gel. The 
membrane was incubated 1h in blocking solution (5% w/v fat free milk powder (Marvel), 
1.2g/l Tris pH 7.4 and 8.75g/l NaCl) and subsequently incubated ON at 4 °C with diluted 
primary antibodies in blocking solution with agitation. The membrane was then washed 
3x10‟ in T-TBS (1.2g/l Tris pH 7.4, 8.75g/l NaCl and 0.1% tween20 20%) and 
subsequently incubated with horseradish peroxidase-coupled secondary antibodies 
(αRabbit and αMouse secondary antibodies are provided by Amersham) diluted 1:5000 in 
blocking solution for 1h at room temperature. The membrane was washed 3x10‟ with T-
TBS and the detection was done using Luminata Crescendo Western HRP substrate 
(Millipore) following manufacturer‟s instruction with Kodak X-Omat photographic films. 
RNA extraction 
At least 1x10
6 
cells were washed once in cold PBS
-/-
. RNA extraction was performed using 
QIAshredder and RNeasy Mini kit (Qiagen) following manufacturer‟s instruction. Residual 
DNA was cleared using the DNA-free kit (Ambion) according to manufacturer‟s 
instruction. RNA was quantified using Nanodrop 
Reverse transcription 
Reverse transcription was performed using Superscript First-Strand Synthesis system 
(Invitrogen). 1µg of RNA was mixed with 1µl of 10mM dNTPs mix and 1µl of 0.25mM 
random primers, topped up to 13µl with RNase-free H2O. The RNA mix was incubated at 
65 °C for 5‟ and then 1‟ at 4 °C. A mix composed of 1µl of 0.1M of DTT, 1µl RNasi-
OUT, 5µl of 4x first strand buffer and 1µl of 200U/µl Superscript III reverse transcriptase 
was added to the RNA mix. The final mix was incubated at 25 °C for 5‟, at 50 °C for 1h 
and at 75°C for 15‟. The obtained cDNA was diluted 10x. 
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Real-time quantitative PCR 
The real-time reaction mix was composed by 2x SYBR Green qPCR mastermix (Qiagen), 
0.3mM primers and 1µl of cDNA in a final volume of 12µl. The program used for RT-
qPCR was: 95 °C for 15‟, then 40x(94 °C for 15‟, 60 °C for 30‟ and 72 °C for 30‟). The 
melting curve was determined from 72 to 90 °C at 0.2 °C intervals. qPCR quantification 
was performed using Bio-Rad CFX96 real-time PCR machine, and was analysed using 
CFX96 Manager Software. The relative abundance of detected transcripts was calculated 
using the ΔΔC(t) method. Briefly, C(t) is the number of amplification steps needed to 
detect the fluorescence of PCR products above background. The relative abundance of the 
gene of interest C(t)1 compared to a reference C(t)2 can be calculated as 2
-ΔC(t)1
/2
-ΔC(t)2
. For 
gene expression, housekeeping genes were used for normalization. 
Chromatin Immune Precipitation (ChIP) 
30x10
6 
cells were washed once in cold PBS-/- and resuspended in 18ml of PBS-/-
 
supplemented with 1mM Disuccinimidyl glutarate (DSG, Thermo Scientific) and 
incubated at a very low speed on a rotating incubator for 30‟ at room temperature. Cells 
were then washed once with PBS-/- and  re-suspended in 18ml of PBS-/-, and fixed again 
with 1% formaldehyde adding 2ml of fixation buffer (0.5mM EGTA pH 8.0, 100mM 
NaCl, 1mM EDTA, 50mM HEPES pH8.0 and 10% formaldehyde in sterile water). The 
cells were incubated at a very low speed on a rotating incubator for 10‟ at room 
temperature. Fixation was stopped by adding glycine at a final concentration of 140mM 
and incubated for 5‟ more. Fixed cells were centrifuged at 4 °C at 3000rpm for 5‟, and 
washed twice with cold PBS-/-. Cell pellet was then re-suspended in 0.5ml of cell lysis 
buffer (25mM HEPES, 1.5mM MgCl2, 0.1% v/v NP40 in sterile H2O) supplemented with 
protease inhibitor cocktail (Roche), and lysed on ice for 15‟. Samples were then pelleted by 
centrifuging at 4 °C for 20‟ at 900rcf, and re-suspended in nuclear lysis buffer (50mM 
Tris-HCl pH 8.1, 10mM EDTA and 0.5% v/v SDS) for 5‟ on ice. Fragmentation of 
chromatin was done by sonication at high speed for 30‟, 30‟‟ on and 30‟‟ off at 4 °C using 
a Bioruptor® (Diagenode). Un-sonicated chromatin and debris were eliminated by 
centrifugating the sample at 25000rcf for 15‟ at 4 °C, and supernatant was taken for ChIP. 
Chromatin was quantified by a 10x dilution in 0.1M NaOH and measured by Nanodrop. 
100µg of chromatin was used for IP. 10µl of Dynabeads® protein G (Life technologies) 
was washed twice in 10 times volume of cold RIPA buffer (150mM NaCl, 10mM Tris-HCl 
pH 7.5, 1mM EDTA pH 8.0, 0.5mM EGTA pH 8.0, 1% v/v TritonX-100, 0.1% SDS, 0.1% 
sodium deoxycholate) and incubated with α-IK-C or control α-IgG for 3h at 4 °C in 
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agitation. Beads were then washed twice with cold RIPA buffer on a magnetic stand. 
100µg of chromatin was incubated ON with beads-antibodies at 4 °C on a rotating 
platform. Unbound chromatin and non-specific binding were washed away by 3x 5‟ 
washes with RIPA buffer, 3x 5‟ washes with high salt RIPA buffer (RIPA buffer with a 
final concentration of NaCl of 500mM), 2x 5‟ washes with LiCl buffer (RIPA buffer with 
the addition of 250mM LiCl) and TE buffer (10mM Tris-HCl pH 7.5, 1mM EDTA). 
Washed beads were suspended in 300µl of elution buffer (50mM Tris, 1mM EDTA, 1% 
v/v SDS, 100µg/ml RNasi A and 50µg/ml protease K) and incubated 2h at 37 °C and ON 
at 65 °C with agitation. DNA was extracted using a phenol/chloroform protocol and 
precipitated with ethanol and sodium acetate. For qPCR analysis, 1µl of 50µl was used per 
reaction in a final volume of 12µl. 
Ikaros induction 
Exogenous ERt2-Ikaros was induced from the cytoplasm to the nucleus by adding 0.5µM 
4hydroxytamoxifen (4OHT, Sigma-Aldrich). Time course experiments were performed by 
inducing Ikaros translocation at different time point and processed at the same end time 
point for subsequent analysis. 
5.3 RESULTS 
Construction of an Ikzf1-ko cell line model 
The murine preB B3 cell line, isolated from an IL-7 transgenic mouse 
14
, was used as a 
model of cycling preB lymphocytes to study the role and kinetics of Ikaros in gene 
expression regulation. The Ikzf1 locus was disrupted using the CRISPR-Cas9 gene editing 
system. Briefly, The CRISPR-Cas9 complex is composed of a small single guide RNA 
(sgRNA) and a non-specific CRISPR-associated endonuclease, Cas9. The sgRNA is 
formed by a scaffold sequence and a user-defined 20 nucleotide target sequence, 
complementary to the genomic DNA to be edited. Cas9 is recruited to target DNA by 
sgRNA, and cuts the double strand DNA with its 2 endonuclease domains. The double-
strand break will be repaired by the error-prone non-homologous end joining (NHEJ) 
system that inserts small indels at the break site. 
The Ikaros knock-out (Ikaros-ko) experiments were performed by Lee Cooper, a PhD 
student in Prof Merkenschlager‟s lab. The single guide RNA (sgRNA) was designed 
complementary to the first 53 nucleotides of the second exon of Ikzf1, which contains the 
start codon. The sgRNA, the human codon optimized SnCas9 and a GFP expressing vector 
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were co-transfected into wt-B3 cells. Single GFP positive cells were sorted into 96-well 
plate to let them proliferate. 
Individual clones were then tested by restriction fragment length polymorphism (RFLP) 
analysis. Briefly, a region of 530 nucleotides containing the target exon was amplified by 
PCR and the products were then digested with TaqaI, a restriction enzyme that cuts within 
the Cas9 target sequence. PCR products from WT clones containing the intact restriction 
site were cut by TaqaI, while in the mutated clones small indels disrupted the site, resulting 
in non-digested PCR products. Heterozygous clones displayed one uncut band and two cut 
fragments, and homozygous clones had 2 uncut bands. DNA sequencing confirmed the 
presence of indels. Following the above method, six clones were selected: C2, D6, E2, E3, 
E9, and G11. 
 
Figure 5.1: Detection of endogenous Ikaros in CRISPR-Cas9 clones. Proteins extracted from 293T cell 
line, wt-B3 cells and from the 6 Ikzf1-ko cell lines C2, D6, E2, E3, E9 and G11 were loaded in the western 
blot. 293T and wt-B3 proteins were loaded as negative and positive controls respectively. Endogenous 
Ikaros was detected using Ikaros antibody. α-tubulin was used as a loading control. The band present in wt-
B3 sample identified Ikaros. No Ikaros was detected in CRISPR-Cas9 clones. 
 
The presence of endogenous Ikaros in this cell line model was checked by immunoblotting 
using an antibody to the C-terminal part of the protein (Figure 5.1). Wt-B3 cells are loaded 
in the gel as positive control, while 293T cells proteins are included as negative control, as 
this human embryonic kidney cell line does not express endogenous IKAROS 
15
. The 
Ikaros band was detected in the wt-B3 cells lane but not in the 6 CRISPR-Cas9 Ikzf1-ko 
clones, as shown by western blot. This data demonstrated the absence of endogenous 
Ikaros in the ko clones, and validated the Ikaros-ko model. 
 
The Ikaros-ko clones were then transducted with an inducible Ikaros system, developed in 
prof Merkenschlager‟s lab. The system consists in a full-length Ikaros sequence fused with 
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a hemagglutinin (HA) epitope at the N-terminus and with the ligand-binding domain of the 
estrogen receptor (ERt2) at the C-terminus. The HA-Ikaros-ERt2 sequence is inserted 
upstream of an internal ribosome entry site (IRES)-mCherry sequence, so HA-Ikaros-ERt2 
protein and the fluorescent mCherry protein are translated from the same transcript (Figure 
5.2A). mCherry fluorescence intensity was used as an indicator of fusion protein 
expression and to sort transfected B3 cells. 
The HA-Ikaros-ERt2 fusion protein is constitutively expressed but is sequestrated in the 
cytoplasm by heat-shock proteins (HSP) that bind the ERt2 domain. To induce the 
translocation of the Ikaros fusion protein to the nucleus, 4-hydroxytamoxifen (4OHT), an 
ERt2 ligand, is added to the culture media. 4OHT abolishes the HSP-Ikaros fusion protein 
interaction, leading to the translocation of the fusion protein to the nucleus thanks to its 
nuclear localization sequence (Figure 5.2B). 
 
Figure 5.2: Schematic representation of the inducible Ikaros system. A) Schematic representation of the 
inducible Ikaros construct cloned in MSCV vector. HA, hemagglutinin; Ikaros, the longest Ikaros isoform; 
ERt2, ligand binding domain of the oestrogen receptor; IRES, internal ribosome entry site; mCherry, a red-
fluorescent protein. B) Schematic representation of the experimental system. Inducible Ikaros is 
constitutively expressed by cells and is  retained in the cytoplasm. Addition of 4-hydroxytamoxifen induces 
Ikaros nuclear translocation. In the nucleus inducible Ikaros binds to target genes. Adapted from Ferreirós-
Vidal I., et al., 2013. 
 
Inducible Ikaros localization and translocation 
The sub-cellular localization of the Ikaros fusion protein was evaluated in non 4OHT-
treated cells by immunofluorescence (IF) microscopy. Inducible Ikaros was detected by α-
HA antibody (green), while the nuclei were marked with DAPI (blue). Cells are imaged by 
confocal microscopy (Figure 5.3). The Ikaros signal localized most abundantly in the 
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cytoplasm, but a fraction of inducible Ikaros co-localized with DAPI staining in the nuclei 
of all B3 clones as well. The same issue was previously observed in the wt-B3 inducible 
Ikaros model expressing endogenous Ikaros. 
Ikaros ability to translocate to the nucleus was then tested by IF (Figure 5.4). Cells were 
treated with 0.5μM of 4OHT for 1h and then fixed, stained and imaged at confocal 
microscopy as previously described. After 1h of 4OHT induction, the majority of inducible 
Ikaros translocated to the nucleus and showed the characteristic toroidal spots at 
pericentromeric regions. Taken together, these data indicate that inducible Ikaros can 
efficiently translocate into the nucleus after 4OHT induction and formed clusters at 
pericentromeric regions. 
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Figure 5.3: Inducible Ikaros localization before 4OHT treatment. Inducible Ikaros was detected by α-
HA antibody (green). Nuclei were stained with DAPI (blue). Images were acquired using a TCS SP5 Leica 
laser scanning confocal microscope. 
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Figure 5.4: Ikaros translocation induced by 4OHT treatment. Ikaros-wt B3-inducible Ikaros cells and 
Ikaros-ko E2 clones were imaged by TCS SP5 Leica laser scanning confocal microscope before (EtOH) and 
after 1 hour (1h) of 4OHT treatment. After 1h most of inducible Ikaros translocated in the nuclei, and 
formed clusters at pericentromeric heterochromatic regions. 
 
For the further characterization of our cellular model, the experiments were conducted in 
the C2 and E9 clones, because these clones displayed the lowest level of Ikaros nuclear 
localization in un-induced cells. 
Inducible Ikaros binding at a target gene 
To further characterize inducible Ikaros function in Ikaros-ko cells, we evaluated its 
binding to the promoter region of Igll1, which encodes the λ5 component of the preB cell 
receptor (preBCR). Ikaros down-regulates Igll1 expression, guiding preB cells from a 
proliferative state to a resting state and initiating the rearrangement of the BCR light chains 
locus 
9
. 
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We addressed the capacity of inducible Ikaros to bind to the Igll1 promoter by ChIP 
experiments after 1h of 4OHT induction. To control for carrier effects, cells were treated 
with ethanol (EtOH) for 1h as control. Ikaros ChIP was performed using α-Ikaros antibody 
to the C-terminus. Ikaros enrichment was evaluated by RQ-PCR and normalized to input 
signal. As a negative control, IgG was included in the experiment. To obtain a precise map 
of Ikaros binding sites at the Igll1 promoter, we used primers that amplified the 
surrounding region on either side of the expected Ikaros binding sites. 
Without 4OHT induction (EtOH), modest Ikaros binding was observed at -200bp and 
100bp from the transcription star site (TSS) consistent with the presence of some inducible 
Ikaros proteins in the nuclei detected by IF. After one hour of induction (4OHT), the Ikaros 
binding at -200bp showed a 5-fold increased in the C2 clone and 11-fold in the E9 clone. A 
second smaller peak appeared at -1300bp in both clones (Figure 5.5). This data suggests 
that inducible Ikaros was able to bind at the Igll1 promoter after 4-hydroxytamoxifen 
induction. 
 
Figure 5.5:Inducible Ikaros binding to Igll1 promoter. The Ikaros binding to Igll1 promoter was detected 
by ChIP-RQ-PCR using Ikaros antibody in untreated (EtOH) or 4OHT treated sample for 1h (4OHT). IgG 
negative controls are reposted. Data shown is an average of 3 biological replicates. Standard errors are 
reported. 
 
Regulation of gene expression 
We then tested the ability of inducible Ikaros to regulate transcription. For this purpose, we 
selected genes that were previously described to be bound and regulated by Ikaros in B3 
cells 
10
. We analyzed 2 Ikaros up-regulated genes, Lig4 and Zfp36, and 3 down-regulated 
genes: Ccnd2, Igll1 and Myc. For gene expression analysis, C2 and E9 cells were sorted for 
high levels of mCherry, corresponding to high levels of inducible Ikaros protein. Cells 
were sorted to obtain comparable inducible Ikaros level between the two clones and the B3 
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inducible Ikaros control.  As Ikaros was demonstrated to regulate transcription very shortly 
after its translocation into the nucleus (Liang Z., personal communication), we monitored 
the expression of candidate genes after 5‟, 15‟, 30‟ and 1h, and finally at 6h after induction 
with 4OHT. To follow these rapid changes in gene expression, intronic-exonic primers 
were used, in order to detect the level of primary unspliced (immature) transcripts. 
Transcript levels were evaluated by RQ-PCR. Expression was normalized to the Ubc and 
Ywhaz housekeeping genes and values were normalized to the EtOH, un-induced sample. 
We performed gene expression experiments also on wt-B3 inducible Ikaros cells and wt-
B3 cells transduced with inducible HA-ERt2-mCherry control vector, as positive and 
negative control of the experiment. Firstly, we analyzed the gene expression of the Ikaros 
up-regulated genes (Figure 5.6). 
In wt-B3 inducible Ikaros cells, Lig4 was up-regulated after 1h and Zfp36 after 15‟ of 
4OHT induction, and their level of expression became progressively higher over the 6 
hours. 
C2 and E9 Ikaros-ko clones showed a significant up-regulation of Lig4 after 6h, and after 
1h for the Zfp36. The Lig4 and Zfp36 up-regulation was faster and stronger in magnitude in 
wt-B3 cells compare to the Ikaros-ko clones. These differences could be ascribed to the 
presence of endogenous Ikaros in the nuclei of wt-B3 cells, that could facilitate inducible 
Ikaros binding to target genes, as well as of small difference in the inducible Ikaros level 
between wt-B3 and Ikaros-ko cells. 
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Figure 5.6: Transcriptional regulation of selected Ikaros up-regulated target genes. Histograms show 
the relative expression of candidate genes normalized to the untreated control (EtOH). RNA samples were 
collected after 5‟, 15‟,30‟, 1h and 6h after addition of 4OHT. The gene expression changes were monitored 
in wt-B3 inducible Ikaros, empty vector control and in Ikaros-ko C2 and E9 cell lines. Student's T test p 
value: *p<0.05, **p<0.01. Data shown is an average of 3 biological replicates. Standard errors are reported. 
 
The behaviour of the down-regulated genes was then analyzed in C2, E9 and wt-B3 
inducible Ikaros cell lines (Figure 5.7). None of these 3 genes were significatively down-
regulated in C2 and E9 cell lines. C2 displayed a small down-regulation of Ccnd2 after 1h, 
and of Igll1 after 30‟, but the changes were not significant. Myc was not regulated after 6 
hours of Ikaros induction. In B3 cells Myc and Ccnd2 levels decreased after 15‟ of 
induction, and the down-regulation became statistically significant at 1h. Igll1 significantly 
reduced its expression at 30‟, and the transcript level decreased dramatically during time 
till the 6h. Taken together, these data highlighted an impaired down-regulation mechanism 
of Ikaros target genes in Ikaros-ko cells. 
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Figure 5.7: Transcriptional regulation of selected Ikaros down-regulated target genes. Histograms 
show the relative expression of candidate genes normalized to the untreated control (EtOH). RNA samples 
were collected after 5‟, 15‟,30‟, 1h and 6h after addition of 4OHT. The gene expression changes were 
monitored in wt-B3 inducible Ikaros, empty vector control and in Ikaros-ko C2 and E9 cell lines. Student's T 
test p value: *p<0.05, **p<0.01, ***p<0.001. Data shown is an average of 3 biological replicates. Standard 
errors are reported. 
 
Myc is an important Ikaros target genes. Its Ikaros-dependent down-regulation is crucial 
for the transition from immature cycling preB cells to maturing resting preB cells
11
. To 
corroborate the gene expression analysis, the cell cycle profiles of C2 and E9, as well as 
B3 inducible Ikaros cells were analysed using PI DNA staining. As a 4OHT control, B3 
cells transduced with HA-ERt2-mCherry control vector are included in the analysis. The 
DNA content profile was examined after 16 hours of 4OHT induction at FACS (Figure 
5.8). 
Wt-B3 inducible Ikaros untreated cells displayed a profile of 40% G1 phase, 40% S phase 
and 20% of G2 phase. After 16h of 4OHT treatment, G1 phase increased to 63%, while the 
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S and G2 phases decreased to 22% and 15%, indicating an arrest of the cell cycle at G1 
phase (Figure 4). Both C2 and E9 clones failed to show any difference in cell cycle 
between 4OHT-treated and untreated cells. Of note, C2 cells present a lower percentage of 
cells in S and G2 phases in untreated sample compare to E9 and B3 inducible Ikaros. In 
conclusion, Inducible Ikaros is able to induce cell cycle arrest in B3 cells, but fails to do so 
in Ikaros-ko cells. 
 
  
Figure 5.8: Cell cycle analysis of inducible Ikaros cells. The histogram shows the percentage of cells in 
different cell cycle stages after 16 hours of induction (4OHT) or in control (EtOH) treated cells. The 
significance reported in the 4OHT bars referred to control (EtOH) treated cells. Student's T test p value: 
***p<0.001. Data shown is an average of 3 biological replicates. Standard errors are reported. 
 
5.4 DISCUSSION 
The aim of this work was the characterization of an Ikaros-ko cellular model designed to 
elucidate the underlying mechanisms of Ikaros gene expression regulation in the absence 
of endogenous Ikaros. Previously, an inducible Ikaros system was set up and characterized 
to deeply elucidate the genome-wide Ikaros target genes
10
, and the kinetic and mechanisms 
of the gene expression changes in a temporal fashion (Liang et al., unpublished data). To 
do that, the B3 murine cycling preB cell line was used as a model. Our model combines the 
power of the inducible Ikaros system for studying Ikaros function with an endogenous 
Ikaros-ko model. Our system should decrease the background noise in the analysis, and 
allowed us to investigate the order of events that occur after Ikaros translocation in an 
“Ikaros-free” nucleus. The Ikzf1 knock-out was confirmed by western blot analysis, and the 
function of the inducible Ikaros system was then tested. Inducible Ikaros was able to 
NS 
NS 
NS NS 
*** 
*** 
NS 
NS 
NS 
NS 
NS 
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translocate into the nucleus and formed toroidal structures at pericentromeric-
heterochromatic regions, as previously reported in the literature
9,10,16,17
. IF analysis 
revealed a small amount of inducible Ikaros in the nucleus before the induction, while the 
majority of Ikaros was located in the cytoplasm. For further characterization of our model, 
we selected the C2 and E9 clones because they displayed the lowest amount of nuclear-
Ikaros. Ikaros could efficiently bind to Igll1 promoter, as demonstrated by ChIP 
experiments. The E9 clone showed a greater difference after induction than C2, with an 
increased in the signal of 11-fold, mostly due to the lower peak in untreated control 
compare to the other clone. A second peak, not present in untreated controls, appeared 
after induction at -1300bp from the TSS, in a secondary Ikaros binding site
9
. The presence 
of a small peak at -220bp in the untreated controls could be explained by binding of some 
inducible Ikaros proteins already present in the nuclei. Interestingly, a peak was found in 
B3 inducible Ikaros cells (expressing the endogenous Ikaros) using an α-HA antibody 
specific for the inducible Ikaros, corroborate the hypothesis of a contamination of nuclear 
inducible Ikaros both models. In wt-B3 system, the interaction between endogenous and 
inducible Ikaros is supposed to be the cause of inducible Ikaros nuclear localization before 
induction. It is also possible that, as inducible Ikaros is over-expressed in cells, HSPs are 
not enough to sequester all inducible Ikaros proteins in the cytoplasm, allowing a small 
portion of them to translocate in the nuclei. The latter would be the explanation of why we 
observed inducible Ikaros nuclear localization in our Ikaros-ko cell lines. 
We next tested the gene-expression modulation by inducible Ikaros in our model. The 
candidate genes we selected were all direct target of Ikaros, with a strong Ikaros binding 
and a strong change of their expression upon Ikaros induction
10
. For gene expression 
experiments, we chose to sort our cells for high expression of inducible Ikaros. 
Upregulation of Lig4 and Zfp36 was observed in our model, but the increased amount of 
their transcripts after 6h was significantly lower compare to the previous model which 
expressed the endogenous Ikaros. Surprisingly, the Ikaros-repressed genes Igll1, Ccnd2 
and Myc do not showed any significant down-regulation after Ikaros induction. Igll1 and 
Ccnd2 displayed a mild decreased in their expression after 1h of induction in C2 clone 
(even if not significant), while in E9 no significant change was observed. Myc does not 
display any difference in gene expression within the 6 hours 4OHT of treatment. 
Indirect evidence corroborating our observation came from the cell cycle analysis. 
Experiments performed in Merkenschlager‟s lab showed that Ikaros induction guide cells 
from a cycling state to a resting state after 16h of induction. This shift in cell state mimics 
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the physiological transition between cycling preB and resting preB cells, and is 
orchestrated by Ikaros, at least partially by direct down-regulation of Myc and 
subsequently of Myc‟s target genes10,11. B3 with endogenous Ikaros displayed an arrest in 
G1 phase after 24h of induction, while both C2 and E9 are not affected by 4OHT 
treatment. This data, even if indirect, suggests us that the gene expression experiments are 
reliable. 
The impairment of Ikaros repressor activity will need further investigations. It is worth to 
note that between the down-regulated tested genes was present Igll1, whose promoter was 
bound by inducible Ikaros, as previously demonstrated in this work by ChIP-RQ-PCR 
experiments. The same analysis needs to be done for the other genes to verify the Ikaros 
status at their promoters. The Ikaros capacity to regulate gene expression is mediated by 
other complexes that interact with it, as histones modifiers and nucleosome remodelers. 
One of the major Ikaros partner involved in gene silencing is the Nucleosome Remodeler 
Deacetylase complex (NuRD)
12,17
, containing the nucleosome remodeler Mi-2β and the 
deacetylases HDAC1 and -2. Liang et al. demonstrated that the rapid changes in gene 
expression are, at least partially, related to changes in nucleosome occupancy at promoter 
and TSS sites (Liang Z. et al., unpublished data). Considering this information, Mi-2β, the 
nucleosome remodeler protein present in the Ikaros-NuRD complex, could be a candidate 
factor for further investigations. 
 
In conclusion, we demonstrated that the Ikaros-ko B3 cell line transduced with the 
inducible Ikaros cassette is a functional and efficient system to study Ikaros-mediated 
regulation of gene expression. The comparison between our model and the previous one 
that maintains endogenous Ikaros protein will allow us to deepen our understanding of 
Ikaros mediated regulation of gene expression. 
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ABSTRACT 
During the progression along the B-cell lineage, B cell progenitors underwent a series of 
proliferation and quiescence stages, in which the immunoglobulin loci were sequentially 
rearranged and expressed. Thus, different stages in the developmental process present 
distinct energetic and biomass precursors demand. The transcription factor Ikaros promotes 
the cycling to resting transition during B-cell development by down-regulating 
proliferation genes, such as Ccnd2/3 and Myc, and up-regulating genes relating to B cell 
differentiation, such as Rag1 and Rag2. Moreover, Ikaros has been shown to down-
regulate genes related to glycolysis and oxidative phosphorylation, indicating an active role 
in cell metabolism changes. Here we report the construction and characterization of 3 
cycling preB cell lines expressing the inducible Ikaros cassette and 3 different FRET-based 
sensors to detect the cellular metabolic changes mediated by Ikaros expression. The 3 
FRET sensors are specific for the detection of cytoplasmic ATP (Ateam) and glucose 
(FLII
12Pglu_700Δ6) levels and for the AMPK activation status (AMPKAR-NES). We set 
up a fluorescence microscopy- and a FACS- based assays to monitor the FRET intensities 
before and after Ikaros induction. Preliminary results from fluorescence microscopy 
indicate a minor glucose uptake and AMPK activation in Ikaros-induced cells, while for 
the ATP level, no clear results have been obtained so far with our experimental design. 
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6.1 INTRODUCTION 
During lymphopoiesis, B cell precursors pass through different stages of proliferation and 
quiescence, necessary for antigen receptor loci rearrangement and cell maturation
1
. The 
succession of these developmental stages is orchestrated by different transcription factors 
acting in synergy or as antagonists
2,3
. At the preB stage, B cell precursors experience a 
burst in proliferation stimulated by preBCR signals guided by cell cycle regulator Cyclin 
D3 and the oncogene Myc
4
.  Subsequently, components of the preBCR are down-regulated 
by piloting the cells out of cell cycle in order to rearrange the Ig light chain loci
1
. The 
transition from cycling preB to resting preB is driven by the activation of the transcription 
factors Ikaros and Aiolos, which directly repress Myc and thereafter Cyclin D3 
expression
5
. 
Cells regulate their metabolism depending on the energetic demand as well as on the 
availability of biomass precursors
6
. In lymphocytes the transition from a resting to a 
proliferative state is accompanied by a switch from a metabolism based on oxidative 
phosphorilation to one based mainly on glycolysis
7,8
, also called aerobic glycolysis since 
oxygen even if present is not required. Although the amount of the ATP produced by 
glycolysis is 18 times lower than by oxidative phosphorylation, the glycolytic process is 
much faster, providing a higher rate of ATP production compared to the tricarboxylic acid 
cycle (TAC). Moreover, glycolysis intermediate products are used by cells as precursors in 
different biosynthetic pathways, essential for biomass production of  proliferating cell
9
. 
Both in T and B cell activation, the up-regulation of aerobic glycolysis and TAC down-
regulation are piloted by Myc activation
8,10
, whereas during the cycling to resting preB 
transition, glycolytic genes are shown to be down-regulated after Ikaros activation. The 
role of Ikaros in the metabolic switch is dual: an indirect one caused by Ikaros-mediated 
down-regulation of Myc and its downstream target genes, and a direct one, as ChIP 
experiments demonstrated Ikaros binding at promoters of glycolysis genes (Ferreirós-Vidal 
I., et al, unpublished data). Here, we reported the construction and characterization of a 
FRET-based model to study the metabolic state of preB cells during the cycling to resting 
transition. Förster resonance energy transfer (FRET) is a quantum mechanical effect 
observed when 2 fluorophores are located in the near-field. Light energy absorbed by a 
donor fluorophore is transferred to a nearby acceptor fluorophore with an absorption 
spectrum that overlaps the emission spectrum of the donor. In our study, we used 3 FRET 
sensors able to detect ATP concentration (Ateam
11
), glucose concentration 
(FLII
12
Pglu_700Δ612) and AMPK activation status (AMPKAR-NES13). ATP concentration 
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is a direct measurement of the energetic state of cells; glucose uptake level is an indicator 
of the type of metabolism used by cells, as glycolysis needs more glucose uptake compared 
to oxidative phosphorylation to produce a comparable amount of ATP. Finally, AMPK is 
activated by a high AMP/ATP ratio
14
 and is therefore considered as a physiological sensor 
of cellular energetic state. 
6.2 MATERAL AND METHODS 
Plasmids 
The inducible-Ikaros sequence, as well as the Ateam, FLII
12
Pglu_700Δ6 and AMPKAR-
NES FRET sensors were contained assembled in murine stem cell virus (MSCV) retroviral 
plasmids. The transcription was driven by the 5‟ MSCV long terminal repeat. 
Cell Culture 
The murine preB cell line B3 was isolated and cloned in Professor Fisher‟s lab from a 
lymphoma occurring in an IL-7 transgenic mouse (Fisher et al 1995). This cell line was 
maintain in culture in Iscove‟s modified Dulbecco medium (IMDM) containing 10% (v/v) 
foetal calf serum (FCS) (Biosera) and antibiotics (100U/ml Penicillin and 100µg/ml 
Streptomycin, GIBCO, Invitrogen) . Cells were kept in culture at a density between 0.1 and 
1 x 10
6
 cells/ml. 
The human embryonic kidney 293T cell line was cultured in Dulbecco modified Eagle 
medium (DMEM) supplemented with 10% (v/v) FCS, 2mM L-glutamine and antibiotics. 
Virus production 
293T cells were cultured in 10cm petri dish at approximately 40% of confluence in 9 ml of 
DMEM medium. 4µg of MSCV vector and 4µg of pECO or 10A1 envelop helper plasmid 
DNA were added to 500 µl of 0.4M CaCl2 solution.  500µl of 2x HEBS (12mM dextrose, 
50mM HEPES, 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4 + 2H2O in sterile water) 
were then added to the plasmid mix drop by drop. The transfecting solution was added to 
the cells drop by drop-wise. The cell medium was changed 12h after transfection. After 
24h, 3.5ml of fresh media was added to cells, and virus-containing media were collected at 
36, 48 and 60 hours from transfection, and pooled together. 
Infection 
The retroviral media was filtered with a 0.22µm filter, and supplemented with 10mM pH 
7.6 HEPES and 4µg/ml polybrene (Sigma-Aldrich). 1.3 millions of B3 cells were 
suspended in 3ml of retroviral media and plated in a 6-well plate. Cells were then 
CHAPTER 6: A FRET-BASED SYSTEM FOR METABOLIC STUDIES ON LYMPHOCYTES 
111 
 
centrifuged for 90‟ at 37 °C at 2500rpm to increase the infection rate. Retroviral media was 
then changed with fresh one and cells were put at 37 °C. 48h later, infected cells were 
sorted by FACS for the positivity at mCherry and eCFP fluorophores. 
Cell sorting 
Cells were sorted using FACSAria IIu, based on positivity to specific panels of fluorescent 
proteins (mCherry). For sorting, cells were resuspended in basic sort buffer (1x phosphate 
buffered saline (PBS) Ca/Mg
++
 free, 1mM EDTA, 25mM HEPES pH 7.0, 1% FCS) and 
collected in PBS Ca/Mg
++
 free supplemented with 20% of FCS. Sorted cells were then 
cultured for at least 24h in complete media supplemented with 5µg/ml of gentamycin. 
Cell cycle analysis 
Cells (0.5x10
6
)
 
were washed once in PBS
-/-
, and then re-suspended in 300µl of propidium 
iodide buffer (PBS-/- supplemented with 10µg/ml RNAsi A (life technologies, NY, USA), 
50µg/ml propidium iodide (Sigma-Aldrich) and 0.05% v/v NP40 (Calbiochem, Merck 
Millipore)). Cells were incubated 10‟ at room temperature and 20‟ on ice and subsequently 
analysed using a DB LSRII flow cytometer. 
Ikaros induction 
Exogenous ERt2-Ikaros was induced to transfer from cytoplasm to the nucleus by adding 
0.5µM of 4hydroxytamoxifen (4OHT, Sigma-Aldrich). Time course experiments were 
performed by inducing Ikaros translocation at different times and processed at the same 
endpoint for subsequent analysis. 
FRET analysis by fluorescent microscopy 
Glass-bottom culture dishes were coated with Poly-L-Lysine (Sigma-Aldrich) for 1h at 37 
°C and then washed twice with PBS-/-. 1x 10
6
 cells were re-suspended in 2ml of complete 
IMDM media and seeded in coated plates for 2h. Ikaros induction was performed as 
previously described, 16h before the analysis. Cells were washed once and then topped up 
with 2ml of DMDM media (Sigma-Aldrich) without phenol-red, supplemented with 25mM 
D-glucose, 25mM HEPES, 1mM sodium pyruvate, 2mM L-glutamine and 10% v/v FCS. 
Living cells were imaged using an OLYMPUS IX70 (Leica) microscope with a Coolsnap 
HQ camera through a 40X dry objective lens in an environmental chamber at 37 °C. eCFP-
eYFP/mVenus and mCherry were excited using 434/17 and 565/25 nm excitation filters 
and were acquired with 470/24, 559/38 and 632/60 nm emission filters respectively. Every 
5‟ 8 image recordings were made for each sample. After the second image, different 
compounds were added to the dishes and changes in FRET signal were monitored every 5‟ 
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for a total of 30‟. For the Ateam sensor, 10µM of Rotenone and 20µM of antimycin 
(Sigma Aldrich) are used (to inhibit the oxidative phosphorylation); 20µM of Phloretin 
(Sigma Aldrich) is used for FLII12R sensor (to inhibit the glucose transporter), and 50µM 
of 991 is added at AMPKAR-NES sensor cells (to activate the AMPK kinase). Analysis 
were performed using Fiji software. The FRET value was calculated as the yellow-to-cyan 
ratio. 
FRET analysis by FACS 
Ikaros induction was performed as previously described, 16h before the analysis. 2 million 
cells were washed once with warm PBS-/-, and then re-suspended in 2ml of DMDM media 
(Sigma-Aldrich) without phenol-red, supplemented with 25mM D-glucose, 25mM HEPES, 
1mM sodium pyruvate, 2mM L-glutamine and 10% v/v FCS. FRET measurements were 
performed wt FACSAria IIu. To measure eCFP and FRET, cells were excited with the 405 
nm laser and fluorescence was collected in the eCFP channel with a 480/40 filter, while the 
FRET-signal was measured with a 525/50 filter. For each sample 10,000 eCFP/eYFP 
positive events were analyzed. 
6.3 RESULTS 
In order to study metabolic changes in developing-B cells, we took advantage of the 
murine preB cell line B3
15
 established in Prof Merkenschlager‟s lab, as a model of cycling-
preB cells. This cell line was transduced with an inducible Ikaros cassette that allows us to 
precisely control the nuclear translocation of Ikaros
16
. For an extensive explanation of the 
inducible Ikaros system, see the results paragraph of chapter 5. 
To study the dynamic alterations in the cellular energetic status prompted by Ikaros, 3 
different FRET sensors were adopted: The Ateam
11
 (Adenosine 5′-Triphosphate indicator 
based on Epsilon subunit for Analytical Measurements) sensor was used to measure ATP 
levels and the FLII
12Pglu_700Δ612 sensor was used to measure glucose concentration. An 
AMPKAR sensor was fused to a nuclear export signal to generate AMPKAR-NES
13
, 
which selectively measures AMPK cytoplasmic activity (Chennel G. et al., unpublished 
data) (Figure 6.1).  Ateam is composed by the ε subunit of the Bacillus sp. PS3 FoF1-ATP 
synthase
11
. The corresponding dissociation constant (kd) is 7.4μM, so it can detect 
differences of ATP levels in the micro-molar range. The glucose-binding domain of the 
FLII
12Pglu_700Δ6 sensor derived from the glucose/galactose chemotactic receptor from E. 
coli, with a kd of 660μM, within the range of physiological glucose concentration changes. 
The AMPKAR-NES sensor is formed by a synthetic peptide optimized for the favourable 
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substrate motif of AMPK, and by the phosphothreonine-binding domain FHA1. 
Phosphorylation of the substrate reporter by AMPK caused its subsequent binding with 
FHA1, resulting in juxtaposition between the donor and the acceptor. In living cells, 
responses obtained by the AMPKAR-NES sensor were consistent with results obtained by 
western blotting with antibodies against AMPK phosphorylation-targets, indicating the 
suitability of the FRET-sensor for detecting AMPK activity
13
. 
 
Figure 6.1: Schematic representation of the FRET-sensors used in this study. A) ATP and glucose 
sensors are formed by a single ligand recognition protein that changes conformation after ligand binding, 
while B) the AMPK-sensor is formed by an AMPK-phosphorylation recognition site that is bound by a 
phosphothreonine-binding module of the same sensor. Binding causes a conformational change that brings 
the fluorophores in close proximity and allows FRET. All sensors are formed by the FRET donor-acceptor 
pair eCFP-eYFP/mVenus (eYFP for FLII12Pglu_700Δ6, and mVenus for Ateam and AMPKAR-NES). 
 
All the sensors were genetically linked with enhanced CFP (eCFP, a variant of the cyan 
fluorescent protein) at the N-terminus and with enhanced YFP (eYFP, in 
FLII
12Pglu_700Δ6) or mVenus (in Ateam and AMPKAR-NES), 2 variants of the yellow 
fluorescent protein) at the C-terminus. These fluorochromes retain the excitation and 
emission spectra of the original CFP and YFP proteins, but were genetically engineered to 
increase the brightness and quantum yield in the case of eCFP
17
, or to be less sensitive to 
pH changes and chloride ions in the case of eYFP/mVenus
17,18
. 
The 3 sensors were separately transduced into B3-inducible Ikaros cells. Each cell line was 
subsequently sorted for eCFP and mCherry to ensure high and homogeneous expression of 
FRET sensors and inducible Ikaros (for a more comprehensive explanation of inducible 
Ikaros and mCherry correlation, please see the results paragraph of chapter 5). 
The cellular levels of Ikaros and FRET-sensors were verified by western blot (Figure 6.2). 
For Ikaros detection, a primary antibody against the C-terminal part of the protein was 
used, while the FRET sensors were detected by using a primary antibody (Clontech JL-8) 
that recognized GFP and GFP-derived variants such as eCFP and eYFP. Ikaros levels were 
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comparable between the 3 cell lines as expected, since they were sorted for the same levels 
of mCherry. The 3 FRET sensors had the predicted molecular weights and were present in 
comparable amounts. 
 
Figure 6.2: Evaluation of Ikaros and FRET-sensors by western blotting. Protein was extracted from the 
3 FRET-sensor cell lines and from wt-B3 inducible Ikaros as a control. Inducible Ikaros was detected by an 
α-Ikaros antibody, the FRET sensors were detected using an α-GFP antibody that recognized GFP and GFP-
derived variants such as eCFP and eYFP. 
 
To test the efficiency of gene regulation by inducible Ikaros in established cell lines, we 
performed gene expression analysis by RQ-PCR after 30‟ and 1h of 4OHT induction, on 3 
Ikaros down-regulated (Ccnd2, Igll1 and Myc) and one up-regulated gene (Lig4). The 
expression was normalized to Ubc and Ywhaz housekeeping genes, and subsequently 
calculated relative to the EtOH control. Igll1 and Myc were significantly down-regulated at 
30‟, and Ccnd2 after 1h; Lig4 enhanced expression is detected after 1h 4OHT treatment. 
Thus, inducible Ikaros could efficiently regulate the expression of its target genes in our 
experimental model. 
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Figure 6.3: Regulation of gene expression triggered by Ikaros induction. Relative expression of genes in 
Ateam, AMPKAR-NES and FLII
12
Pglu cells before (EtOH) or after 30‟ or 1h of 4OHT induction are 
displayed. Data shown are an average of 3 biological replicates. Standard errors are reported. Student T test 
p value: *p<0.05, **p<0.01, ***p<0.001. 
 
It is important to keep in mind that the observed gene-expression changes referred to the 
level of immature transcripts. Alterations in cell metabolism are slower, and require that 
modifications at gene expression level are translated to protein levels. 
During B cell development, the metabolic switches take places concomitantly with 
proliferation-state changes. Ikaros and the Ikaros family member Aiolos had previously 
been reported to block cell cycle progression in preB cells, mainly caused by direct down-
regulation of transcription factor Myc, leading to an accumulation in the G1 phase
16,19
. To 
confirm the cell cycle block induced by Ikaros, the cell cycle profile of Ateam, AMPKAR-
NES and FLII
12Pglu_700Δ6 cells was investigated at different time points by propidium 
iodide (PI) DNA staining (Figure 6.4). 
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Figure 6.4: The cell cycle profile of Ateam cells after Ikaros induction. PI staining was performed at 
different time points after Ikaros induction. The graph reports the percentages of cells in G1, S and G2 
phases of the cell cycle. 
 
Cells were induced with 4OHT at different time points, and were analysed by FACS at 2h, 
4h, 8h, 12h, 16h and 24hours after 4OHT treatment. The DNA content profile of Ateam 
cells, as an example, is displayed in Figure 6.4. The cell cycle arrest at G1 started at 8h and 
increased in magnitude during induction. G1 was more powerful in our models compared 
to the previously published data on the B3 inducible Ikaros cells
16
. This was probably due 
to the very high level of inducible Ikaros present in our cells. FACS analysis on Ateam 
cells at 24h revealed a population of cells with altered forward and side scatter parameters. 
Cell stress after long periods of Ikaros induction had been observed earlier and is probably 
due to an impairment of the differentiation process in preB cells due to the lack of a proper 
niche that normally provides for essential surviving signals. Considering that, further 
experiments were conducted on cells treated with 4OHT for 16h. 
Ikaros translocation caused changes in the energetic state of B3 cells 
To measure metabolic changes upon Ikaros induction, the 3 FRET-sensor cell lines were 
seeded in glass-bottom culture dishes coated with Poly-L-Lysine, and were cultured for 
16h in the presence of 4OHT or carrier (EtOH). Cell medium was changed to DMDM 
(Sigma-Aldrich) without phenol-red, to limit the auto-fluorescence of the media, and 
supplemented with 25mM D-glucose, 25mM HEPES, 1mM sodium pyruvate, 2mM L-
glutamine and 10% v/v FCS to maintain the same concentration of these metabolites as 
compared to the usual cell culture medium. Cells were then positioned in an environmental 
chamber at 37°C and were imaged using an OLYMPUS IX70 (Olympus) epi-fluorescence 
microscope. For each experiment, 4OHT-treated samples and controls were imaged 
synchronously. To measure the resonance energy transfer between the eCFP donor 
fluorochrome and the eYFP/mVenus acceptor, we excited the eCFP with a 434/14 nm 
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excitation filter and we acquired the eYFP/mVenus emission (sensitizedYFP, sYFP) with a 
YFP 559/38nm emission filter. eCFP and mCherry emission signals were acquired as well 
for further analysis with a 470/24nm and 632/60nm emission filters respectively. In our 
experimental conditions, the sYFP signal can be influenced by 2 factors: 1) direct YFP 
excitation caused by eCFP excitation filter, and 2) a bleed-through of eCFP emission in the 
sYFP detection filter. By using the 434/14nm excitation filter to excite eCFP, the direct 
excitation of YFP is negligible. Instead, the eCFP signal partially bled through into the 
YFP emission filter. The bleed-through component is consistent between the treated and 
control samples, so we initially wanted to see if changes in FRET signal could be detected 
over the bleed-thought noise. For every experiment, 2 images were taken every 5 minutes. 
As control of the functionality of the biosensors, after the second image, either inhibitors or 
activators were added to the cell medium and the response monitored by acquiring 
additional 6 images every 5 minutes. Specifically, in order to perturb ATP production, we 
added rotenone and antimycin that inhibit oxidative phosphorylation. To block glucose 
uptake, we used phlorerin, that inhibits the GLUC- transmembrane glucose-transporters
20
. 
To assess AMPK activation we used compound 991, a direct activator of AMPK
21
. 
FRET was calculated as the ratio between sYFP/eCFP emissions at the different time 
points. We first evaluated the possible photo-bleaching of eCFP. To do that, we acquired 
eCFP signal 3 times every 5‟. eCFP signal did not significantly change over time in our 
experimental conditions, indicating the absence of photo-bleaching. 
Figure 6.5 reports the results obtained from one replicate of the FLII
12Pglu_700Δ6 cell line 
as an example of the performed analysis. eCFP, sYFP and mCherry levels were 
extrapolated, for each time point, from 368 and 306 treated and control cells, respectively. 
The FRET value of 4OHT and EtOH treated samples was calculated as the average of the 
excitedYFP and eCFP signals of the first 2 images. FRET ratio was significantly lower in 
Ikaros-induced cells compare to control sample, suggesting a lower glucose uptake in these 
cells (Figure 6.5A). This result was confirmed when eCFP and sYFP channels were 
analyzed individually. As shown in Figure 6.5B, the eCFP signal was higher and the sYFP 
was lower in 4OHT treated cells compared to control samples. Finally, we analyzed the 
cellular response to the glucose transport inhibitor phloretin (Figure 6.5C). Five minutes 
after phloretin addition, the eCFP signal increased, and the increment remained constant 
over the 30‟ of the experiment. The sYFP decreased its intensity over time, but in a lower 
amount compared the increment of eCFP signal. This phenomenon could be explained by a 
bleed-through effect of eCFP in the eYFP channel, as the eCFP emission spectrum 
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partially overlaps with that of eYFP. These results were confirmed in another biological 
replicate. Taken together, these data demonstrate that after Ikaros induction, the glucose 
uptake in cells diminished. In our experimental conditions, we were able to detect changes 
in FRET values caused by Ikaros induction and by the addition of phloretin. Analysis of 
single channels behaviour corroborated our results, showing that a change in the FRET 
ratio value was due to a change in both eCFP and sYFP channels, at opposite directions. 
Similar experiments were conducted on the Ateam and AMPKAR-NES expressing cells. 
AMPK activity as detected by the AMPKAR-NES sensor was significantly decreased after 
Ikaros induction, as demonstrated by a lower FRET ratio in 4OHT treated cells compared 
to the EtOH control (Figure 5.6D). Analysis of individual channels before addition of 
compound 991 showed a higher eCFP signal in Ikaros induced- compare to controlled 
cells, while the sYFP channel was lower respect to the control sample, confirming the 
FRET-ratio data. However, the results obtained for this sensor did not reach statistical 
significance in the second biological replicate we performed. For Ateam cells, in our 
experimental conditions we were not able to detect any clear difference between 4OHT 
and EtOH controls neither between pre and post inhibitor addition. One possible 
explanation could be that the differences we were trying to detect were too small for the 
sensitivity of our sensors, or the bleed-through of the eCFP covered the small changes in 
the FRET signal between Ikaros-induced and un-induced cells. In this regard, increasing 
the number of analyzed cells might allow to detect small significant differences between 
4OHT treated- and control samples. 
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Figure 6.5: FRET measurements by epi-fluorescence microscopy. FLII
12Pglu_700Δ6 cells were treated 
with 4OHT or EtOH for 16h and subsequently imaged by fluorescence microscopy. Cells were then treated 
with 20μM Phloretin and imaged every 5‟ for a total of 30‟. A) FRET was calculated as 
sensitizedYFP/eCFP signals. The FRET value before phloretin addition was calculated as the average of the 
2 acquired images, while the signal after phloretin addition refers to the last acquisition, after 30‟ of 
phloretin treatment. 368 treated cells and 306 control cells were acquired; B) Relative intensities of eCFP 
and excitedYFP of 4OHT and EtOH treated cells before phloretin addition; C) Variation over time of eCFP 
and excitedYFP signals before and after addition of phloretin of 4OHT treated cells; D) FRET intensities in 
AMPKAR-NES cells treated with 4OHT or EtOH for 16h. After 2 acquired images, 50μM of compound 
991 was added to AMPKAR-NES cells. 410 treated 4OHT- and 495 EtOH control cells were analyzed for 
AMPKAR-NES. Mann-Whitney Rank Sum test p value: ***p<0.001. 
 
To overcome these problems, we set up a methodology to read the FRET signal by flow 
cytometry. To establish a FACS assay, we produced 2 cell lines expressing only CFP or 
YFP fluorochromes. To do that, we permanently transduced wt-B3 cells with a MSCV 
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vector containing the CFP coding sequence under the control of MSCV long terminal 
repeat. CFP positive cells were then sorted by FACS. The eYFP single positive cells were 
primary lymph node cells from a CD4Cre transgenic mouse with lox-STOP-lox-YFP 
targeted into the endogenous Rosa26 locus. 24h before the FACS reading, T cells were 
activated using α-CD3 and α-CD28 antibodies to more closely resemble B3 cells in size 
and background fluorescence. We gated on living cells according to forward and sideward 
scatter parameters and then adjusted the photomultiplier tube voltages and compensation to 
avoid bleed-through between the channels. CFP was excited at 405nm and the signals were 
acquired at 480nm for CFP and at 525nm for YFP. 
Ateam and FLII
12Pglu_700Δ6 cells were then analyzed (Figure 6.6). We took 2 
measurements of each sample, before and after 30‟ of rotenone and antimycin or phloretin 
treatment. After compound treatments, FACS detected an increase in eCFP signal and a 
decrease in the excitedYFP signal, indicating that our assay was able to detect changes in 
the FRET ratio. 
 
Figure 6.6: FRET measurements by flow cytometry. Ateam and FLII12Pglu_700Δ6 cells were analyzed 
by FACS before and after 30‟ of inhibitor treatment (Rotenone and antimicyn for Ateam, phloretin for 
FLII12Pglu_700Δ6). eCFP was excited at 405nm, and eCFP and excitedYFP were acquired with 480_40 
and 525_50 emission filters respectively. 
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6.4 DISCUSSION 
In this chapter, we constructed and characterized 3 preB cell lines in order to study changes 
in the cellular metabolism triggered by Ikaros activation. Three FRET sensors were 
transduced in wt-B3 cells already transduced with the inducible Ikaros cassette. The 3 
FRET sensors were specific for ATP, glucose, and the AMPK activity, 3 important 
indicators of cellular energetic state. Using FRET-based analysis, we attempted to measure 
changes induced by Ikaros induction in real time and in living cells. 
To test our models, we induced Ikaros translocation and analysed the effects 16hours later, 
when cells had stopped cycling. Preliminary results obtained by fluorescence microscopy 
showed a decreased glucose  level in cells hence a decreased uptake by Ikaros induced 
cells and a decrease in AMPK activity. Taken together, the information obtained from the 
2 sensors suggested a metabolic switch from aerobic glycolysis (2 ATP produced from 
every glucose molecule) to oxidative phosphorylation (36 ATPs produced from a single 
glucose molecule). Switching to oxidative phosphorylation as the main metabolic pathway, 
cells would require less glucose to produce a higher amount of ATP that results in a lower 
activation of AMPK decreasing the ratio of AMP/ATP. The data analysed so far were 
consistent with a lower uptake of glucose in Ikaros induced cells, while for the other 2 
sensors data did not in all cases reach statistical significance and further analysis is 
required. The possible causes of discrepancies between biological replicates can be the 
very small change in ATP level before and after Ikaros induction, hard to detect for our 
FRET sensor, as well as the bleed-through between the eCFP and eYFP channels. To 
refine our analysis, CFP and YFP single positive cells were generated and will be imaged 
by microscopy. FRET analysis will be performed with the aid of software designed to 
correct the FRET-channel signal to the undesired bleed-through signal
22
. 
In parallel to microscopy analysis, we started to set up a FACS-based methodology to 
detect and quantify the FRET signal. Flow cytometry will allow us to acquire in a 
reasonable amount of time the eCFP, excitedYFP and mCherry levels of a large number of 
cells, adding robustness to our analysis. Moreover, FACS is a powerful tool to reduce the 
bleed-through signal between channels, by means of compensation and gating. Very 
preliminary experiments performed at FACS on Ateam and FLII
12Pglu_700Δ6 cells before 
and after addition of inhibitors demonstrated that FACS can detect a difference in FRET 
signal, indicating that this technique can be applied for further experiments. Next we will 
test Ateam, FLII
12Pglu_700Δ6 and AMPKAR-NES cells after Ikaros induction. 
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CHAPTER 7 
DISCUSSION 
Since its discovery in 1992
1
, the transcription factor IKAROS and other protein family 
members became one of the most studied transcription factors in B-cell development and 
malignancies. Ikaros is expressed since the earliest stages of haematopoiesis, where 
contributes to CLP specification enhancing lymphoid-priming genes expressions and 
extinguishing genes related to stemness, myeloid and erythroid specification
2
. In 
lymphopoiesis, Ikaros expression pilots B cells through subsequent developmental stages, 
activating genes involved in immunoglobulin loci maturation and down-regulating genes 
involved preBCR signalling and proliferation
3–5
. Ikzf1 transgenic mice models displayed 
severe haematological disorders, including delayed and impaired thymocytes 
differentiation, a complete block of B- and NK cells commintment
6–8
, and developed T-cell 
leukaemia/lymphoma at high penetrance
9
. 
In human, IKZF1 deletions were found in 15% of B cell precursors paediatric and adult 
acute lymphoblastic leukaemia, and in 70% of Philadelphia+ BCP-ALL
10
. The clinical 
relevance of ΔIKZF1 in paediatric BCP-ALL, as well as its possible introduction as a risk 
stratification factor is however still debated. The ΔIKZF1 prognostic impact was recently 
evaluated in 2 paediatric Ph+ BCP-ALL cohorts before and after the introduction of TKI in 
clinical protocols
11
. ΔIKZF1 correlated with worse EFS and CIR in pre-TKI patients, and 
with a worse OS in post-TKI patients stratified as „good-prognosis‟. Considering the high 
incidence of IKZF1 deletions and their negative impact on prognosis, we took advantage of 
next generation amplicon deep-sequencing to evaluate the presence of point mutations and 
very small indels in Ph+ BCP-ALL patients. Since Ph+ ALL represent 2% of the total ALL 
paediatric cases, we set up an European multicenter study collecting 98 IKZF1-not deleted 
and 61 IKZF1-deleted specimens. We found that 4% of IKZF1 non deleted- and 3.2% of 
IKZF1 deleted-patients carried mutations in the IKZF1 coding sequence, mainly located in 
exons 5 and 8. Ikaros mutations and macrodeletions behaved in the same manner 
concerning the impact on prognosis, as the majority of IKZF1 mutated patients that 
experienced an adverse event (relapse or dead) when treated before the introduction of TKI 
in clinical protocols. The milder effect of IKZF1 aberrations on prognosis in TKI-treated 
patients may indicate a possible effect of imatinib on the activation status of IKZF1. 
CHAPTER 7: DISCUSSION 
126 
 
Thanks to our approach, we identified a new class of patients carrying previously under-
estimated mutations
12,13
, with an impact on IKAROS activity that has to be take into 
consideration in future studies in order to have a precise evaluation of IKZF1-aberrations 
impact in prognosis. This could be particularly important for other leukemic subgroups, 
such as Ph-like or B-other patients, where ΔIKZF1 are still predictors of lower EFS and 
higher CIR
14–20
. 
 
A further advantage of NGS technique is its capacity to provide a quantification of the 
mutation load in terms of a MAF of the detected mutations. In the wake of this new 
approach we identified the first case of a familial IKZF1 germline mutation. Genetic 
familial predisposition to leukaemia was thought to be an extremely rare event, and only 
recently 3 familial leukaemia cases related to a point mutation in a well-known leukemic 
gene were described 
21,22
. The single nucleotide frameshift deletion was identified in both 
proband‟s diagnosis and remission samples with a MAF of 50%, was consistent with a 
constitutive heterozygous mutation. Sequencing analysis on proband‟s parents uncovered 
the same aberration in the mother‟s DNA. The mutation was then observed in 3 other 
members of the family among 3 generations, all without any manifested haematological 
disturbances; a brother of the mother had died of leukaemia during childhood, but no 
material was available to evaluate the genetic state of IKZF1. The mutated allele was found 
to be actively transcribed in proband‟s mRNA at remission and in his sister‟s mononuclear 
cells, and the predicted truncated proteins was identified in proband sister‟s peripheral 
cells. The mutated protein, expressed in a HeLa cell model, revealed a diffuse nuclear 
localization, indicating a null-effect of the mutation on IKAROS function. The low 
penetrance of leukaemia in mutation carriers points to the importance of secondary adverse 
events for the instauration of a leukemic cell clone. Indeed, the leukemic clone at diagnosis 
carried the t(9;22) translocation, a strong leukemogenic factor. 
 
Even if the importance of Ikaros in lymphopoiesis is well established, mainly through 
genetic ablation studies in transgenic mice
6,7,9,23
, the mechanisms and the temporal order of 
events that culminates in Ikaros-mediated gene expression regulation are only partially 
understood. Ikaros can interact with both inhibitors and activators of transcription, 
depending on the cell type and the developmental stage of a cell
5,24–27
. We took advantage 
of an inducible Ikaros system developed in Prof. Merkenschlager‟s lab3 to construct and 
characterized 2 cellular models to further insight in the role of Ikaros in B-cell 
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development using a murine preB cell line. The inducible Ikaros system allowed us to 
control in a temporal fashion the translocation of Ikaros protein in the nuclei, where it 
exploits its functions. 
 
In the first model, endogenous Ikaros was knocked-out using the CRISPR-Cas9 gene 
editing tool. As a result, we were able to study the effects of Ikaros in gene expression 
regulation in “Ikaros free” nuclei. Inducible Ikaros was able to efficiently translocate in the 
nuclei after induction with 4-hydroxytamoxyfen, and bound the promoter region of a well 
known Ikaros target gene, Igll1. The gene expression regulation of selected Ikaros target 
genes was then evaluated. In the endogenous Ikaros-ko context, inducible Ikaros was able 
to up-regulate target genes, but was not shown to down-regulate some of its most 
important targets, among which Igll1 and Myc. After Ikaros induction, Ikaros-ko cells did 
not experience any block in the cell cycle, whereas in endogenous-Ikaros wt cells a 
prominent block in G1 phase after inducible Ikaros translocation was displayed. 
 
The Ikaros-piloted cell cycle arrest in our preB cell model partially recapitulates the 
transition from cycling preB to resting preB cells, a crucial step during B-lymphocytes 
development. 
In the second model, Inducible Ikaros was used to study the metabolic changes caused by 
its translocation in endogenous-Ikaros wt cells after the cell cycle arrest. Three FRET 
sensors were expressed in B3 inducible Ikaros cells, to monitor the cellular level of ATP 
and glucose, and the activation of AMPK protein. The FRET-reading was tested by 
fluorescent microscopy after 16 hours of Ikaros induction. Preliminary results on Ikaros 
induced cells show a diminished level of glucose uptake, and a lower level of AMPK 
activation, consistent with a metabolic switch from aerobic glycolysis to oxidative 
phosphorylation. These results need to be corroborated by further experiments and 
biological replicates. Finally, a method to read the FRET signal by flow cytometry was 
evaluate, and preliminary tests on ATP and glucose sensors showed that FACS can 
efficiently detect changes in donor and acceptor channels after treatment with inhibitors of 
glucose transporters and oxidative phosphorylation. 
 
In conclusion, we studied the role of IKZF1 in haematopoiesis and in paediatric leukaemia, 
in order to provide new insight and tools to better elucidate IKAROS‟ position in 
leukemogenesis and regulation of normal blood cell development. 
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Reﬁnement of IKZF1 status in pediatric Philadelphia-positive
acute lymphoblastic leukemia
Leukemia (2015) 29, 2107–2110; doi:10.1038/leu.2015.78
Philadelphia-positive B-cell precursor acute lymphoblastic leuke-
mia (Ph+ BCP-ALL) identiﬁes an unfavorable subgroup of pediatric
ALL characterized by the presence of the BCR-ABL1 chimeric
protein. However, clinically Ph+ BCP-ALL remains a heterogeneous
disease with an unfavorable response to therapy in a critical
percentage of patients. Even though introduction of tyrosine
kinase inhibitors (TKIs) has improved outcome in pediatric Ph−
BCP-ALL patients, 30% still relapse or die.1
Recurrent genomic deletions within the IKAROS (IKZF1) gene
locus have been identiﬁed in Ph+ BCP-ALL2 and BCP-ALL in
general, and recent the work of van der Veer et al.3 has shown that
clinical heterogeneity in response to therapy at least in part may
be attributed to the mutation status of IKZF1 in Ph+ BCP-ALL
patients.4,5
IKAROS is a transcription factor composed of two regions: the C
terminal, including two zinc-ﬁnger (ZF) domains, that is respon-
sible for the homo–hetero dimerization of the protein,6 and a
N-terminal domain with four ZFs, responsible for the DNA-binding
activity: ZF2 and ZF3 ensure a stable DNA-binding, whereas ZF1
and ZF4 regulate the interaction to speciﬁc genomic sites.7,8
Deletions of IKZF1 can be subdivided into three categories:
dominant-negative deletions, characterized by loss of the DNA-
binding domain, deletions causing haploinsufﬁciency that lack the
C-terminal dimerization domain and null deletions, that corre-
spond to large chromosome 7 deletions or loss of the ATG codon.9
Even though the role of IKZF1 deletions as a prognostic factor has
been extensively investigated, remaining sometimes controversial,5
little is known about other genetic alterations at the IKAROS
locus.4,10 The aim of this study was to assess the incidence of single-
nucleotide mutations and in/del in the coding sequence of IKZF1.
Leukemic samples of 98 pediatric Ph+ BCP-ALL patients at
diagnosis were collected from six European centers that
participated in the ‘Ponte di Legno’ (pre-TKI) cohort11 study and
the European study for Ph+ ALL (EsPhALL).1 The latter study used
a combination of high-risk chemotherapy and imatinib treatment.
The 98 patients we analyzed had previously been considered
IKZF1 wild type (WT) as they were free from IKZF1 deletions as
revealed using the MLPA analysis (see Supplementary Figure S3).
Sequencing analysis of IKZF1-coding exons, from exon2 to
exon8 (Supplementary Table ST2), was performed using amplicon
next generation sequencer GS Junior 454 (Roche Applied Science,
Penzberg, Germany), using two-step universal-tailed amplicon
sequencing. Today, next-generation sequencing-based sequen-
cing strategies are a well-accepted robust substitute for Sanger
sequencing12 that can be applied in a clinical setting. Moreover,
next-generation sequencing reliably detects mutations well below
the detection rate of Sanger sequencing, provides a mutant allele
frequency rate (MAF) and allows a robust and sensitive detection
of insertions or deletions. Sequences of 882 amplicons were
obtained with predicted average coverage per amplicon of 250
reads (range 102–853) and a minimum coverage of 50 reads in
forward and reverse strands. Amplicon sequences were analyzed
using the Amplicon Variant Analyzer (Roche Applied Science)
software, obtaining a total of 313 variants. To identify predicted
deleterious mutations a pipeline (Supplementary Figure S1) was
applied that exclude intronic variants, homopolymeric stretches,
known single-nucleotide polymorphisms and silent mutations. In
addition, a threshold of 10% of variant detection in both strands
was set. Finally, we obtained 14 variants with predicted
deleterious effects in the IKZF1-coding sequence corresponding
to 12 distinct mutations in 12 out of 98 patients (12.2%) including
three patients from three different centers that were carrying the
same mutation (Figure 1 and Supplementary Table ST1). The 12
mutations can be subdivided into two categories: those localized
in the DNA-binding domain with a predictive dominant-negative
effect (ﬁve missense mutations) and haploinsufﬁciency aberra-
tions, that impaired the dimerization activity of IKAROS (seven
frameshift mutations).
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The ﬁve missense mutations were located in exon5, of which
four were localized within the ZF2-coding sequence, essential for
DNA–protein interaction. All missense mutations were predicted
to be ‘probably deleterious’ by PolyPhen213 (score 0.999) and
‘damaging’ by SIFT14 (score 0.001) bioinformatic tools.
Regarding the mutated amino acids in the ZF2 domain, Asn159
and Arg162 (Figure 1) are known to be crucial for the maintenance
of the α-helix domain structure, and their substitutions are
described to have impaired the DNA-binding activity of the
protein.8 The Cys150 (mutated into Arg) is one of the four Cys/His
residues that coordinate the zinc atom of the domain, and the
mutation is predicted to severely impair the function of the
domain as well. Of note, the p.Asn159Ser (c.A4764G) substitution
is carried by three patients (3% of IKZF1 non-deleted patients).
Altogether six patients carried point mutations in the ZF2-coding
sequence with a predicted deleterious impact.
The seven frameshift mutations (two deletions, four insertions
and one InDel) were identiﬁed at different positions within the
IKZF1 locus, two in exon5, one in exon7 and four in exon8. These
mutations cause shifts in the reading frame that predict the
formation of premature stop codons and consequent depletion
the C-terminal dimerization domain of the protein.
The MAF of IKZF1 mutations was in most cases consistent
with a heterozygous mutation in the entire blast population
(Supplementary Table ST1); only in three cases (MRC-UK-12, BFM-
G-1 and AIEOP-24) MAF suggested a IKZF1-mutated subpopulation.
Two patients carried double mutations: in one case, the two
mutations in exon5 were reciprocally exclusive (p.Glu142Profs*49
and p.Arg143Gln), whereas in the second case mutations were
located in different exons (p.Leu160Val in Exon5 and p.Arg274* in
Exon7). In both cases one of the two mutations was present at a
higher MAF (60% for p.Glu142Profs* versus 25% for p.Arg143Gln,
and 51,5% for p.Leu160Val versus 36% for p.Arg274*), indicating the
presence of leukemic subpopulations characterized by different
IKZF1 mutations. For six of 12 mutated patients, a remission sample
was available, and Sanger sequencing demonstrated absence of the
mutations in the tumor-free bone marrow.
The clinical characteristics of the 12 mutated patients are
described in Supplementary Table ST1. Among the six mutated
patients who had been treated before the introduction of TKI (pre-
TKI cohort), four relapsed and one died in continuous complete
remission (CCR). The latter is in line with the previously reported
impact of IKZF1 deletions in pre-TKI patients and suggests that
IKZF1 mutations behave in the same manner as deletions in terms
of their associations with poor outcome in Ph+ patients. In the
EsPhALL cohort, only one of the six mutated patients who were
treated with imatinib failed (died in CCR), pointing to a diminished
impact of aberrant IKZF1 on patient outcome.
Figure 2. Overview of IKZF1 in Ph+ BCP-ALL pediatric patients. Percentages were calculated for each group on the basis of the number of
IKZF1-mutated patients detected by amplicon NGS in 98 patients. NGS, next-generation sequencing.
Figure 1. Location and type of IKZF1 mutations: gray squares deﬁne the coding exons of IKZF1; red squares represent the zinc-ﬁnger domains.
Each circle represents a detected mutation.
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Recently, we reported the impact of IKZF1 deletions on outcome
of Ph+ BCP-ALL.3 The study included 191 patients (see
Supplementary Figure S3); 84 recruited in the pre-TKI cohort and
107 in the EsPhALL, post-TKI cohort. Overall, 65 patients (40%)
were deﬁned as ‘wild-type’ on the basis of the absence of IKZF1
deletions and, of these, 64 had been included in our mutation
screening (one was excluded because of lack of material). Six of
these 64 patients carried IKZF1 deleterious mutations, three from
the pre-TKI cohort and three from the EsPhALL cohort. IKZF1-
mutated and -deleted patients were grouped together (N= 132,
‘IKZF1-aberrant’ patients) and their outcome compared with that
of ‘true’ WT IKZF1 (without deletion or mutations) Ph+ BCP-ALL
patients (N= 59). The new disease-free survival curves of pre-TKI
and EsPhALL cohorts conﬁrmed the poor prognosis of patients
with IKZF1 aberrations (deletions plus mutations; 4-year disease-
free survival 28.1% (standard error (SE) 6.4) versus 64.3% (SE 9.7),
P= 0.0036 in pre-TKI; 4-year disease-free survival 55.7% (SE 6.8)
versus 59.8% (SE 11.6; P= 0.348) in EsPhALL, 4-year disease-free
survival 56.8% (SE 9.4) versus 75.0% (SE 21.7) in EsPhALL Good risk
group; Supplementary Figure S2).
In conclusion, this work has demonstrated the presence of
IKZF1 mutations in 410% of pediatric Ph+ BCP-ALLs previously
classiﬁed as IKZF1 WT on the basis of deletion analysis alone.
Exon5, which encodes ZF2 and ZF3 domains, carried 9 out of 14
aberrations: 7 point mutations and 2 deletions. The presence of
the high number of mutations in the domain and the recurrence
of one of them in three patients prompt us to consider this region
as a hotspot locus for mutation acquisition. All missense mutations
are predicted to be deleterious by two bioinformatic tools
employed in this study and by in vitro mutagenesis studies,8
and all the small in-del aberrations lead to the formation of
premature stop codons. Overall, our observations have contrib-
uted to the reﬁnement of disease-free survival analysis of Ph+
BCP-ALL patients with IKZF1 aberrations. In the pre-TKI cohort,
IKZF1-mutated patients showed a similar outcome as compared
with IKZF1-deleted patients. The prognostic impact of the IKZF1
mutations in imatinib-treated patients is more attenuated and
may indicate the presence of other pathogenic mechanisms,15 as
well as a possible effect of therapy on the activation status of
IKZF1. Considering the high incidence of nucleotide aberrations
observed in our study, we would like to stress the importance of
including these mutations in the overview of IKZF1 aberrations
(Figure 2 and Supplementary Figure SF4). This new category of
IKZF1-mutated patients, previously masked in the IKZF1 WT group,
behaves in the same manner as IKZF1-deleted patients in both
pre- and post-TKI era, and needs to be considered for a precise
estimation of the impact of aberrant IKZF1 in leukemogenesis and
disease progression.
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PD-L1/PD-1 presence in the tumor microenvironment and
activity of PD-1 blockade in multiple myeloma
Leukemia (2015) 29, 2110–2113; doi:10.1038/leu.2015.79
Despite remarkable therapeutic improvement in multiple mye-
loma (MM), prognosis is very poor once patients become
refractory to or ineligible for proteasome inhibitors and immuno-
modulatory drugs. Accordingly, new drugs are clearly needed for
this patient population, and extensive efforts are leading to a new
breed of antimyeloma drugs.1 In this regard, the PD-1/PD-L1 axis
has recently emerged as a master immune checkpoint that
controls antitumor immune responses against many neoplasms.
Namely, PD-L1-expressing tumor cells in the tumor microenviron-
ment engage PD-1 on tumor-inﬁltrating T lymphocytes to repress
antigen-driven activation.2 PD-L1 expression is also considered an
adaptive resistance mechanism as PD-L1 is induced on tumor cells
when under immune attack in response to immune-stimulating
cytokines such as interferons.2 Importantly, antibodies to PD-1 and
PD-L1 have already shown clinical activity in melanoma,3 renal-cell
carcinoma,4 non-small-cell lung cancer,2 refractory Hodgkin
lymphoma and bladder cancer. Predictive correlates of response
mainly based on the expression of PD-L1 and the abundance of
T lymphocytes are being intensively investigated.3,4
In MM, clinical trials targeting the PD-L1/PD-1 axis are already
being conducted,5 even though only two (discordant) studies
have investigated expression of PD-L1 on CD138+ PCs: one
showed that PD-L1 is commonly present (although at low levels),6
whereas the other report found PD-L1 to be positive in only ~ 25%
of patients.7 Accordingly, it could be the case that not all MM
patients are equally likely to beneﬁt from therapeutic targeting of
the PD-1/PD-L1 axis, at least when used in monotherapy
strategies. Discordant results have also emerged regarding levels
of PD-1 expression on T and Natural killer (NK) cells from
MM patients.8–10 In vitro experiments showed increased MM cell
death after enhancement of T-cells9 and NK-cells8 with anti-PD-1
monoclonal antibodies (mAb), whereas only two in vivo studies
have been performed; both evaluated anti-PD-L1 mAb in the
5T33 mouse model either after autologous (syngeneic) stem-cell
transplantation plus administration of a cell-based vaccine or after
lymphodepleting irradiation, showing survival improvement.9,11
Here, we sought to deﬁne the expression of PD-L1 and PD-1 in
clonal PCs as well as T and NK cells on bone marrow (BM) aspirates
from monoclonal gammopathy of undetermined signiﬁcance
(MGUS) and MM patients at diagnosis, after treatment (minimal
residual disease (MRD)) and upon relapse by using standardized
multidimensional ﬂow cytometry (MFC). We then evaluated
efﬁcacy of anti-PD-1 mAb therapy in a syngeneic mouse model
after intravenous injection of 5TGM1 secretory MM cells.
We prospectively studied 107 patients, including 20 MGUS and
87 MM (47 at diagnosis, 25 after treatment to monitor MRD and 15
at relapse); normal BM samples were obtained from healthy
volunteers or individuals undergoing orthopedic surgery (n= 9).
All samples were collected after receiving informed consent, in
accordance with local ethics committees and the Helsinki
Declaration.
MFC was performed on EDTA anticoagulated BM samples,
immunophenotyped using a direct 8-color immunoﬂuorescence
stain-and-lyse technique, with the following combination
of monoclonal antibodies (PacB/OC515/FITC/PE/PerCP-Cy5.5/PE-
Cy7/APC/APCH7): CD45/CD138/CD38/CD56/PD-1/CD19/PD-L1/CD3
and HLA-DR/CD27/CD45RA/CCR7/PD-1/CD25/CD8/CD4. In the
ﬁrst combination, we measured PD-L1 (Biolegend, San Diego,
CA, USA; clone 29E.2A3) expression on normal and clonal PCs after
careful discrimination according to aberrant phenotypic proﬁles,12
as well as the percentage of PD-1+ NK-cells (SSCloCD45+CD56+
CD19–CD3–) using the Inﬁnicyt software (Cytognos, Salamanca,
Spain). In the second combination, we determined the percentage
of PD-1+ CD4 and CD8 T-cells, as well as the distribution of PD-1+
versus PD-1– according to peripheral maturation stage and
activation status. Data acquisition was performed for ⩾ 106
leukocytes/tube in a FACSCantoII ﬂow cytometer (BD Biosciences,
San Jose, CA, USA) by using FACSDiva software (BD Biosciences;
version 6.1). Instrument performance was monitored daily with
cytometer setup beads (BD Biosciences) and rainbow 8-peak
beads (Spherotech, Inc.; Lake Forest, IL, USA) after laser stabiliza-
tion, following the EuroFlow guidelines; sample acquisition was
systematically performed after longitudinal instrument stability
was conﬁrmed. Flow data were analyzed with Inﬁnicyt software
(Cytognos).
We established mouse 5TGM1 myeloma cells from the
transplantable mouse 5T33 myeloma of spontaneous origin.13
5TGM-1 cells (0.75 × 106 per mouse) were intravenously inoculated
via the tail vein into 6- to 8-week-old female naive C57BL/
KaLwRijHsd mice.14 Immediately after tumor cell inoculation, mice
were randomly assigned for treatment with control rat immu-
noglobulin G antibody (Sigma-Aldrich, St Louis, MO, USA) or
anti-PD-1 mAb (RPMP1-14 BioXcel). Doses were 100 μg of mAb
every other day for three doses on days 3, 6, and 9 after tumor cell
inoculation. Mice were checked twice weekly for survival or signs
of terminal disease. Weight loss appeared only when mice
reached a terminal status and could not be attributable to
potential side effects. We assessed 5TGM1-speciﬁc monoclonal
paraprotein (IgG2bκ) in sera prepared from whole blood obtained
by submandibular vein puncture of tumor-bearing mice under
light methoxyﬂurane-induced anesthesia. We assayed mouse
IgG2bκ levels by using a speciﬁc in-house sandwich enzyme-
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Impact of IKZF1 deletions on IKZF1 expression
and outcome in Philadelphia chromosome 
negative childhood BCP-ALL. Reply to “Incidence
and biological significance of IKZF1/Ikaros gene
deletions in pediatric Philadelphia chromosome
negative and Philadelphia chromosome positive 
B-cell precursor acute lymphoblastic leukemia” 
We thank Dr. Qazi and Dr. Uckun for their letter that
focused on the biological relevance of IKZF1 deletions in
pediatric acute lymphoblastic leukemia (ALL), and in par-
ticular on the lack of correlation between IKZF1 deletions
and the expected deregulation of IKZF1 expression. This
information clearly supports the findings of our study1 and
our suggestion that the unfavorable prognostic role report-
ed for Ikaros deletion may be due to general genetic insta-
bility rather than to Ikaros deletion per se, and justifies the
hypothesis put forward by Qazi and Uckun that no speci-
fic biological effect is associated to Ikaros deletion. This
issue is extremely relevant in this field, since a precise de-
finition of the pathogenic mechanisms associated to IKZF1
deletions is crucial for the ongoing efforts to define new
targeted therapies for ALL.
Whilst the authors did infer IKZF1 gene expression data
without knowing the exact correspondence of IKZF1
deleted and wild-type (wt) cases, to experimentally test
the hypothesis, we have analyzed the gene expression
data of IKZF1 wild-type versus deleted cases in our own
gene expression data set of pediatric ALL patients. From
the MILE study2 and further proprietary unpublished data,
array-based gene expression was analyzed for 60 IKZF1
wild-type and 10 deleted cases belonging to the cohort of
410 patients reported in our recent paper on IKZF1-rela-
ted outcome.1 Through analysis of the expression levels of
two probe sets located in exon 4, no changes in IKZF1
expression were observed that could be expected from
heterozygous deletions of IKZF1 (Figure 1). It has to be
considered, however, that analysis of gene expression data
of single probe sets is not the most appropriate method to
detect gene expression variances of single genes or iso-
forms. In particular, probe sets 1565816_at and
1565818_s_at both show overall a very low expression,
which largely reduces the probability to detect expression
variance, if there is any. Therefore, we performed the
analysis of IKZF1 gene expression by real-time quantita-
tive-PCR (Figure 2). Although there was a tendency for a
lower IKZF1 expression in IKZF1 deleted cases compared
to wt, this difference did not reach statistical significance,
because of several outliers in both groups. This supports
the hypothesis by Qazi and Uckun that IKZF1 expression
deregulation is very likely not a driving biological player in
BCP-ALL cases with intragenic or entire deletions of
IKZF1, thus raising the question on what is the biological
mechanism related to IKZF1 deletions and prognosis in
ALL. 
Our data do not support, however, the suggestion of
Qazi and Uckun that in pediatric BCP-ALL IKZF1 dele-
tions occur in a minority of leukemic cells in an oligoclonal
heterogeneous population of leukemic B-cell precursors. In
our study,1 having applied the low-sensitivity multiplex lig-
ation-dependent probe amplification (MLPA) technique
(which is not able to detect aberrations in minor cell pop-
ulations), we should in fact have detected only IKZF1 dele-
tions in major cell subpopulations.1 Although alternative
sensitive tests could detect IKZF1 subclonal deletions,3
their prognostic significance should be evaluated.
On the other hand, whether IKZF1 deletions occur in
‘inactive’ alleles, although fascinating, must be formally
demonstrated in a context different from the canonical one
for IG/TR loci,4 as a new mechanism of escape from major
damage, that, to our knowledge, has yet to be described in
literature. 
Certainly, the hypothesis that IKZF1 deletion-associated
adverse outcome would be a reflection of underlying
genomic instability in aggressive leukemic clones, rather
than lost or diminished IKZF1 function caused by IKZF1
haploinsufficiency, as originally proposed,5,6 merits further
investigation. 
haematologica 2013; 98:e164
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Figure 1. Gene expression values for IKZF1 probes 1565816_at (A)
and 1565818_s_at (B) in patients with (DEL) and without (WT)
IKZF1 deletions. 
Figure 2. Gene expression values for IKZF1 by RQ-PCR in patients
with (DEL) and without (WT) IKZF1 deletions. Boxes include 10-90
percentile, mean (internal line) and median (cross) are shown.
Dots indicate outliers. 
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The prognostic significance of IKZF1 deletions in our
study1was, indeed, enhanced when additional copy num-
ber abnormalities (CNA) involving other genes were pre-
sent. We specifically looked by MLPA 385 kit at
CDKN2A/B, PAR region, PAX5, ETV6, BTG1, RB1 and
EBF1 deletions. In our series, out of 54 IKZF1 deleted
cases, 28 carried additional CNA. More precisely, 16 had at
least one additional lesion (in 11 of 16 this was the ETV6
deletion), 6 had 2 and 6 had 3 additional CNA. The inci-
dence of additional CNA was the same in final Standard or
Intermediate Risk groups. Out of the only 4 cases at High
Risk, one had no CNA additional to IKZF1 deletion. Nine
were the relapses among the 28 IKZF1 deleted cases with
additional CNA versus only 3 out of 25 IKZF1 deleted cases
without additional CNA, pointing to a poor outcome
when a major genetic instability was observed.1
Still, we are also puzzled by having observed no differ-
ence in outcome in haploinsufficient patients (with whole
IKZF1 gene deletion) versus cases carrying the dominant
negative ∆4-7 deletion variant.1 Interestingly, in Ph+ ALL,
which frequently carry IKZF1 deletions, the haploinsuffi-
cient cases have an even worse outcome compared to
cases carrying the ∆4-7 deletion variant (A van der Veer et
al., 2013, submitted manuscript). This further observation
indicates that either the suspected deleterious (post-tran-
scriptional) effect of the dominant negative ∆4-7 deletion
variant is not worse than losing one IKZF1 copy, or that
both aberrations are epiphenomena of genetic instability.
It is also interesting to observe that IKZF1 deletions and
other CNA are over-represented in the so-called ‘Ph-like’
subgroup of BCP-ALL cases with gene expression signa-
tures similar to Ph+ ALL without the presence of the t(9;22)
translocation.6-8 Thus, it remains difficult to separate the
contribution of single gene aberrations from a cumulative
effect of several aberrations on the biology of leukemic
cells, as reflected by a common gene expression signature.
In any case, if the hypothesis of IKZF1 deletions in inac-
tive alleles holds true, and/or assuming that the IKZF1
deletion is only an epiphenomenon of the accumulation of
CNA, it still remains to be demonstrated that other CNA
occur in active alleles, and altogether (or specifically some
of them) are responsible for the worse outcome as a mani -
festation of broader chromosomal instability. One interest-
ing candidate to look at is the CRLF2-P2RY8 fusion, which
has been shown to have an independent worse outcome.9
It would be very instructive to collect cases carrying both
IKZF1 deletions and CRLF2-P2RY8 fusion and analyze the
effect of their combination on outcome and evaluate
whether this could be separated from additional CNA. 
Chiara Palmi,1 Tobia Lana,2 Daniela Silvestri,3 Angela
Savino,1 Geertruy Te Kronnie,2 Valentino Conter,4 Giuseppe
Basso,2 Andrea Biondi,4 Maria Grazia Valsecchi,3
and Giovanni Cazzaniga1
1Centro Ricerca Tettamanti, Clinica Pediatrica, Università di
Milano Bicocca, Ospedale San Gerardo/Fondazione MBBM,
Monza; 2Laboratorio di Oncoematologia, Dipartimento di Pediatria,
Università di Padova; 3Centro di Biostatistica per l’Epidemiologia
Clinica, Università di Milano Bicocca, Monza; and 4Clinica
Pediatrica, Università di Milano Bicocca, Ospedale San
Gerardo/Fondazione MBBM, Monza, Italy.
Correspondence: abiondi.unimib@gmail.com
doi:10.3324/haematol.2013.099077
Key words: IKZF1 deletions, pediatric Ph- BCP-ALL, 
copy number abnormalities, prognosis.
Acknowledgments: this work was supported by grants from:
Fondazione Tettamanti (Monza), Fondazione Città della Speranza
(Padova), Associazione Italiana Ricerca sul Cancro (AIRC) (to GB,
AB, MGV, GteK and GC), MIUR (to GB and AB), Fondazione
Cariplo (to AB, GC and GteK) and CARIPARO project of 
excellence (to GteK). This work was (partly) funded by the
European Commission (FP7) under the contract ENCCA 
(NoE-2011-261474).
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
References
1. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter
V, et al. What is the relevance of Ikaros gene deletions as prognostic
marker in pediatric Philadelphia negative B-cell precursor acute lym-
phoblastic leukemia? Haematologica. 2013;98(8):1226-31.
2. Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, et
al. IKZF1 deletion is associated with a poor outcome in pediatric B-
cell precursor acute lymphoblastic leukemia in Japan. Cancer Med.
2013;2(3):412-9. 
3. Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V,
et al. Breakpoint-specific multiplex polymerase chain reaction
allows the detection of IKZF1 intragenic deletions and minimal
residual disease monitoring in B-cell precursor acute lymphoblastic
leukemia. Haematologica. 2013;98(4):597-601. 
4. Brady BL, Steinel NC, Bassing CH. Antigen receptor allelic exclu-
sion: an update and reappraisal. J Immunol. 2010;185(7):3801-8. 
5. Mullighan CG, Su X, Zhang J, Radtke I, Philips LAA, Miller CB, et
al. Deletion of IKZF1 and Prognois in Aute Lymphoblastic
Leukemia. N Engl J Med. 2009;360(5):470-80.
6. Mullighan CG, Miller CB, Radtke I, Phillips LA, Ma J, White D, et al.
BCR-ABL1 lymphoblastic leukemia is characterized by the deletion
of Ikaros. Nature. 2008;453(7191):110-4.
7. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH,
Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute
lymphoblastic leukaemia with poor treatment outcome: a genome-
wide classification study. Lancet Oncol. 2009;10(2):125-34.
8. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS,
Bedrick EJ, et al. Identification of novel cluster groups in pediatric
high-risk B-precursor acute lymphoblastic leukemia with gene
expression profiling: correlation with genome-wide DNA copy
number alterations, clinical characteristics, and outcome. Blood.
2010;116(23):4874-84. 
9. Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G,
et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2
over-expression in children with intermediate risk B-cell precursor
acute lymphoblastic leukemia. Leukemia. 2012;26(10):2245-53.
haematologica 2013; 98:e165
LETTERS TO THE EDITOR
©
F
e
rr
a
ta
 S
to
rt
i F
o
u
n
d
a
tio
n
  
2
0
1
3
APPENDIX 
141 
 
APPENDIX 3 
 
  
Analyst
PAPER
Cite this: DOI: 10.1039/c5an02377g
Received 17th November 2015,
Accepted 23rd November 2015
DOI: 10.1039/c5an02377g
www.rsc.org/analyst
Sensing protein antigen and microvesicle analytes
using high-capacity biopolymer nano-carriers†
Saroj Kumar,‡§a Gloria Milani,‡b Hideyo Takatsuki,‡a Tobia Lana,b Malin Persson,a
Chiara Frasson,b Geertruy te Kronnieb and Alf Månsson*a
Lab-on-a-chip systems with molecular motor driven transport of analytes attached to cytoskeletal
ﬁlament shuttles (actin ﬁlaments, microtubules) circumvent challenges with nanoscale liquid transport.
However, the ﬁlaments have limited cargo-carrying capacity and limitations either in transportation speed
(microtubules) or control over motility direction (actin). To overcome these constraints we here report
incorporation of covalently attached antibodies into self-propelled actin bundles (nanocarriers) formed by
cross-linking antibody conjugated actin ﬁlaments via fascin, a natural actin-bundling protein. We demon-
strate high maximum antigen binding activity and propulsion by surface adsorbed myosin motors. Analyte
transport capacity is tested using both protein antigens and microvesicles, a novel class of diagnostic
markers. Increased incubation concentration with protein antigen in the 0.1–100 nM range (1 min)
reduces the fraction of motile bundles and their velocity but maximum transportation capacity of >1
antigen per nm of bundle length is feasible. At sub-nanomolar protein analyte concentration, motility is
very well preserved opening for orders of magnitude improved limit of detection using motor driven con-
centration on nanoscale sensors. Microvesicle-complexing to monoclonal antibodies on the nanocarriers
compromises motility but nanocarrier aggregation via microvesicles shows unique potential in label-free
detection with the aggregates themselves as non-toxic reporter elements.
Introduction
Cheap, rapid and sensitive methods for diagnostics of disease
using simple blood or urine samples aid strategies to overcome
accelerating health care costs. In this context, there is growing
interest to develop lab-on-a-chip devices1–3 where a series of
analyses are performed on a single chip. These devices are pre-
ferably integrated with nanoscale sensors for optimal sensitivity
and multiplexing capabilities4 e.g. to detect a panel of analytes/
biomarkers (proteins, nucleic acid fragments, exosomes, micro-
vesicles etc.). However, despite significant progress,2 existing
devices often use expensive and bulky accessory equipment2,3
including pumps for driving liquid flow. Moreover, liquid flow
does not overcome limitations associated with diﬀusion of bio-
markers to nanoscale detectors.4 Other potential problems
include biosafety issues5 e.g. related to the use of potentially
toxic inorganic nanostructures as reporter elements signaling
the presence of analyte molecules.
In order to circumvent the above problems, lab-on-a-chip
systems with molecular motor driven transport have been
proposed.6–11 In some tested versions of such arrangements,
recognition molecules, e.g. antibodies12–14 or oligonucleo-
tides15,16 are attached to cytoskeletal filaments (actin filaments
and microtubules) that are propelled by molecular motors for
nanoseparation and concentration on a detector area.8,17,18
Importantly, due to self-propelling features of the system
(driven by turnover of adenosine-5′-triphosphate, ATP), these
motor-propelled cytoskeletal shuttles19 do not require external
pumps. Furthermore, they capture biomarkers from a large
solution volume and actively7 transport them to the detec-
tor,6,8,9 thereby overcoming diﬀusion limitations. In addition,
the detection may be achieved in unique ways, e.g. by obser-
vations of co-localization and co-transportation of filaments
and biomarkers12,20–22 or by aggregation of the cytoskeletal
filaments via analyte.10,23 Due to the large number of fluo-
rescent dye molecules that may be attached to each filament,
†Electronic supplementary information (ESI) available: Materials and methodo-
logical details including protein preparations, preparation of flow cells, antibody
conjugation to actin, in vitro motility assays and formation and characterization
of antibody-labeled fascin–actin bundles, CD45 expression: screening of cell
lines and MVs isolation, MVs isolation and preservation in MOPS buﬀer, optim-
ization of CFSE staining and extended MV shelf-life. Furthermore, ESI figures
and movies. See DOI: 10.1039/c5an02377g
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aggregates are readily detected without labeling with e.g. fluo-
rescent, and potentially toxic, nanoparticles.
Both the actin and myosin II motor system (underlying
muscle contraction) and the kinesin or dynein and micro-
tubule systems (underlying intracellular transport) have been
explored in work towards motor driven lab-on-a-chip devices
(cf.;12,20–22 reviewed in ref. 10 and 24) each with diﬀerent
advantages and challenges.10 The actin filaments thus exhibit
ten-fold higher speed with rapid transport to a detector
site10,18 whereas microtubule based transport may be more
robust against cargo induced disturbances.10 Furthermore, the
higher flexural rigidity of microtubules facilitates guiding
along microfabricated tracks25 and enhances concentration on
a detector.18,26
For both the microtubule- and actin-based system, anti-
bodies have been covalently attached to single filaments but it
would be desirable to increase the total number of active anti-
bodies on the surface of each nanocarrier.14 For optimized
molecular motor driven lab-on-a-chip devices it is also of inter-
est to combine the advantages of the microtubule and actin
based systems. It has been suggested27–29 that this should be
possible using unipolar bundles of actin filaments formed by
cross-linking via fascin, the protein that underlies actin-bund-
ling in filopodia at the leading end of motile cells. The fascin–
actin bundles exhibit high flexural rigidity similar to that of
microtubules28,30,31 but are propelled by myosin motors at
similar high velocity as individual actin filaments. The
bundles also have the capacity to carry cell-sized cargoes
without disturbances in motility.27 However, only streptavidin-
biotin links have been tested for cargo attachment with biotin
non-covalently attached to the actin filament via phalloi-
din.27,29 This approach cannot form the basis for a practically
useful device because the phalloidin-actin binding is reversible
with a dissociation half-time of around 20 min.32 It is, on the
other hand, not clear whether covalent antibody-conjugated
actin filaments14 can be incorporated into bundles together
with fascin. Furthermore, if this turns out to be possible it is
not self-evident that such a construct maintains self-propul-
sion and antigen binding.
Here we first demonstrate successful incorporation of co-
valently antibody-conjugated actin filaments into fascin–actin
bundles with well-preserved self-propulsion and an unpre-
cedented maximum capacity to bind and transport protein
antigens. The use of this novel nanocarrier allowed 10-fold
improvement in the signal-to-noise ratio for fluorescence
detection of protein antigens compared to single actin fila-
ments. We also studied binding and transport of microvesicles
(MVs), an emerging class of biomarkers in the form of lipid
vesicles (100–1000 nm) that are pinched oﬀ from living cells in
physiological and pathological conditions.33 The MVs exhibit
appreciable potential as biomarkers in cancer and other
diseases.34–42 Here, we found that MVs released by cells positive
for CD45 antigen were captured by actin filaments and actin
filament bundles functionalized with anti-CD45 monoclonal
antibodies. Even if nanocarrier based transportation of the MVs
was challenging, the capacity to capture the MVs opens for
novel label-free sensing schemes based on aggregation of fluo-
rescent actin filaments or fascin–actin bundles.23
Results and discussion
We report findings at the interface of biology, chemistry,
materials science and clinical medicine. A key element is pro-
duction of a novel self-propelled nanomaterial, a nanocarrier,
where covalent conjugation of antibodies to actin filaments is
combined with self-assembly of the filaments by specific bio-
molecular recognition using actin-binding proteins as cross-
linkers. We evaluate the performance of this nanocarrier in cap-
turing, transporting and detecting protein antigens as well as
microvesicles, a novel class of clinically relevant biomarkers.
Assembly of nanocarrier and capture of protein antigen
Actin filaments were first covalently conjugated with anti-
bodies, either polyclonal anti-rabbit IgG (a-rIgG) or mono-
clonal anti-CD45 (a-CD45), using hetero-bifunctional cross-
linkers.14,43–45 These antibody conjugated filaments formed
bundles upon mixing with the actin-binding protein fascin28,31
(Fig. 1). The success of this approach was somewhat surprising
in view of appreciably larger molecular weight (150 kDa) of the
antibodies than of fascin (∼57 kDa) and also a shape (Y-shape)
with expected larger eﬀective space occupancy. However, the
actin–fascin bundles with antibodies contained only 7.3 ± 2.2
filaments (mean ± 95% CI; N = 46 bundles), lowered (p < 0.05;
Fig. 1 Schematic illustration of the formation of fascin–actin bundles
with antibodies and subsequent transportation of antigen (Rh-rIgG) cap-
tured by antibodies. (a) Bundle formation from antibody-conjugated
G-actin monomers (I) via actin ﬁlaments (II) and ﬁnally, assembled
bundles (III). (b) HMM driven transport of Rh-rIgG antigen captured by
anti-rabbit IgG antibody.
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t-test) to 4.1 ± 1.7 filaments (N = 15) approximately 5 min after
ATP addition due to bundle disassembly (size distributions in
Fig. S1†). Simultaneously, the bundle fraction was reduced
from 15.3 and 14.6% to 7.6 and 10.6%, respectively, in two
experiments, reducing the fraction of filaments incorporated
into bundles from close to 60% to about 30%. The bundle size
was less than without antibodies (∼20).28,31,46 However,
antigen-binding to antibodies seemed to reduce the ATP-
induced disassembly, possibly due to cross-linking of neigh-
bouring filaments via antigen. For instance, the average
observed bundle size 5 min after ATP-addition was 6.4 ± 2.2
(N = 30) in the presence of 1 nM rhodamine labeled rabbit IgG
(Rh-rIgG).
Successful incorporation of a-rIgG conjugated actin fila-
ments (also Alexa Fluor®-488 phalloidin (APh) labeled) into
fascin–actin bundles was verified using fluorescence
microscopy (Fig. 2a–d and S2†) after immobilizing bundles to
a surface coated with heavy meromyosin (HMM) in the
absence of ATP. For this purpose we used fluorescent rabbit
IgG (Rh-rIgG) as antigen. Binding of Rh-rIgG to a-rIgG-actin
was observed both for individual actin filaments and fascin–
actin-bundles following 1 min of incubation (Fig. 2). The
results imply eﬀective incorporation of antibody-functionalized
actin filaments into the bundles as well as eﬀective antigen
binding of these antibodies.
Evaluation on basis of Rh-rIgG fluorescence intensity
(Fig. 2e), showed a concentration-dependent increase in the
fraction of bundles (independent of size) and single filaments
with observed Rh-rIgG labeling. The concentration depen-
dence of the binding was also reflected in increased stoichio-
metric ratio of Rh-rIgG to actin.
The fraction of labeled fascin–actin bundles increased from
1–5% at 0.1 nM to 100% at 10 nM Rh-rIgG, following 1 min
incubation (Fig. 2e). The results demonstrate appreciably
improved detection of antigen binding to bundles compared
to isolated filaments with limit of detection lowered from the
range 1–10 nM to 0.1–1 nM. Here, the number of Rh labeled
bundles and filaments were used as relevant signals. With
about 30% or more of all filaments incorporated into bundles
(see above) only limited additional improvement would be
achieved by preventing bundle disassembly by further cross-
linking (e.g. covalent or streptavidin-biotin based).
The degree of Rh-rIgG labeling was estimated for the most
heavily Rh-rIgG labeled bundles by comparing the Rh and the
APh intensity of the same bundles (see Experimental section).
This analysis suggests a highly variable maximum Rh-rIgG/
actin stoichiometric ratio of 0.14, 0.16 and 0.80 (at 10 nM Rh-
rIgG), in three independent experiments.
HMM driven transportation of captured protein antigen
We next asked whether the velocity and fraction of motile
HMM propelled filaments/bundles were aﬀected either by anti-
body-labeling (anti-rabbit IgG) and/or by the subsequent
binding of protein antigen (Rh-rIgG). Our results (Fig. 3 and
Movies S1–S4†) show that the mean fraction of motile bundles
and the mean sliding velocities decreased with increased Rh-
rIgG concentration. Whereas most (>80%) fascin–actin
bundles that were labeled with Rh-rIgG at 10 nM incubation
concentration were non-motile, one bundle with >1200 Rh-
rIgG bound per µm of its length (at 0.14 actin-Rh-rIgG ratio
and with ∼20 actin filaments) was propelled for more than
10 µm at a velocity of 2.4 µm s−1. This was more than 50% of
the velocity observed for bundles in the absence of antigen
and clearly demonstrates that high degree of Rh-rIgG loading
does not necessarily inhibit motility.
For large bundles the motility inhibition at high Rh-rIgG
binding was partly due to the formation of cross-links between
diﬀerently oriented parts of the bundles via antigens
(cf. Fig. S3†). On the other hand, the motility of an appreciable
fraction of single filaments, particularly small fragments was
also inhibited. This is related to the observation that the
amount of non-specifically adsorbed antigen outside filaments
and bundles was clearly increased when the Rh-rIgG concen-
Fig. 2 Capture of Rh-rIgG antigen by APh labeled actin ﬁlaments and
fascin–actin bundles. (a, c) APh labeling observed using a ﬂuorescein
isothiocyanate (FITC) ﬁlter set in epi-ﬂuorescence microscope. (b) Same
region as in (a) a few seconds later after switch to a tetramethyl rhoda-
mine isothiocyanate (TRITC) ﬁlter set for observation of Rh-rIgG anti-
gens (incubation with 10 nM for 1 min) captured by a-rIgG antibodies on
ﬁlaments and bundles. (d) Same region as in (c) a few seconds later after
switch to TRITC ﬁlter set for observation of Rh-rIgG antigens (incubation
with 1 nM for 1 min) on bundles. Inset. After histogram stretching for
maximum contrast and brightness. Full length arrows indicate bundles
whereas arrow-heads indicate occasional single actin ﬁlaments. Similar
exposure time and gain in (a) and (b) (exposure time 0.1 s) and in (c) and
(d) (0.4 s). The ﬁlaments and bundles are bound to a trimethyl-
chlorosilane (TMCS) derivatized surface coated with HMM in the
absence of ATP. (e) The fraction of isolated actin ﬁlaments (circles, black)
and fascin–actin bundles (squares, red) with Rh-rIgG labeling and the
Rh-rIgG/actin stochiometric ratio for the 2–4 bundles with most exten-
sive Rh-rIgG labeling (blue open circles). Incubation time, 1 min. Data
from 3 independent experiments at each Rh-rIgG concentration. Error
bars: range.
Analyst Paper
This journal is © The Royal Society of Chemistry 2015 Analyst
Pu
bl
ish
ed
 o
n 
23
 N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 d
i P
ad
ov
a o
n 
22
/1
2/
20
15
 1
9:
36
:2
6.
 
View Article Online
tration increased within the range 1 to 100 nM (shown for 0, 1
and 10 nM Rh-rIgG in Fig. S4†).
The eﬀect of Rh-rIgG binding on the fraction of motile
bundles was small for incubation concentrations of 0.1–1 nM
and motility was observed for several bundles carrying Rh-rIgG
antigen after incubation at 0.1 nM (Fig. 4). The good motility
under these conditions is in accordance with very low density
of Rh-rIgG, both non-specifically adsorbed to the surface and
specifically bound to antibodies on the bundles. However,
small but statistically significant changes in mean velocity and
increased variability in velocity (Fig. 3b) suggest disturbance of
motility also at low Rh-rIgG concentrations (<1 nM). Neverthe-
less, we have demonstrated that actin–fascin-antibody bundles
show appreciable potential to function as a novel nanocarrier
under several conditions.
Specific capture of CD45 positive microvesicles on actin
filaments
Leukemic cell lines were screened in order to select a cell
system positive for the CD45 cell surface antigen and for
robust in vitro production of MVs with CD45 positivity similar
to that of the cells. On this basis we selected the human T-cell
leukemia cell line DND41 cells as positive control (CD45+) and
an MG63 human osteosarcoma cell line as negative control
(CD45−) (Fig. S5 and S6†). MVs were isolated from both cell
lines and checked for CD45 presence by flow cytometry
(Fig. S7 and S8†).
Because MV-capture has not previously been attempted
using antibodies on single filaments, we first performed
experiments using isolated actin filaments labeled with CD45
specific monoclonal antibodies. Experiments were performed
using dilutions in the flow cell of 1/10–1/50 of standard MV
preparations from cell lines giving less than 200 MVs per
image frame after 5 min incubation. This includes non-specifi-
cally surface adsorbed MVs and MVs specifically captured by
antibodies. The specific capturing by anti-CD45-conjugated
actin filaments of CD45+ MVs, labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE), was confirmed by fluo-
rescence co-localization experiments. In these experiments
(Fig. 5), CFSE labeled DND41 MVs were captured by anti-CD45-
Fig. 3 Eﬀect of increasing Rh-rIgG incubation concentration on motility quality of fascin-crosslinked bundles composed of anti-rabbit-IgG-conju-
gated actin ﬁlaments also labeled with APh. (a) The fraction of motile bundles. Individual data points (black) from ﬁve observed image frames at 3
diﬀerent experimental occasions given with overall mean ± SEM (red). Signiﬁcant diﬀerence between overall mean values was observed at 0 and 0.1
nM on the one hand and 10 nM on the other. ***, p < 0.001; **, p < 0.01. (b) Sliding velocity. Individual data points (N = 10–31 bundles: black) at
each Rh-rIgG concentration from 3 diﬀerent experimental occasions given with overall mean ± SEM (red). Statistically signiﬁcant diﬀerence (p <
0.05) between mean values in all separate groups except in the case indicated by “n.s.” Temperature, 21–23 °C. Statistical hypothesis testing was per-
formed using one way analysis of variance (ANOVA) followed by Tukey’s post hoc test for diﬀerences between separate groups.
Fig. 4 Observation of motile fascin–actin bundles with captured Rh-
rIgG antigen after 1 min incubation with 0.1 nM Rh-rIgG. (a) Snapshot
(0.4 s) illustrating APh labeled actin ﬁlaments and fascin–actin bundles
imaged using epi-ﬂuorescence microscope and FITC ﬁlter set. Numbers
and circles depict three bundles that are motile and that transport Rh-
rIgG molecules as shown in (b). (b) ImageJ-derived Z-stack of same area
as in (a) after shifting to TRITC ﬁlter set. This image shows the standard-
deviation of the pixel intensities of 35 (0.4 s) image frames starting
approximately 10 s after the snapshot in (a). The weak bright traces (1–3)
indicate the motion of Rh-rIgG molecules during the 35 frame period.
The dashed lines indicate the approximate paths of the Rh-rIgG-carrying
bundles from the observations in (a).
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actin filaments in solution and then transferred to a HMM
coated surface. Epi-fluorescence microscopy using both FITC
and TRITC filter sets then clearly revealed CD45+ MV co-local-
ization with a-CD45-actin filaments (Fig. 5a). This suggests
extensive cross-linking of actin filaments with the formation of
large aggregates.
To assess the specificity of the binding of CD45 positive
MVs to anti-CD45-actin filaments, two diﬀerent analyses were
performed. First, no co-localization was observed between
anti-CD45-actin filaments and CD45 negative MVs, isolated
from MG63 cells (Fig. 5b). As a second negative control, CD45
positive MVs were incubated with tetramethylrhodamine iso-
thiocyanate-phalloidin (RhPh) labeled actin filaments (without
antibody) in solution. Neither in this case was any non-specific
binding of CD45 positive MVs to actin filaments detected
(Fig. 5c).
Capture and transportation of MVs by anti-CD45-fascin–actin
bundles
Anti-CD45 monoclonal antibodies were next incorporated into
fascin–actin bundles as described above for a-rIgG. We tested
whether these antibodies could capture CD45+ MVs and
whether the MVs could be transported by HMM. For this
purpose, the HMM coated flow cells were first incubated with
fascin-anti-CD45-RhPh actin filament nanocarriers and then
with MVs labeled with CFSE. After MgATP addition, the sliding
of the nanocarrier was observed (Fig. 6 and Movies S5, S6†)
using TRITC filter (RhPh labeled) while the possible transpor-
tation of MVs bound to carrier was visualized using FITC filter
(CFSE labeling). First, in 3 independent experiments (30–39
bundles in each) we found that 27 ± 5.4% (mean ± SEM) of all
bundles were associated with at least one CFSE labeled MV.
Fig. 5 Co-localization of antibody-conjugated or antibody-free actin ﬁlaments (RhPh labeled; TRITC panel, red) and CFSE labeled MVs (FITC panel,
green). (a) CFSE labeled CD45+ MVs captured by anti-CD45 conjugated actin ﬁlaments. Co-localization (yellow) observed in merged panel.
(b) MG63 MVs labeled with CFSE mixed with RhPh labeled and CD45 conjugated actin ﬁlaments. Note, no co-localization observed in merged panel.
(c) RhPh labeled actin ﬁlaments without antibodies mixed with CFSE-labeled and CD45+ MVs. Note, no co-localization observed. Scale bar: 10 µm.
Images in (c) subjected to smoothing and brightness adjustment by histogram stretching to reveal weak MV-CFSE ﬂuorescence. The labelling, “FITC”
and “TRITC” refer to ﬂuorescence ﬁlter used.
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The fraction of motile nanocarriers with or without captured
MVs were, in these experiments, 0.23 ± 0.09 (mean ± SEM)
when a MV was bound to the bundle and 0.28 ± 0.02 other-
wise. The velocity (µm s−1) of anti-CD45 antibody labeled
nanocarriers with and without captured MVs was 3.13 ± 0.28
and 3.28 ± 0.11. Thus, both velocity and the fraction of motile
carriers were similar in these experiments whether microvesi-
cles were observed to bind to the bundles or not.
However, the fraction of motile nanocarriers was reduced
following incubation with MVs (compared to >60% motile frac-
tion without MVs). This suggests that motility inhibition is
partly due to the exposure to the MV-containing solution and
not due to MV binding per se. However, cross-linking of
bundles via microvesicles, with formation of aggregates, also
contributes to motility inhibition, at least after some time of
sliding (Fig. 6b).
Key findings and relation to previous results
A central finding is the eﬀective incorporation of antibody-con-
jugated actin filaments into fascin–actin bundles to form a
novel complex biopolymer nanocarrier. This carrier exhibited
maintained fast actomyosin driven transportation and an un-
precedented maximum capacity to transport protein anti-
gens.14,22 A second key finding is the observation, for the first
time, of the MV capture by monoclonal antibodies on fila-
ments and bundles and aggregation of these filaments/
bundles via the MVs. Particularly, the aggregation in solution
is the first experimental verification of a recently patented idea
Fig. 6 Image sequences showing HMM propelled microvesicles and aggregation of fascin–actin bundles conjugated by CD45 antibody in the
in vitro motility assay. (a) Unidirectional movement of bundle (red) carrying microvesicle (green). (b) Small and large aggregates of stationary bundles
(red) formed by microvesicles (green) during transport. Bundles (red) and microvesicles (green) were visualized under TRITC and FITC ﬁlters, respect-
ively. Switch between ﬁlters between 4 and 6 s and 6 and 8 s in A and B, respectively. Arrows and arrowheads denote individual bundles with MVs
and stationary bundle-MV aggregates, respectively. Scale bar: 10 µm.
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for biosensing23 and our results demonstrate the potential of
this approach in detection of the emerging class of vesicular
biomarkers.33
The HMM driven velocity of bundles that carried protein
antigen was reduced by increased incubation concentration
but the eﬀects on motility were minimal after 1 min incu-
bation at concentrations of 1 nM or less. The statistically sig-
nificant eﬀects on velocity and fraction of motile filaments
seen in the 1–10 nM range could be useful as a basis for bio-
sensing applications.47 On the other hand, the minimal eﬀects
on motility at sub-nM concentration are also important by
enabling use of the nanocarrier in rapid nanoseparation and
concentrator nanodevices.8,18 At higher Rh-rIgG binding the
fraction of motile nanocarriers was reduced as well as the
sliding velocity but transport was occasionally maintained for
an analyte/G-actin stochiometric ratio up to almost 20%. This
is similar to what has been observed for single actin fila-
ments.14 However, importantly, with the bundles it corre-
sponds to as much as one analyte molecule every 1 nm (about
250 fluorophores per diﬀraction limited spot of 250 nm with
bundle diameter <100 nm). This can be compared to only 1
per about 20 nm for single actin filaments and microtubules.22
That is, the bundles provide 20-fold increased maximal
binding and transportation capacity per unit length. This
explains that all bundles had bound fluorescent analyte after
1 min incubation with protein antigen at 10 nM concentration
and that the limit of detection was improved one order of mag-
nitude compared to single filaments (see also14).
Our results suggest that the average antigen binding
capacity of the antibodies on nanocarries is at least as good as
for antibodies on isolated single filaments despite expected
complications due to inaccessibility to the bundle interior (see
above). This may be due to more eﬀective two-dimensional
diﬀusional search on the bundle surface compared to a fila-
ment surface,48 or to preferential location of antibodies on the
outside surface of the bundles.
Binding and transport of MVs has not been attempted pre-
viously whether microtubules, actin filaments or actin bundles
have been used as shuttles. On the other hand, lipid vesicles
of simple composition and with attachment to biotinylated
single actin filaments via streptavidin, appreciably compro-
mised motility of isolated filaments27,49 but not of fascin–actin
bundles.27 The latter finding is in contrast to the rather poor
transportation of MVs observed here, probably reflecting the
complexity of our cell-derived system compared to lipid
vesicles.
Mechanism of motility inhibition with increased analyte
concentration
Fascin cross-links actin filaments in a parallel arrangement,
with the same polarity of all filaments, i.e. with all rapidly
polymerizing plus ends of individual filaments in the same
direction.28,31,46 This arrangement is the basis for the eﬀective
transportation28,31 of fascin–actin bundles by myosin motor
fragments in the in vitro motility assay. Due to the large size of
antibodies compared to fascin one would expect a disturbance
in the ordered arrangement. Because the largest HMM-trans-
ported bundles contained 24 filaments, several filaments
must, in this case, be in the bundle interior. With an inter-fila-
ment distance of ∼8 nm50 determined by the size of the fascin
cross-links there would be little room for antibodies (dimen-
sions 14 × 8 × 4 nm3).51 This implies disturbances of the paral-
lel arrangement of the actin filaments which in that case may
have detrimental eﬀects on motile function. Alternatively, anti-
bodies attached to actin filaments are mainly on the bundle
surface (see above). The fact that bundle integrity was well
maintained with antibody conjugation is consistent with the
second alternative. This alternative is also consistent with well-
maintained motility49 in the absence of antigen capture and
for occasional large motile bundles. The idea also fits with
considerations that the energetic penalty of bundle formation
would be lowest with the covalently attached antibodies point-
ing outwards. We therefore conclude that antibody induced
disturbances in internal bundle structure has negligible eﬀect
on motility quality.
Instead we considered the possibility that a large fraction of
the antibodies and bound antigen on the outside of the
bundles inhibits actin–HMM interactions. Fluorescence data,
cannot distinguish between fluorophores in the interior of
bundles and on their surface. This suggests that the stoichio-
metric ratio between analyte molecules (preferably on the
bundle surface) and actin subunits (distributed uniformly over
the bundle cross-section) is higher on the bundle surface than
overall (i.e. >0.15). Therefore, the antibodies and their bound
protein antigens most likely block an appreciable fraction of
the actin monomers from HMM binding. Whereas this may be
a factor behind motility inhibition at high Rh-rIgG loading of
the bundles, we found no mandatory motility inhibition under
these conditions of maximum labeling. This accords with
recent findings49 where streptavidin was linked to 1/5 of the
actin monomers on biotinylated actin filaments without
reduction in sliding velocity.
One may then ask why the fraction of motile nanocarriers
and their velocity was reduced with increased analyte concen-
tration. After discarding the above suggestions we attribute
this finding to two mechanisms. First, several bundles and
filaments become cross-linked to each other via Rh-rIgG mole-
cules due to polyclonal a-rIgG antibodies on the bundles/fila-
ments (Fig. 5). Unlike the isolated fascin–actin bundles, these
higher order structures do not have all actin filaments oriented
in parallel and with their fast-growing plus end in one direc-
tion. Clearly, since the actin polarity determines the sliding
direction with myosin II walking towards the plus end of actin
filaments, such non-polar aggregates will inhibit motility.
Second, motility may also be inhibited if antibodies on fila-
ments and bundles cross-link to analytes non-specifically
bound to HMM or to the underlying motility assay surface.
Antibodies on the surface of the fascin–actin bundles that are
oriented downwards towards the HMM layer will not be readily
reached by diﬀusion during the incubation period. Upon
addition of ATP and gliding to other areas they may therefore
bind surface adsorbed analyte molecules, causing inhibition
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of motility in analogy to what is seen with so called loaded
motility assays.52 That the density of surface adsorbed analyte
molecules is increased at high analyte incubation concen-
tration was apparent from fluorescence micrographs (Fig. S4†).
Cross-linking of diﬀerent bundles via antigen was observed
to even higher degree in attempts to transport microvesicles.
However, also other factors may contribute to poor motility in
this case such as the lipid composition of the microvesicles.
The fact that the negatively charged actin filaments with anti-
CD45 antibodies formed cross-links with CD45-positive but
not with CD45-negative microvesicles is consistent with evi-
dence53 that the microvesicles predominantly express nega-
tively charged phospholipids on their surface. This finding is
of importance for detection schemes that rely on cytoskeletal
filament aggregation23 via antibodies on the filaments/
bundles and antigen on MV surfaces. If the MVs instead had
exhibited positive surface charge, non-specific aggregation via
negatively charged actin filaments would be expected.54 On the
other hand, for detection schemes relying on transpor-
tation,6,8,17,18 the negative surface charge may be detrimental
by binding of MVs to the positively charged actin binding
region of myosin.54 The fact that transportation of MVs could
be observed occasionally may be explained by MV attachment
to the bundle in a way that prevents contact with the myosin
coated surface or that the particular MV has diﬀerent surface
properties than the majority of the MV. A related factor that
needs to be considered is the isoelectric point (pI) of the IgG
antibodies that may vary between 5 and 9.55 We did not
measure pI but lack of eﬀect of antibody conjugation on
myosin driven motility and actin–myosin binding, which
depend strongly on electrostatic interactions,56 suggest that
antibody conjugation does not substantially modify the
electrostatic properties of actin filaments/bundles. A final
factor that may be operational in explaining motility inhibition
after addition of MVs is rupture of MVs to release proteins
from their interior. This is consistent with the inhibition of
motility also of those bundles that were not observed to have
bound MVs and with recent findings of motility inhibition
upon addition of cytosolic protein components to motility
assays.21
With regard to detection by filament aggregation, it is
important to exclude presence of aggregates or aggregate-like
structures e.g. by incomplete resuspension of MV pellets
during the enrichment phase. However, this risk was con-
sidered and minimized and we did not observe any aggregates
immediately after resuspension. One may also consider the
risk of fusion of several small vesicles, mimicking aggregate
formation, as previously shown for phosphatidylserine con-
taining liposomes.57 However, we did not include Ca2+ in the
buﬀer which was important in mediating fusion in the pre-
vious studies. Furthermore, importantly, we did not observe
aggregate-like assemblies of MVs in the absence of actin fila-
ments/bundles with specific anti-CD45 antibodies (Fig. 5).
Nevertheless, in a future device it will be important to rule out
any form of non-specific aggregation or membrane fusion
eﬀects. Therefore, proper negative controls (as in Fig. 5) need
to be integrated with the system at all times. Furthermore, con-
ditions will be optimized to prevent aggregation and mem-
brane fusion (e.g. low Mg2+ and Ca2+ concentrations).
Towards practical diagnostics applications
A range of detection principles that take advantage of specific
properties of cytoskeletal filaments and of motor driven
nanoseparation and concentration to detector areas have
been suggested for use in diagnostics
applications.6,8,10,12,16–18,23,26,58–60 Out of these principles, fila-
ment or bundle aggregation via analytes,23 such as observed
here with MVs, has however, not been observed to any useful
degree previously. The large aggregates formed between fila-
ments and MVs in solution or between bundles and MVs on
the motility assay surface, signal the presence of analyte (MVs)
without the need to fluorescence-label these. Eﬀective detec-
tion of the aggregates in solution will be feasible by pelleting
using a simple table-top centrifuge followed by observation of
fluorescence attributed to the large number of fluorophores on
the actin filaments. This procedure is facilitated by novel
methods53 for isolation and eﬀective pre-concentration of
microvesicles.
In contrast to the MV data, our results with protein antigen
show that the use of fascin–actin-antibody nanocarriers will
enhance motor driven nanoseparation/concentration pro-
cedures due to appreciably improved antigen binding capacity
compared to single filaments and maintained high actomyosin
velocity at low antigen labeling. The data in Fig. 2 show about
ten-fold improvement in sensitivity by switching from fila-
ments to bundles. Further, optimizations to achieve picomolar
to femtomolar sensitivity for protein antigens will require a
range of routine tests. However, it is obvious that a ten-fold
increase of the incubation time would increase sensitivity
about ten-fold by increased antigen binding to the bundles. A
further ten-, to hundred-fold improvement in detection limit
would be achieved using motor-driven nanoseparation and
concentration methods.8,18 This may be further improved
using enhanced fluorescence detection approaches20,60–62 and
elimination of background fluorescence as well as magnetic
pre-separation steps.63
Conclusions
We have demonstrated production of high-capacity nano-
carriers in the form of fascin–actin bundles covalently conju-
gated with antibodies. The nanocarrier shows unprecedented
maximum antigen carrying capacity for protein antigens and
combines advantages of actin-, and microtubule based
systems, e.g. the speed is similar to that of myosin propelled
actin filaments whereas the flexural rigidity is similar to that
of microtubules. In addition to the expected usefulness in
nanoseparation and concentration devices for high-sensitivity
detection of protein antigens we have also demonstrated the
usefulness for specific detection of antigen presenting MVs by
aggregation via these vesicles. In this scheme, the fluorescence
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labeled filaments/bundles contain thousands of APh dye mole-
cules thereby also serving as bright reporter elements, substi-
tuting potentially toxic inorganic nanoparticles.
Experimental section
Protein preparations and in vitro motility assays
Actin filaments and heavy meromyosin (HMM) proteolytically
derived from myosin II from fast rabbit skeletal muscle were
prepared as described previously.14,64,65 All experiments using
animal material were performed in accordance with national
and EU-legislation and were approved by the Regional Ethical
Committee for Animal experiments (reference # 96-11),
Linköping, Sweden. The actin filaments were labeled by using
APh or RhPh (both from Molecular Probes Invitrogen, Eugene,
OR). In vitro motility assays with actin filaments propelled by
HMM (room temperature: 21–23 °C) were performed as
described recently. Briefly, flow cells, with trimethyl-
chlorosilane (TMCS) derivatized coverslips as HMM binding
substrate,14 were incubated with HMM (120 µg ml−1), followed
by blocking with bovine serum albumin (BSA) before adding
fluorescent actin filaments and ATP-containing assay solu-
tion.14,64 The latter contained 1 mM MgATP and had an ionic
strength of 60 mM. After the standard incubation for an
in vitro motility assay, we added antigen, either Rh-rIgG for
1 min or DND41 MVs or MG63 MVs for 5 min.
Antibodies conjugated to F-actin and formation of
fascin : actin bundles
F-actin was conjugated with a-rIgG (Rockland Immunochem-
icals, Gilbertsville, USA) or a-CD45 monoclonal antibody (Uni-
versal Biologicals LTD, Cambridge, UK) using
heterobifunctional cross-linkers14 followed by assembly into
fascin–actin bundles. In brief, non-conjugated or antibody-
conjugated F-actin (0.25 mg mL−1; 6 µM on monomer basis)
with fluorescent phalloidin (RhPh or APh) in labeling buﬀer
(10 mM 3-morpholinopropane-1-sulfonic acid (MOPS), 60 mM
KCl, 2 mM MgCl2, 0.1 mM K2-ethylene glycol tetraacetic acid
(EGTA), 3 mM NaN3) was gently mixed with His-tagged fascin
(Novus Biologicals, Novus Europe, UK) in 20 mM Tris-HCl
buﬀer (including 100 mM NaCl, 2 mM dithiothreitol (DTT)
and 20% glycerol), followed by overnight incubation at 4 °C.
The procedure is schematically illustrated in Fig. 1. The solu-
tions contained actin and fascin in molar ratios of 1 : 1 and
1 : 2 for F-actin-a-rIgG and F-actin-a-CD45, respectively. This is
expected28 to produce fascin–actin bundles containing actin
and fascin at 4 : 1 and 2 : 1 molar ratios. The bundles were
stored on ice before use in experiments and protein concen-
trations were measured by Bradford assay.
Analysis of antibody incorporation and protein antigen-
binding to filaments and bundles
The degree of incorporation of actin filaments conjugated with
a-rIgG into fascin–actin bundles was evaluated by detection of
Rh-rIgG binding. Here, the fluorescence intensity due to Rh-
rIgG reflects the number of a-rIgG molecules with antigen
binding capacity. For these analyses, the flow cells were pre-
incubated as for a standard in vitro motility assay before
addition of, fascin-a-rIgG-actin bundles (60 nM; labeled with
APh). Image sequences were recorded using an EMCCD
camera as described above and fluorescence intensity per rho-
damine molecule was estimated from the fluorescence inten-
sity per actin filament length assuming 362 fluorescent
phalloidins per 1 µm of the actin filament. The number of
fluorescent antigens per bundle and the antibody/actin
subunit ratio were then calculated from the corrected
(Fig. S9†) ratio of the background subtracted Rh-rIgG and APh
fluorescence intensities. In this process bleed-through eﬀects
due to APh fluoresence in the TRITC filter-set, were too small
to be of significance when analyzing week Rh-fluorescence.
Cell culture and screening of cell lines for CD45 expression
Human leukemic cell lines were purchased from DSMZ
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany) while the MG63 osteosarcoma cell
line was purchased from ATCC (Manassas, VA, USA). B leuke-
mic cell lines SEM and RS(4;11) and T leukemic cell lines P12
ICHIKAWA, TALL1, CEM, MOLT3 and DND41 were cultured in
RPMI 1640 (GIBCO, Invitrogen Life Technologies, Carlsbad,
CA, USA) with 10% fetal calf serum (FCS), L-glutamine (2 mM;
GIBCO), penicillin (100 U ml−1; GIBCO) and streptomycin
(100 μg ml−1; GIBCO), and maintained at 37 °C in a humidi-
fied atmosphere with 5% CO2. MG63 cells were maintained in
DMEM 1× (GIBCO) supplemented with 10% FCS, L-glutamine
(2 mM; GIBCO), penicillin (100 U ml−1; GIBCO) and streptomy-
cin (100 μg ml−1; GIBCO), at 37 °C in a humidified atmosphere
with 5% CO2. In order to detect cells with CD45 expression, we
stained cell pellets with anti-human CD45 monoclonal anti-
body (Beckman Coulter, Inc., Miami, FL) and CD45 expression
was detected by flow cytometry (Fig. S5 and S6†).
MVs isolation from cell lines
For MVs isolation, culture medium was centrifuged twice at
2500 g for 15 minutes to remove cells and bigger bodies. Cell-
free media was filtered by means of a 1.2 µm size cut-oﬀ filter,
followed by centrifugation at 18000 g for 1 h at 4 °C. Impor-
tantly the latter step leaves all vesicles smaller than 0.1 µm
(such as exosomes) in the supernatant. This means (consider-
ing the previous filtering step) that MVs with a diameter
between 0.1 and 1.2 µm were recovered as pellet. The latter
was carefully re-suspended in PBS (1×, pH 7.4; GIBCO).
MVs staining and detection by flow cytometry and
fluorescence microscopy
To detect MVs by flow cytometry (FACS ARIA III, Becton Dickin-
son, Franklin Lakes, NJ), MVs were stained using the cyto-
plasmic dye CFSE (1 µM; CellTrace™ CFSE Cell Proliferation Kit,
Molecular Probes, Invitrogen, Eugene, OR). The CFSE is retained
in MVs for long time due to covalent coupling with intravesicu-
lar molecules. In order to check for the presence of CD45, MVs
were also stained with anti-human CD45 monoclonal antibody
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(Beckman Coulter, Inc.) following the manufacturer’s instruc-
tions and then detected by FACS (Fig. S7 and S8†).
For motility assays, CFSE+ MVs were suspended in MOPS
buﬀer (buﬀer A; cf. Fig. S10†). For fluorescence microscopy
based detection of MVs on the HMM coated surface, CFSE
staining was optimized, increasing the CFSE incubation con-
centration to 10 µM to better discriminate MVs from back-
ground (Fig. S11†). Another centrifugation step and CFSE+
MVs resuspension in PBS 1× was also added after the staining.
Once isolated, CFSE+ MVs were stored in PBS 1× at 4 °C for up
to 2 weeks before use (Fig. S12†).
The number of MVs present in a microscope image (84 ×
84 µm2) was obtained using an inverted fluorescence micro-
scope (Eclipse TE300, Nikon, Tokyo, Japan) equipped with a
Nikon 100× objective (NA 1.4 and a CCD camera (C9100-12,
Hamamatsu, Hamamatsu City, Japan).
Analysis of MV-binding to filaments and bundles in solution
For studies of MV binding to actin filaments and fascin–actin
bundles, the following mixtures were prepared: (i) DND 41-
MVs (10 µl) mixed with a-CD45 actin filaments (6.25 µl) (ii)
MG63-MVs (10 µl) mixed with a-CD45-actin filaments (6.25 µl)
and (iii) DND 41-MVs (10 µl) mixed with actin filaments
without antibodies (6.25 µl). Subsequently 108 µl of buﬀer D
(buﬀer A with 1 mM DTT) was added followed by incubation
for 15 min at 21–23 °C. Flow cells (see above), for observation
of the mixtures, were pre-incubated as for a standard in vitro
motility assay until the step before addition of fluorescent
actin filaments. At this point we instead incubated with one of
the mixtures i–iii for 3 min, followed by wash with buﬀer D,
and addition of r60 solution (buﬀer A with 10 mM DTT,
35 mM KCl, ionic strength 60 mM) supplied with an anti-
bleach system (final activity concentrations of 3 mg mL−1
glucose, 20 U mL−1 glucose oxidase and 870 U mL−1 catalase).
The co-localization between actin filaments and MVs was
observed using epi-fluorescence microscopy with TRITC and
FITC filter sets (details in ESI;† exemplified in Fig. 5 below).
Data analysis
Velocities of single F-actin or fascin–actin bundles were
measured using a tracking program developed in a Matlab
environment (The MathWorks Inc, Natick, MA).66 Linear and
non-linear curve fittings were performed using Graphpad Prim
software (version 6.0, Graphpad software, CA). Image J and Fiji
software (Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/,
1997–2012.) were used for analyses of brightness as well as for
thresholding and superimposition of images.
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